BriaCell Therapeutics Corp. Annual Report 2023

← All annual reports

FY2023 Annual Report · BriaCell Therapeutics Corp.

Loading PDF…

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended July 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from [●] to [●]

Commission File Number: 001-40101

BRIACELL THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)

British Columbia
(State or other jurisdiction
of incorporation or organization)

Suite 300 – 235 15th Street
West Vancouver, BC V7T 2X1
(Address of principal executive offices)

47-1099599
(I.R.S. Employer
Identification No.)

V7T 2X1
(Zip Code)

(604) 921-1810
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Shares, no par value
Warrants to purchase common shares, no par value

Trading Symbol
BCTX
BCTXW

Name of each exchange on which registered
The Nasdaq Stock Market LLC
The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and
will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form 10-K. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in

the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation

received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the
Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting
company ☒

Emerging growth
company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared
or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates based on a closing sale price of $7.48 per share, which
was the last sale price of the common shares as of January 31, 2023, the last business day of the registrant’s most recently completed second fiscal quarter,
was $105,163,751.

As of October 25, 2023, 15,981,726 shares of the registrant’s common shares, no par value per share, were issued and outstanding.

Business

Item 1
Item 1A Risk Factors
Item 1B Unresolved Staff Comments
Item 2
Item 3
Item 4

Properties
Legal Proceedings
Mine Safety Disclosures

TABLE OF CONTENTS

PART I

PART II

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
[Reserved]
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 5
Item 6
Item 7
Item 7A Quantitative and Qualitative Disclosures About Market Risk
Item 8
Item 9
Item 9A Controls and Procedures
Item 9B Other Information
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Financial Statements and Supplementary Data
Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

Item 10
Item 11
Item 12
Item 13
Item 14

Directors, Executive Officers, and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationship and Related Transactions, and Director Independence
Principal Accountant Fees and Services

PART III

Item 15
Item 16

Exhibits
Form 10-K Summary

SIGNATURES

PART IV

Page

5
31
49
49
49
49

50
50
50
54
54
54
54
54
54

55
64
66
67
68

69
70

Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based
on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve
substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual
results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our
forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks in the section titled “Risk Factors”, that
may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of
activity, performance or achievements expressed or implied by these forward-looking statements. In addition, you are directed to factors discussed in the
“Business” section and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section, as well as those discussed
elsewhere in this Annual Report on Form 10-K.

All of our forward-looking statements are as of the date of this Annual Report on Form 10-K only. In each case, actual results may differ
materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct.
An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form 10-
K or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and
Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as
required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans,
assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on
Form 10-K, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements
or disclosures by us following this Annual Report on Form 10-K that modify or impact any of the forward-looking statements contained in this Annual
Report on Form 10-K will be deemed to modify or supersede such statements in this Annual Report on Form 10-K.

This Annual Report on Form 10-K may include market data and certain industry data and forecasts, which we may obtain from internal company
surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and
surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from
sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies, clinical trials
and publications are reliable, we have not independently verified market and industry data from third-party sources.

Risk Factor Summary

Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we
believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our
risk factors in the section titled “Risk Factors”, together with the other information in this Annual Report on Form 10-K. If any of the following risks
actually occurs (or if any of those listed elsewhere in this Annual Report on Form 10-K occur), our business, reputation, financial condition, results of
operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe
are not material, may also become important factors that adversely affect our business.

● We have a history of losses, may incur future losses and may not achieve profitability;
● We are a pre-revenue clinical stage company;
● We are developing novel technologies which may not be effective or safe;
● We have an unproven market for our product candidates;
● We are heavily reliant on third-parties to carry out a large portion of our business;
● Pre-clinical studies and initial clinical trials are not necessarily predictive of future results;
● We must obtain additional capital to continue our operations;
● We are highly dependent on our key personnel;
● We may not succeed in completing the development of our products, commercializing our products or generating significant revenues;
● We may not successfully develop, maintain and protect our proprietary products and technologies;
● Changes in legislation and regulations may affect our revenue and profitability;
● If we or our licensees are unable to obtain U.S., Canadian and/or foreign regulatory approval for our product candidates, we will be unable to

commercialize our therapeutic candidates;

● Short sellers may be manipulative and may drive down the market price of our common shares;
● Our 2/3rd owned subsidiary BriaPro Therapeutics Corp. (“BriaPro”) may not generate revenue as expected;
● Clinical trials involve a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future

trial results;

● Future issuance of our common shares could dilute the interests of existing shareholders; and
● We have a significant number of options and warrants outstanding, and while these options and warrants are outstanding, it may be more difficult to

raise additional equity capital.

ITEM 1. BUSINESS

Overview of the Company

PART I

BUSINESS

BriaCell Therapeutics Corp. (the “Company”), is a clinical-stage biotechnology company that is developing novel immunotherapies to transform
cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and
destroy cancer cells. The Company is currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in
a pivotal1 Phase 3 study in advanced metastatic breast cancer. BriaCell recently reported benchmark-beating patient survival and clinical benefit in
advanced metastatic breast with median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients vs. 6.7-9.8 months for
similar patients reported in the literature2. A completed Bria-IMT™ Phase 1 combination study with retifanlimab (an anti-PD1 antibody manufactured by
Incyte) confirmed tolerability and early-stage efficacy. BriaCell is also developing a personalized off-the-shelf immunotherapy, Bria-OTS™, which
provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein
therapeutic which acts both as a stimulator of the immune system as well as an immune checkpoint inhibitor.

Market

It is estimated by the National Cancer Institute that in 2023, approximately 297,790 women will be diagnosed with breast cancer in the United
States. That means that every two minutes an American woman is diagnosed with breast cancer and more than 43,170 are projected to die in 2023.
Although about 100 times less common than in women, breast cancer also affects men. It is estimated that the lifetime risk of men getting breast cancer is
about 1 in 1,000, and the American Cancer Society estimates that approximately 2,800 new cases of invasive male breast cancer will be diagnosed and
approximately 530 men will die from breast cancer in 2023.

According to the May 2023 “Global Oncology Trends 2023” report by the IQVIA Institute, the global market for cancer drugs (including
immunotherapy drugs) is expected to reach nearly $375 billion by the end of 2027, growing at a compound annual growth rate (“CAGR”) of 17% between
2023 and 2027, of which about 20% is expected to be immuno-oncology drugs.

1 “Pivotal” is an industry term referring to a Phase 3 clinical study intended to show and confirm the safety and efficacy of a treatment.
2 Cortes J, et al. Annals of Oncology 2018; Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17; O’Shaughnessy J et al. Breast Cancer Res Treat. 2022;
Tripathy D, et al. JAMA Oncol. 2022

About 13% percent of women will be diagnosed with breast cancer at some point during their lifetime. In 2022, over 4 million women were living
with female breast cancer in the United States. Approximately 83% of cases present as invasive breast cancer. Approximately 6% of new breast cancer
diagnoses are Stage IV (metastatic breast cancer (“MBC”), which has already spread to other organs). Twenty to thirty percent of all women diagnosed
with breast cancer will develop MBC. Breast cancer can be subdivided based on receptor status – the hormone receptors for estrogen (ER) and
progesterone (PR), collectively referred to as hormone receptors (HR), and the Her2/neu growth factor receptor (HER2). Based on the latest SEER
statistics, 68% were found to be HR+/HER2−, 10% were triple-negative (HR−/HER2−), 10% were HR+/HER2+, and 4% were HR−/HER2+.1

It is estimated that over 150,000 women in the US are living with MBC.2 For those with metastatic disease at diagnosis, their 5-year survival rate
is 30%.1 For patients who develop MBC after initially having localized disease, if they had a good response to treatment (i.e. a disease-free interval of
more than 24 months), their survival rate is similar to that of patients with MBC at initial diagnosis, but if their disease-free interval is less than 24 months,
their prognosis is worse.4 We currently propose that Bria-IMT’s™ indication will be for the treatment of patients with MBC who have no approved
alternative therapies available. Similarly, another study showed that the median overall survival among patients with de novo stage IV MBC was 39.2
months, while for patients with relapsed disease it was 27.2 months.5 Median progression free survival after first-line therapy is only 9 months and the
survival benefit decreases with subsequent lines of therapy.6 One study showed that of 386 patients with MBC, 374 (97%) received first-line therapy, 254
(66%) received second-line therapy, 175 (45%) received third-line therapy, and 105 (27%) received therapy beyond third-line.7

1 See https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2022-2024-breast-cancer-fact-
figures-acs.pdf
2 Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United
States. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815.
3 Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.
4 Lobbezoo, D. J. A. et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most
favorable outcome. Breast Cancer Res. Treat. 141, 507–514 (2013).
5 Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann
Oncol. 2010 Nov; 21(11):2169–74.
6 Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, Puglisi F. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is
Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? Oncologist.
7 Kotsakis A, Ardavanis A, Koumakis G, Samantas E, Psyrri A, Papadimitriou C. Epidemiological characteristics, clinical outcomes and management
patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results

Figure A: Overview of current drugs for breast cancer, demonstrating the pattern of novel therapeutic introductions and significant market uptake. These
precedents demonstrate a strong market pull for Bria-IMT™.

The best response to the Bria-IMT™ monotherapy regimen to date is in patients who matched Bria-IMT™ at one or more HLA alleles, with
higher response rates for patients with 2+ HLA allele matches. If one HLA allele match is found to be sufficient, we will be able to treat ~50-60% of the
patient population, while patients with 2+ HLA matches constitutes ~15-35% of cases.8 We also saw higher clinical benefit rates for patients with grade I/II
tumors. Tumor differentiation in breast cancer cell lines is often described by their classification as Luminal, Basal A and Basal B subtypes, with Luminal
representing well differentiated tumors, Basal B poorly differentiated tumors, and Basal A an intermediate stage tumor (“moderately” differentiated).2 Yao
and colleagues in 2005 identified a 9-gene signature (AURKB, CENPI, DEPDC1, DEPDC1B, FAM83D, FGD3, NCAPH, TNFRSF18, FCGR1A)
discriminating poorly (grade 3) from moderately (grade 2) differentiated tumors.3 To understand the place of SV-BR-1-GM in this model, we compared its
RNA expression profile with those of three other cell lines representing Luminal (MCF-7), Basal A (MDA-MB-468) and Basal B (MDA-MB-231), using a
10-gene signature (AURKB, CENPI, DEPDC1, DEPDC1B, FAM83D, FGD3, NCAPH, DLGAP, KIF2C, VAV3) derived from those by Yao and
colleagues. The results, shown in the figure below, demonstrate that Bria-IMT™ most closely clusters with MDA-MB-468 and as such is considered a
grade II “moderately differentiated” cell line.

Greece: Results from the EMERGE multicenter retrospective chart review study. BMC Cancer. 2019 Jan 18;19(1):88.
8 Gragert, Loren, Abeer Madbouly, John Freeman, and Martin Maiers. 2013. “Six-Locus High Resolution HLA Haplotype Frequencies Derived from
Mixed-Resolution DNA Typing for the Entire US Donor Registry.” Human Immunology.
2 Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell.
2006;10(6):515-527. Doi:10.1016/j.ccr.2006.10.008)
3 Yao F, Zhang C, Du W, Liu C, Xu Y. Identification of gene-expression signatures and protein markers for breast cancer grading and staging. PloS One.
2015;10(9). Doi:10.1371/journal.pone.0138213)

Based on a publication of patients with relapsed breast cancer, we estimate that this will account for ~40% of relapsed metastatic breast cancer
cases (33% grade II and 7% grade I) (Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985-2016. Breast. 2017 Feb;31:46-
50. Doi: 10.1016/j.breast.2016.10.005. Epub 2016 Nov 2). In patients with relapsed disease, the overall survival following relapse appears similar for those
with grade II and grade III tumors.9

More recent information comes from combination therapy studies of the Bria-IMT™ regimen with immune checkpoint inhibitors (CPI). In the
ongoing study of BRI-ROL-001, in phase I the Bria-IMT™ regimen was dosed in combination with Keytruda ® in 11 patients and in 12 patients with
Zynyz® with one patient starting on the combination with Keytruda® and crossing-over to the combination with Zynyz® (22 patients total). In phase II of
the study, the Bria-IMT™ regimen is being dosed in combination with Zynyz® with patients randomized to either receive the Bria-IMT™ regimen first (12
patients) or Zynyz® first (12 patients). For the 11 patients treated in combination with Keytruda® in phase I, the disease control data is shown below:

■ 11 patients were treated with Bria-IMT™ + Keytruda®
■ All patients were very heavily pre-treated with a median of 7 prior systemic therapy regimens (i.e. chemotherapy), further underscoring BriaCell’s

positive patient outcomes

■ Tolerability excellent with no dose-limiting toxicities
■ Clinical benefit demonstrated: 1 PR and 3 SD in 8 immune responders

For the 12 patients treated in combination with Zynyz® in phase I, the disease control data is shown below:

■ 12 patients were treated with Bria-IMT™ plus Zynyz®
■ All patients were very heavily pre-treated with a median of 5 prior systemic therapy regimens (i.e. chemotherapy), further underscoring BriaCell’s

positive patient outcomes

■ Tolerability excellent with no dose-limiting toxicities
■ Efficacy: 70% (7/10) of evaluable patients showed disease control (5/10 evaluable patients including 1 PR and 4 SD) and/or progression-free

survival (PFS) benefits compared with their last therapy regimen.

The overall survival of the patients for all patients on this study has been evaluated in an ongoing fashion. Since the study was largely on hold
during COVID (2020 and 2021), patients dosed in 2019 and 2020 have been followed for a longer time. Therefore survival data has been evaluated for
patients dosed before 2022 and since 2022. This should be considered in the context of clinical studies in patients with advanced breast cancer who have
failed at least 2 prior regimens. Several recent publications are noted here:

■ Cortes J, et al. Annals of Oncology 2018: Open-label randomized phase 3 trial

■ Patients: Median 4 prior lines of Rx; ~20% HER2 positive, ~20%TNBC; n= 298 vs 296 (vinflunine vs alkylating agent)
■ Overall Response Rate (ORR) 6% vs 4%; Clinical Benefit Rate (CBR) 44% vs 35%; Progression Free Survival (PFS) 1.9 vs 2.5

months; Overall Survival (OS) 9.3. vs 9.1 months

■ Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17: Overall survival analysis

■ Patients: 2 prior lines of Rx; 229 Rx w eribulin, 134 gemcitabine, 80 capecitabine; 29% TNBC, 62% HR+/HER2-, 9% HER2+
■ Median OS eribulin 9.8 months, gemcitabine 7.2 months, capecitabine 9.1 months

■ O’Shaughnessy J et al. Breast Cancer Res Treat. 2022: Phase 3 randomized ASCENT study

■ Patients: 4-5 prior lines of Rx; 235 on Sacituzumab, 233 on TPC; 31% non-TNBC initially, 69% TNBC at Dx
■ Patient w/o initial TNBC: ORR 31% vs 4% ; CBR 44% vs 7%; PFS 4.6 vs 2.3 months; OS 12.4 vs 6.7 months
■ Patients w initial TNBC: ORR 36% vs 5%; CBR 45% vs 10%; PFS 5.7 vs 1.6 months; OS 12.1 vs 6.9 months

■ Tripathy D, et al. JAMA Oncol. 2022: Phase 3 ATTAIN Randomized Clinical Trial

■ Patients:~90% ≥4 prior lines of Rx; 92 on Etirinotecan Pegol 86 TPC; ~15% HER2+ ~40% TNBC
■ ORR 4.8% vs 2.7%; CBR 24.1% vs 9.5%; PFS 2.8 vs 1.9 months; OS 7.8 vs 7.5 months

In contrast, the Bria-IMT™ regimen with a CPI has shown a median overall survival (OS) of 13.3 months for patients treated before 2022 and
13.5 months for all patients by the Kaplan Meier method, as shown in the Figure below. For patients treated since 2022, the median OS has not been
reached.

Figure B. Overall Survival of Patients with Metastatic Breast Cancer treated with the Bria-IMT™ regimen with a CPI.

The market for breast cancer drugs is a multibillion-dollar market with new drugs being approved on an ongoing basis, indicating the shortage of
safe and effective treatments for this deadly disease. Figure A summarizes current drugs on the market utilized in combination therapy along with their
reported market sales, which further supports market potential for Bria-IMT™ to be used for combination therapy for breast cancer patients.

We propose the following calculation in order to show the rationale behind the number of patients that we anticipate can be currently treated by

SV-BR-1-GM:

Breast Cancer Incidence
Mortality

Incidence Growth Rate
Relapse rate

USA – 2022

128.3/100K
Stage I & II: 0.2% Stage
III: 3%
Stage IV*: 93%

0.53%

Stage I & II: Local relapse:
0.5%
Reg. Relapse: 6.1%
Distant Relapse: 1.4%

Stage split

Stage I & II: 61% Stage III:

28%
Stage IV: 11%
39%

Advanced stage Incidence Rate

Therapy Compliance Rate
Stage IV LoT mPFS

Expected Launch Date

Peak % Market Share

Cannibalization
Gross Price (Yearly)

% Gross to Net discount

287K
Stage I & II: 321
Stage III: 2.3K
Stage IV*: 24K

Stage III: Local relapse:
5.4%
Reg. Relapse: 0%
Distant Relapse: 35%
Stage I & II: 118K Stage
III: 80K Stage IV: 29K

● Breast cancer incidence and mortality. Source:

References

SEER10

● Stage IV mortality rate represents 3L+ patient

mortality rate

● De novo incidence growth rate of 0.53% / year

● Liang, T.-J.; Wang; et al. (2013)11

● Source: SEER10

● Dawood.S; Broglio. K; Ensor. J; et al. (2010)12

84%
1L: 9.0 months
2L: 9.7 months
3L: 5.6 months
2026 (BriaIMT)
2029 (BriaOTS)
BriaIMT – 10%
BriaOTS – 20%;
Peak in 5 year
60%
$186k;
0% yearly price growth
-10%

112K

● Includes US only stage III and IV patients.

Source: SEER10

● Zhao, H.; Lei, X.; Niu, J.; et al. (2021)13.
● Secondary research based on SOC therapy data

● Estimated launch date

● PMR

● Management input
● Current annual cost of model PD-(L)1i

● Internal assumption

9 See note 5, above.
10 Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press).
2019 Apr 10;11:151-164. SEER Cancer Statistics Factsheets: Female Breast Cancer. National Cancer Institute. Bethesda, MD; American Cancer Society.
Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.
11 Liang TJ, Wang BW, Liu SI, Yeh MH, Chen YC, Chen JS, Mok KT, Chang HT. Recurrence after skin-sparing mastectomy and immediate transverse
rectus abdominis musculocutaneous flap reconstruction for invasive breast cancer. World J Surg Oncol. 2013 Aug 14;11(1):194. Doi: 10.1186/1477-7819-
11-194. PMID: 23945398; PMCID: PMC3751148.
12 Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer.
Ann Oncol. 2010 Nov;21(11):2169-2174. Doi: 10.1093/annonc/mdq220. Epub 2010 Apr 28. PMID: 20427349; PMCID: PMC2962259. .
13 Zhao H, Lei X, Niu J, Zhang N, Duan Z, Chavez-MacGregor M, Giordano SH. Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant
Hormonal Therapy Among Commercially Insured Patients With Breast Cancer. JCO Oncol Pract. 2021 Jun;17(6):e794-e808. Doi: 10.1200/OP.20.00248.
Epub 2021 Feb 17. PMID: 33596096; PMCID: PMC8257979.
14 See note 5, above.

Competition

Currently available therapeutic options for breast cancer offer some hope for patients, but there is much room for improvement. Comparable
studies looking primarily at second line or later treatment are shown in Table “A”, below. Evaluating response rates (partial and complete responses =
ORR), progression free survival (“PFS”) and overall survival (“OS”) from clinical trials in similar subjects with metastatic or recurrent breast cancer
indicate that response rates range from 2.7% up to 59%, depending on the population studied and the intervention (median 24%). PFS ranges from 8 weeks
to 12 months (median 5 months) and OS from 6 months to 31 months (median 13 months).

Table A: Studies evaluating second-line or later treatment options. Data depict an unpredictable response rate to treatment ranging from 6.9-59%, therefore
establishing and confirming the opportunity for Bria-IMT™.

Study

Licchetta15
Harvey16

Rivera17

Gradishar18

Perez19
Leyland-Jones20
von Minckwitz21

Verma22

Geyer23

Bartsch24
Blackwell25

Cortes26

Kazmi27

O’Shaughnessy28

Tripathy29

Treatment & Design

# of Pts

ORR

PFS/TTP

Cyclophosphamide and megestrol acetate
Docetaxel Monotherapy 60 mg/m2
Docetaxel Monotherapy 75 mg/m2
Docetaxel Monotherapy 100 mg/m2
Docetaxel Monotherapy q3wk
Docetaxel Monotherapy qwk
ABI-007 (Nab paclitaxel)
Paclitaxel Monotherapy
ABI-007 (Nab paclitaxel) 2nd line
Paclitaxel Monotherapy 2nd line

Ixabepilone Monotherapy
Trastuzumab with paclitaxel
Trastuzumab with capecitabine
Capecitabine Monotherapy
Trastuzumab emtansine

lapatinib plus capecitabine
Lapatinib plus capecitabine
Capecitabine Monotherapy
Capecitabine and trastuzumab
Lapatinib Monotherapy
Lapatinib with trastuzumab
Vinflunine

alkylating agent

Eribulin
Gemcitabine
Capecitabine
Sacituzumab
Treatment of Physicians Choice
Etirinotecan Pegol
Treatment of Physicians Choice

29
122
146
139
59
59
229
225
132
136
126
32
78
78
495
496
163
161
40
148
148
298
296
229
134
80
235
233
92
86

31%
22.1%
23.3%
36.0%
35.6%
20.3%
33%
19%
27%
13%
11.5%
59%
48.1%
27.0%
43.6%
30.8%
22%
14%
20%
6.9%
10.3%

7.4 mo
12.7 wk
15.0 wk
16.6 wk
5.7 mo
5.5 mo
23.0 wk
16.9 wk
20.9 wk
16.1 wk
3.1 mo
12.2 mo
8.2 mo
5.6 mo
9.6 mo
6.4 mo
8.4 mo
4.4 mo
8 mo
8.1 wk
12.0 wk

31%
4%
4.8%
2.7%

4.6 mo
2.3 mo
2.8 mo
1.9 mo

13.4 mo
10.6 mo
10.3 mo
12.3 mo
18.3 mo
18.6 mo
65.0 wk
55.7 wk
56.4 wk
46.7 wk
8.6 mo

25.5 mo
20.4 mo
30.9 mo
25.1 mo

24 mo
39.0 wk
51.6 wk
9.8 mo
7.2 mo
9.1 mo
9.1 mo
9.3 mo
12.4 mo
6.7 mo
7.8 mo
7.5 mo

MBC treated with second or higher lines of therapy has a very poor prognosis and few effective therapies that consistently induce long-term
remission,29 which indicates the market demand and clinical need for new and improved therapeutic drugs and treatment options in order to improve these
response outcomes and patient survival rates. Thus, Bria-IMT™ has the potential to induce long-term remission, especially in combination with
immunotherapies. Current treatment of MBC is outlined in Figure “B”, below, which illustrates different therapeutic treatment options and drugs used upon
diagnoses from biopsy and identification of breast cancer biomarkers.30

15 Licchetta A, Correale P, Migali C, Remondo C, Francini E, Pascucci A, Magliocca A, Guarnieri A, Savelli V, Piccolomini A, Carli AF, Francini G. Oral
metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother. 2010 Jun;22(3):201-4.
16 Harvey, V. et al. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. J. Clin. Oncol. 24, 4963–
4970 (2006).
17 Rivera, E. et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Cancer 112, 1455–1461 (2008).
18 Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl). 2012;6:159-71.
19 Perez, E. A. et al. Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an
Anthracycline, a Taxane, and Capecitabine. J. Clin. Oncol. 25, 3407–3414 (2007).
20 Leyland-Jones, B. et al. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. J.
Clin. Oncol. 21, 3965–3971 (2003). Only 41% of patients had prior systemic chemotherapy.
21 von Minckwitz G et el. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast
cancer. Eur J Cancer. 2011 Oct;47(15):2273-81. Prior therapy limited to trastuzamab alone or in combination with a taxane.
22 Verma, S. et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
23 Geyer, C. E. et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
24 Bartsch, R. et al. Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer. J. Clin. Oncol. 25, 3853–3858 (2007).
25 Blackwell, K. L. et al. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-
Refractory Metastatic Breast Cancer. J. Clin. Oncol. 28, 1124–1130 (2010).

26Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X,
Beliakouski V, Román García J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with
heavily pretreated metastatic breast cancer. Ann Oncol. 2018 Apr 1;29(4):881-887. Doi: 10.1093/annonc/mdy051. PMID: 29481630.
27Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases
treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat. 2020 Nov;184(2):559-565. Doi: 10.1007/s10549-020-05867-0. Epub 2020
Aug 17. Erratum in: Breast Cancer Res Treat. 2021 Jun;187(2):603. PMID: 32808239; PMCID: PMC7599186.
28O’Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K,
Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3
randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. Doi:
10.1007/s10549-022-06602-7. Epub 2022 May 11. PMID: 35545724; PMCID: PMC9374646.
29Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J. ATTAIN:
Phase III study of etirinotecan pegol versus treatment of physician’s choice in patients with metastatic breast cancer and brain metastases. Future Oncol.
2019 Jul;15(19):2211-2225. Doi: 10.2217/fon-2019-0180. Epub 2019 May 10. PMID: 31074641; PMCID: PMC7466911.
30 NCCN Guidelines Version 2.2019, 07/02/2019 © 2019 National Comprehensive Cancer Network (NCCN®).

Figure B: Current treatment paradigm for metastatic breast cancer including between different treatment strategies and combination therapies dependent
upon biomarker identification and activity within the breast cancer signaling pathway.

Of patients treated with trastuzumab for MBC, one study showed that 241/331 (72%) progressed within 27 months (32% per year) with median
survival of 13-14 months (CI 10-15 months).31 This indicates the high unmet need in this patient population which should facilitate regulatory review of
novel therapies such as Bria-IMT™.

While there are many biotech companies working to create an effective breast cancer vaccine, a significant gap remains in the effectiveness and
safety of second or higher lines of therapy . The most studied targeted immunotherapy, Neuvax (Galena), a HER2 peptide vaccine, failed a Phase III trial,
but there is encouraging data to support at least three ongoing clinical trials combining trastuzumab with HER2 epitope immunogens.32 The National
Cancer Institute (“NCI”) randomized trial adding PANVAC (a poxviral-based immunogen) to docetaxel increased the median PFS from 3.9 months to 7.9
months and is to be used as a basis for larger, more sophisticated clinical trials.33 An immunogen targeting a carbohydrate antigen, globo-H, was associated
with improved PFS, but only in the subset able to mount antibody responses.34 A Johns Hopkins breast cancer trial using a breast cancer cell line
transfected with the gene for GM-CSF has not been positive but, using the same cell line with trastuzumab, 40% of patients enjoyed clinical benefit
(CR+PR+stable) at one year.35 Finally, the study of targeted cancer immunotherapies in combination with other therapies is receiving much attention,
particularly combination with checkpoint inhibitors.36

31 Rossi, V.; Nole, F.; Redana, S.; Adamoli, L.; Martinello, R.; Aurilio, G.; Verri, E.; Sapino, A.; Viale, G.; Aglietta, M.; Montemurro, F., Clinical outcome
in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast 2014, 23 (1), 44-9.
32 Mittendorf, E. A.; Peoples, G. E., Injecting Hope—A Review of Breast Cancer Vaccines. Oncology (Williston Park) 2016, 30 (5), 475-81, 485.
33 Heery, C. R.; Ibrahim, N. K.; Arlen, P. M.; Mohebtash, M.; Murray, J. L.; Koenig, K.; Madan, R. A.; McMahon, S.; Marte, J. L.; Steinberg, S. M.;
Donahue, R. N.; Grenga, I.; Jochems, C.; Farsaci, B.; Folio, L. R.; Schlom, J.; Gulley, J. L., Docetaxel Alone or in Combination With a Therapeutic Cancer
Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2015, 1 (8), 1087-95.
34 Huang, C.; Yu, A.; Tseng, L., Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. J
Clin Oncol 2016, 34 (15).
35 Chen, G.; Gupta, R.; Petrik, S.; Laiko, M.; Leatherman, J. M.; Asquith, J. M.; Daphtary, M. M.; Garrett-Mayer, E.; Davidson, N. E.; Hirt, K.; Berg, M.;
Uram, J. N.; Dauses, T.; Fetting, J.; Duus, E. M.; Atay-Rosenthal, S.; Ye, X.; Wolff, A. C.; Stearns, V.; Jaffee, E. M.; Emens, L. A., A feasibility study of
cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res
2014, 2 (10), 949-61.
36 McArthur, H. L.; Page, D. B., Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in
combination immunotherapy. Clin Adv Hematol Oncol 2016, 14 (11), 922-933.

There are several other approaches to developing targeted breast cancer immunotherapies. These include using peptide cocktails, a triple peptide
regimen, recombinant HER2, antigen-pulsed dendritic cells, DNA immunogens, whole cell allogeneic GM-CSF secreting SKBR3 or T47D cells, an
(HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein, oxidized mannan-MUC1, and personalized peptide immunogens.

Among the most promising results in patients with advanced disease have been using whole-cell preparations, particularly if the cells are
engineered to express GM-CSF. We are taking this approach and capitalizing on positive initial results with Bria-IMT™ monotherapy in difficult to treat
patients using a regimen that both limits regulatory T cell activity (using low dose cyclophosphamide pre-treatment) and boosts the immune response
(using post-dose alpha interferon in the inoculation sites). The combination with PD-1 inhibitors is a logical extension of our findings where 21 of 23 MBC
patients had demonstrable PD-L1 expression on the circulating tumor cells (“CTCs”) and/or circulating cancer-associated macrophage-like cells
(“CAMLs”). The overall strategy, once the initial milestones have been met, to enroll additional patients for product registration, will allow rapid
progression of the best therapeutic option to a Biologics License Application (“BLA”).

Products/Pipeline

Bria-IMT™

Bria-IMT™, BriaCell’s lead candidate, is a whole-cell immunotherapy. Bria-IMT™ in combination with an immune check point inhibitor is
undergoing pivotal Phase 3 clinical testing in patients with advanced MBC patients who have failed prior lines of therapy. The pivotal Phase 3 combination
study is listed on ClinicalTrials.gov as NCT06072612.

Bria-IMT™ is currently under Fast Track Designation by the U.S. Food and Drug Administration (the “FDA”) intended to accelerate the review
process of novel treatments that address unmet medical needs. Positive completion of the pivotal study, following review by the FDA, could lead to full
approval of the Bria-IMT™ immune checkpoint inhibitor combination in advanced metastatic breast cancer.

The FDA has agreed that improvement in overall survival in the Bria-IMT™ combination arm as compared to the physician’s choice of treatment
arm will be the primary endpoint of the study. The study is expected to enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in
the treatment of physician’s choice arm. To gather additional information on the Bria-IMT™ regimen alone, 50 patients are expected to be enrolled in this
regimen and will be eligible for combination therapy following their initial post treatment evaluation. The study will have an interim evaluation for efficacy
which could result in early completion of the study. We expect frequent and responsive FDA communication under our Fast Track status during our pivotal
Phase 3 study.

The successful completion of the pivotal study would allow BriaCell to subsequently submit a Biologics License Application and accelerate the

path to commercialization.

BriaCell’s recently announced partnership with New York Cancer & Blood Specialists (“NYCBS”) as clinical site with more than 30 locations and
35 hospital affiliations throughout Nassau and Suffolk counties, in the Bronx, Manhattan, Queens, Staten Island, and Brooklyn to conduct its pivotal Phase
3 Study of Bria-IMT™ in Advanced Breast Cancer.

In collaboration with Prevail InfoWorks, Inc. (“InfoWorks”), a Philadelphia, PA based contract research organization, BriaCell expects to recruit
additional sites to speed up the patient recruitment process. BriaCell has signed a Master Service and Technology Agreement (“MSTA”) agreement with
InfoWorks to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer. Services include
clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and the use of InfoWork’s
integrated real-time data analytics platform, The Single Interface ®, for clinical support and real-time data analysis.

Prevail Partners, LLC (“Prevail Partners”), an investment fund and affiliate of InfoWorks, has purchased 463,408 BriaCell common shares at a
price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day volume-weighted average price of the
common shares of the Company on the Nasdaq Stock Exchange. The transaction closed on May 19, 2023.

Recent Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Phase 2 Clinical Trial of Bria-IMT™ in High-Risk Early-Stage
Triple Negative Breast Cancer

BriaCell recently announced that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and
Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties’ plans and
commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell’s novel immunotherapy, Bria-IMT™,
in combination with a check point inhibitor, in early stage, newly diagnosed, high-risk triple negative breast cancer patients who have failed to achieve a
pathological complete response in the neoadjuvant setting.

Phase 1/2 Clinical Trial of Bria-IMT™ in Combination with Immune Check Point Inhibitors in Advanced Metastatic Breast Cancer

BriaCell has been conducting a Phase 1/2a clinical trial of Bria-IMT™, in combination with immune checkpoint inhibitors such as pembrolizumab
(KEYTRUDA®; manufactured by Merck & Co., Inc.) and retifanlimab, an immune checkpoint inhibitor manufactured by Incyte). The combination study
is listed in ClinicalTrials.gov as NCT03328026 under FDA-approved BB-IND 10312 under protocol BRI-ROL-001 at ten clinical sites throughout the
United States.

BriaCell recently announced benchmark-beating patient survival and clinical benefit in advanced metastatic breast cancer with median overall

survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients vs. 6.7-9.8 months for similar patients reported in the literature.

BriaCell has achieved proof of concept based on data from a Phase 1/2a study of Bria-IMT™ in advanced breast cancer patients. In essence,
BriaCell has demonstrated disease control and clinical benefit in a high proportion of patients with advanced breast cancer who have exhausted other
therapeutic options. There is also promising data on overall survival as noted above.

Positive Proof of Concept

● Bria-IMT™ has been evaluated in a regimen including pre-dose low-dose cyclophosphamide (to reduce immune suppression), intradermal
inoculation with 20-50 million irradiated Bria-IMT™ cells between two and three days later, with subsequent intradermal inoculation with
interferon-α2 approximately two days later. This is known as the Bria-IMT™ regimen.

● BriaCell has evaluated the Bria-IMT™ regimen in two Phase I/IIa studies of Bria-IMT™ in advanced breast cancer patients. Both were single arm

studies, so there were no untreated patients for comparison.

● There were four evaluable patients treated in one study (Study SVMC #01-026) and 23 evaluable patients treated in another study (Study WRI-
GEV-007) with this regimen with cycles every two weeks for the first month and then monthly. They were heavily pre-treated with a median of
four prior systemic therapy regimens.

● The data shows an outstanding safety and tolerability profile for Bria-IMT™ in advanced breast cancer patients.

Study SVMC #01-026

● In the SVMC #01-026 study, treatment was limited to six cycles over five months. Four post-menopausal white women were enrolled aged

between 58.7 and 73 years. Three had breast cancer and one had Her2+ ovarian cancer. All had failed at least one prior systemic therapy.

● These patients received between four and six cycles of treatment on protocol. One patient had an additional 13 cycles off protocol.

● The only adverse events that occurred in more than one patient were itch and rash at the inoculation sites. No deaths were reported during this
study. There were four serious adverse events (“SAEs”) in 3 patients with one (transient urticaria, grade 3) judged probably related to treatment.
All SAEs were manageable with community practice therapies.

● The Bria-IMT™ regimen was able to elicit delayed-type hypersensitivity (“DTH”) responses in all patients. DTH is a measure of cell-mediated
immunity. This response involves the interaction of T-cells, monocytes, and macrophages. This reaction is caused when CD4+ Th1 helper T cells
recognize foreign antigen in a complex with the Class II HLA molecule on the surface of antigen-presenting cells. These can be macrophages or
dendritic cells that secrete monokines such as IL-12 and IL-15, which stimulates the proliferation of additional CD4+ Th1 cells. CD4+ T cells
secrete other cytokines including IL-2 and interferon gamma, inducing the further release of other TH1 cytokines, thus mediating the immune
response. This results also in the activation of CD8+ T cells which destroy target cells on contact, and activated macrophages which produce
hydrolytic enzymes.

● The DTH response involves the interaction of T-cells, monocytes, and macrophages. This reaction is caused when CD4+ Th1 helper T cells
recognize foreign antigen in a complex with the Class II HLA molecule on the surface of antigen-presenting cells. These can be macrophages or
dendritic cells that secrete monokines such as IL-12 and IL-15, which stimulates the proliferation of additional CD4+ Th1 cells. CD4+ T cells
secrete other cytokines including IL-2 and interferon gamma, inducing the further release of other Th1 cytokines, thus mediating the immune
response. This results also in the activation of CD8+ T cells which destroy target cells on contact and activated macrophages which produce
hydrolytic enzymes.

● One patient (A002) had a partial response with regression of breast lesions, resolution of lung and soft tissue lesions, and improvement of stability
of bone lesions. She completed therapy and 3 months after her last Bria-IMT™ inoculation, imaging studies identified regrowth of tumor notably
in the breast, lung, and brain. After consultation with the FDA, the patient was treated off-protocol which also produced tumor regression,
including the resolution of brain metastases. The HLA-DRB3 and HLA-DRB1 alleles of patient A002 matched with that of SV-BR-1-GM. Her
tumor was grade II (moderately differentiated). One other patient on this study (B001) with a grade II tumor had disease limited to bony
metastases. She did not have measurable disease but was felt to progress on study.

● Median time to tumor progression was 144 days (range 64 – 223 days) for the initial round of treatment. Overall survival was more than 33

months in all patients except B001 (7 months).

Study WRI-GEV-007

● In the WRI-GEV-007 study, patients were treated with a median of three cycles of therapy (range 1-8).

● The Bria-IMT™ regimen was able to elicit both cellular immune responses (as evidenced by DTH responses in 85% of patients evaluated) and

antibody responses (present in 58% of patients evaluated).

● The most common adverse events seen were local irritation at the inoculation sites.

● Several patients showed evidence of anti-tumor activity of the Bria-IMT™ regimen in spite of their being heavily pre-treated advanced breast
cancer patients. Specifically, one patient (designated 01-002) had regression or disappearance of 20 lung metastases, and stable disease in liver
metastases (as the liver metastases were the target lesions, she did not qualify as a partial response). She displayed a robust DTH response, had a
grade I tumor and matched Bria-IMT™ at 2 HLA loci. One patient (05-002) had a reduction in the size of a breast lesion but progression of a liver
lesion and did not meet criteria for a partial response. She also displayed a robust DTH response, had a grade II tumor and matched Bria-IMT™ at
2 HLA loci. One patient (01-005) had a marked reduction in cutaneous involvement but developed restrictive cardiomyopathy (unrelated to study
drug) with subsequent mortality. She had a grade III (poorly differentiated) tumor and matched Bria-IMT™ at one HLA locus. She was not on
study long enough to be evaluated for her response.

● Patients 01-002, 05-002 and 01-005 who showed objective evidence of tumor shrinkage all matched the Bria-IMT™ cell line at least at one HLA
locus and all had evidence of DTH responses to Bria-IMT™ and/or the parent cell line (SV-BR-1 – the breast cancer cell line from which Bria-
IMT™ was derived). Patients who did not develop a DTH response did not show evidence of tumor shrinkage.

● Patients 01-002 and 05-002 had grade I/II tumors. Both of them also had two HLA matches with Bria-IMT™. Two other patients with grade II
tumors (patient 03-001 and 06-001) had stable disease on the study and were also considered to have received clinical benefit from the treatment.
(Clinical benefit was defined as some evidence of tumor shrinkage (including a mixed response with shrinkage of some tumors but progression of
others, as for 05-002) with over 90 days on study; or as stable disease, a partial response or a complete response as per RECIST criteria). Neither
03-001 nor 06-001 had HLA matches with Bria-IMT™, suggesting that HLA matching may not be required for clinical benefit in patients with
grade I/II tumors. Thus, four of the six patients with grade I/II tumors exhibited clinical benefit. One of the remaining patients showed no evidence
of an immune response as evaluated by DTH. Thus, four of the five grade I/II patients able to develop an immune response, as noted by DTH,
exhibited clinical benefit.

● These preliminary data indicate that the Bria-IMT™ regimen in advanced breast cancer patients is well tolerated, able to elicit an immune

response and able to induce reduction in tumor burden.

Study BRI-ROL-001

● Another phase I/IIa study (BRI-ROL-001) was initiated evaluating the combination of the Bria-IMT™ regimen with KEYTRUDA®
(pembrolizumab). This combination combines the induction of an immune response by Bria-IMT™ (i.e. “putting the foot on the gas” of the
immune response) with the ability of KEYTRUDA® to block the PD-1 – PD-L1 immune checkpoint (i.e. to “take the foot off the brakes” of the
immune response).

● Eleven patients with advanced breast cancer (median of four prior systemic therapy regimens) have been treated with this regimen with cycles

every three weeks for a median of three cycles (range 1 – 9 cycles).

● Two patients had evidence of tumor regression, both of whom had robust immune responses (as measured by DTH) to Bria-IMT™. Both of them
had grade II tumors. One matched Bria-IMT™ at two HLA types (06-005) while the other did not match Bria-IMT™ at any HLA types (06-001,
who “rolled over” from the WRI-GEV-007 study where she had stable disease), suggesting that the Bria-IMT™ regimen, when given in
combination with a PD-1 inhibitor, may be able to induce tumor regression without an HLA match especially in patients with grade I/II tumors.
One additional patient (06-004) in this study had a grade II tumor and was noted to have stable disease. The other seven patients treated had grade
III tumors (poorly differentiated). Thus, all three of the patients with grade I/II tumors showed evidence of clinical benefit.

● Following the establishment of a collaboration with Incyte Corporation, this study was altered to evaluate the combination of the Bria-IMT™

regimen with retifanlimab (anti-PD-1 antibody similar to KEYTRUDA®). The combination with KEYTRUDA® has been discontinued.

● A total of 12 patients were treated in the phase I part of the study in combination with retifanlimab. One of then switched from the Keytruda®

combination to the retifanlimab combination.

● 50% of the evaluable patients showed disease control (stable disease or a partial response) with the safety profile again excellent.

● Dosing in this study is ongoing in the randomized phase II portion, with patients randomized either to receive Bria-IMT™ first for retifanlimab

first.

● Overall survival data has been evaluated for all patients as of 2023 September 8. The median overall survival is 13.5 months, which compares

favorably with literature reports of similar patients where overall survival has been 6.7-9.8 months (see references above).

● The data confirms the clinical activity of the Bria-IMT™ regimen in combination with an immune checkpoint inhibitor and justifies further

evaluation in a pivotal registration study.

About Bria-IMT™

Developed and characterized by a team of dedicated scientists and clinicians, Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy being
developed for the treatment of breast cancer. Bria-IMT™ is a genetically engineered human breast cancer cell line with features of immune cells and
clinically applied as a targeted immunotherapy.

In short, Bria-IMT™ immunotherapy is a genetically engineered human breast cancer cell line derived from a grade II tumor which activates the

immune system to attack and destroy breast cancer tumors.

Mechanism of Action of Bria-IMT™

The mechanism of action of Bria-IMT™ is currently under investigation. It is likely that the expression of certain breast cancer antigens (proteins
expressed in breast cancer cells) in Bria-IMT™ generates strong T cell and potentially antibody responses – resulting in recognition and destruction of
cancerous cells.37

Bria-IMT™ is designed to secrete GM-CSF, a factor that stimulates components of the immune system. Specifically, GM-CSF activates dendritic
cells, the cells that start immune responses. These activated dendritic cells then activate T cells, a key component of the immune system, to recognize the
tumor cells as foreign, and eliminate them. To amplify this action, we have combined Bria-IMT™ with other immune system activators including
cyclophosphamide (used in low doses to reduce immune suppression), and interferon-α, a cytokine that further activates the immune system. We believe
this approach of simultaneous activation of the immune system via different pathways will improve the immune system response to attack and destroy
cancer cells.

Bria-OTS™

Using BriaCell’s novel technology platform and our strong research and development capabilities, BriaCell plans to develop Bria-OTS™, a

personalized off-the-shelf immunotherapy for breast cancer, and similar immunotherapy cell lines for other cancer indications.

● Bria-OTS™ is under development as an off-the-shelf personalized immunotherapy for advanced breast cancer.

● The concept for Bria-OTS™ comes from BriaCell’s work with Bria-IMT™, where BriaCell noted that if a patient “matches” Bria-IMT™ in their

HLA type, they were more likely to respond.

● HLA molecules are the molecules that start immune responses but are polymorphic – i.e. they are different in different people, although some

people will share the same HLA molecules (referred to as HLA alleles or HLA types).

● Bria-OTS™ is made from cell lines that are genetically engineered to expresses the immune boosters GM-CSF and interferon-α, as well as

specific HLA types (a.k.a. alleles).

● Different cell lines are being pre-manufactured to express different HLA types covering >99% of the overall breast cancer patient population.

● Using the BriaDX™, a companion diagnostic test performed on the patient’s saliva, the suitable personalized treatment will be selected for each

patient for administration.

● This approach allows personalized treatment without the need for personalized manufacturing. Additionally, it saves time, and skips expensive and

complicated manufacturing procedures associated with other personalized treatments.

● Bria-OTS™ cell lines are being engineered and transferred to good manufacturing practice (“GMP”) production and clinical evaluation is planned
to commence in 2023 (expected authorization by FDA and expected first patient to be dosed in 2023) with safety and efficacy data expected to be
released during 2023 and 2024.

● Bria-OTS™ cell lines have also been engineered to express co-stimulatory molecules and additional cytokines that can activate naïve T cells

(those that have not been pre-activated). These “Bria-OTS™ 2.0” cells are expected to be very potent in eliciting an anticancer immune response.

● Bria-OTS™ 2.0 cell lines for breast cancer and prostate cancer cells should be entering GMP manufacturing in 2023 or early 2024. Similar cell

lines for lung cancer and melanoma will follow.

● Bria-OTS™ 2.0 cell lines have the potential to transform cancer treatment as with simple intradermal injections tailored to the individual patient, a
potent and broad immune response against their cancer can be elicited, which should result in marked destruction of the tumors by the patient’s
own immune system.

37 Lacher M.D., Bauer G. Fury B., Graeve S., Fledderman E.L., Petrie T.D., Coleal-Bergum D.P., Hackett T., Perotti N.H., Kong Y.Y., Kwok W.W., Wagner
J.P., Wiseman C.L., and Williams W.V. SV-BR-1-GM, a Clinically Effective GM-CSF- Secreting Breast Cancer Cell Line, Expresses an Immune Signature
and Directly Activates CD4+ T Lymphocytes. Frontiers in Immunology 2018; 9: Article 776.

Development of Additional Immunotherapy Cell Lines

● Based on these observations, BriaCell is extending this technology to other types of cancer by developing additional immunotherapy cell lines.

● Cell lines currently being genetically engineered include a breast cancer cell line, a prostate cancer cell line, a non-small cell lung cancer cell line

and a melanoma cell line.

● The genetic engineering has been completed for the breast cancer cell line and GMP manufacturing completed. Release testing is underway with
the goal to initiate clinical studies in 2H2023. The prostate cancer cell line is expected to initiate GMP manufacturing in late 2023 or early 2024
with the lung cancer and melanoma cell lines to follow.

● IND filings for these immunotherapy cell lines are anticipated starting in 2023.

Early Phase Programs

On August 4, 2022, BriaCell announced that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to
develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer. Under the terms of the agreement, BriaCell has the
worldwide rights to develop and commercialize sCD80, while UMBC maintains ownership of the patents. BriaCell will pay royalties to UMBC upon the
commercialization of the product plus patent management costs. The licensing agreement was coordinated by UMBC’s Office of Technology
Development.

The patents are listed as the following: USPN 8,956,619 B2; USPN 9,650,429 B2; USPN 10,377,810 B2

CD80 is an important co-stimulatory molecule present on antigen-presenting cells and key for activating T cells. CD80 also acts as an immune
checkpoint inhibitor. As noted in the patents, significant data has been generated showing that in animal models sCD80 is capable of enhancing anti-cancer
immune responses and shrinking tumors in model systems. The sCD80 appears to act both as an immune stimulator and checkpoint inhibitor. This makes it
an ideal candidate to combine with BriaCells’s cellular immunotherapy platform.

Current timelines project that the sCD80 may be ready to enter the clinic in early 2025.

Marketing and Sales Strategy

The product will initially be marketed to oncologists who are well-versed in the use of immunotherapy for cancer. Partnering with other
pharmaceutical companies in order to market combinations with a number of drugs is also an option that we intend to pursue. This study will utilize a
frozen formulation which consists of irradiated SV-BR-1-GM cells in viable freezing media. This formulation will permit stockpiling of immunotherapy so
that it can be sent on demand to clinical sites. The eventual goal is to reach all oncologists who treat late-stage breast cancer, either by direct outreach or by
partnering with another company that has an established presence in the oncology space.

Other Commercial Considerations

There is a high unmet medical need in late-stage breast cancer, providing potential for accelerated approval of Bria-IMT™. The FDA is interested
in facilitating the availability of novel therapies of patients with unmet medical needs, especially those that can target the population most likely to respond.
In addition, the FDA has granted “Fast Track” status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer. These two
facts may help facilitate the accelerated approval of Bria-IMT™.

Production and Marketing Plan

Bria-IMT™ cells grow in simple tissue culture media and are irradiated prior to inoculation. Bria-IMT™ manufacturing will be performed by
Contract Manufacturing Organizations. We have been working with KBI Biopharma, Inc. (“KBI”) and the University of California, Davis Health System
(“UC Davis”) GMP facility, who have developed a frozen formulation where the cells are grown, harvested and irradiated, followed by cryopreservation in
a viable state. The cells are stockpiled and shipped directly to clinical sites for inoculation. Each lot of Bria-IMT™ is tested for potency (i.e. GM-CSF
production), identity (i.e. HER2+ and ER/PR-) and adventitious agents to rule out contamination with infectious agents. To date, there have been no issues
with these tests. Additional manufacturing facilities have been evaluated and may be enlisted as demand grows.

Marketing will target oncologists who are well-versed in the use of immunotherapy and especially breast cancer treatment centers. The initial
target will be patients with metastatic or recurrent breast cancer who have failed at least two prior treatment regimens. We plan to develop the clinical data
for Bria-IMT™ and to use this information to reach out to oncologists seeking additional therapeutic options for their patients. We will include in this effort
a physician education campaign targeting the oncologists most likely to treat metastatic breast cancer. As these physicians become more aware of the data
regarding Bria-IMT™ in breast cancer, we will make sure they also understand how best to use Bria-IMT™ in combination with other therapies that have
complementary synergistic mechanisms of action. This will also come from the clinical studies described above focusing on combination therapy.
Partnering with other pharmaceutical companies in order to market a number of drugs is also an option that we intend to pursue. Our eventual goal is to
reach all oncologists who treat late stage breast cancer, either by direct outreach or by partnering with another company that has an established presence in
the oncology space.

License Agreements

On July 24, 2017, the Company entered into a Share Exchange Agreement with its wholly-owned subsidiary, BriaCell Therapeutics Corp.,
Sapientia, and all the shareholders of Sapientia. Sapientia, a biotechnology company based in Havertown, PA, is developing novel targeted therapeutics for
multiple indications, including several cancers and fibrotic diseases.

Pursuant to the terms of the Share Exchange Agreement, BriaCell Therapeutics Corp. agreed to acquire from the Sapientia shareholders all of the
issued and outstanding shares in the capital of Sapientia in consideration to the Sapientia shareholders, pro rata, of an aggregate of 8,333 common shares in
the capital of BriaCell (the “Transaction”), which were issued on September 5, 2017.

As part of the Transaction, BriaCell acquired the license agreement Sapientia entered into with Faller-Williams Technology (“FWT”), dated March
16, 2017, (the “License Agreement”), pursuant to which BriaCell acquired all rights, including composition of matter patents (the “PKCδ Patents”), and
preclinical study data to a novel therapeutic technology platform, PKCδ inhibitors, which represents a unique, highly-targeted approach to treat cancer and
to boost the immune system.

Pursuant to the License Agreement, FWT is eligible to receive certain milestone payments, including i) $5,000,000 upon the filing of each New
Drug Application with the FDA with respect to products disclosed and/or described in the PKCδ Patents (the “PKCδ Products”); ii) $25,000,000 upon final
approval of each New Drug Application by the FDA for the marketing of a PKCδ Product; iii) $1,000,000 upon the filing of each Marketing Authorization
Application (“MAA”) with the Medicines and Healthcare Products Regulatory Agency of United Kingdom or the Committee for Medicinal Products for
Human Use of the European Commission with respect to a PKCδ Product; and iv) $5,000,000 upon the final approval of each MAA with the Medicines
and Healthcare Products Regulatory Agency of United Kingdom or the Committee for Medicinal Products for Human Use of the European Commission for
the marketing of a PKCδ Product.

FWT is eligible to receive certain royalty payments under the License Agreement. Following the first commercial sale of a PKCδ Product in the
United States, FWT shall receive i) 5% of worldwide net sales of PKCδ Products encompassed by one or more valid claims of the PKCδ Patents and/or
improvements thereto, and ii) 2.5% of worldwide net sales from PKCδ Products not encompassed within one or more valid claims of the PKCδ Patents.
Additionally, upon BriaCell’s receipt of marketing approval for a PKCδ Product from the FDA, the Medicines and Healthcare Products Regulatory Agency
of United Kingdom, the Committee for Medicinal Products for Human Use of the European Commission or an equivalent authority, FWT shall receive
minimum royalty payments of $250,000 per year.

Unless terminated earlier pursuant to the provisions therein, the License Agreement shall expire ten years after the last PKCδ Patent expires.

Intellectual Property

The proprietary nature of, and protection for, the Company’s current and/or any future product candidates, processes and know-how are important
to its business, as is its ability to operate without infringing on the proprietary rights of others, and to prevent others from infringing its proprietary rights.
The Company seeks patent protection in the U.S. and internationally for its current and future product candidates it may develop through other technology.
In order to protect its proprietary technologies, the Company relies on combinations of applications for patent and trade secret protection, as well as
confidentiality agreements with employees, consultants, and third parties.

The Company has filed and own or have licensed all rights in the following pending patent applications and issued patents:

Filed with the United States Patent and Trademark Office (“USPTO”) on June 14, 2004, U.S. Patent No. 7,674,456 B2, includes claims to the following:

Compositions comprising SV-BR-1 cells

Therapeutic methods of using said compositions

On February 27, 2017, BriaCell™ filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its
intellectual property portfolio underlying the Company’s current and anticipated pipeline of whole-cell cancer immunotherapeutics including Bria-IMT™
and Bria-OTS™. The PCT application (PCT/US2017/019757) claims priority to two provisional patent applications filed by the Company with the USPTO
in 2016. It, in essence, provides the framework for additional whole-cell cancer immunotherapeutics beyond Bria-IMT™ and strategies for patient-specific
selection of the most likely effective whole-cell immunotherapeutic (BriaDx™). The PCT application entered the National Phase in the second half of 2018
and was granted in Japan on June 21, 2021.

BriaCell was recently awarded an Australian patent (Patent No. 2017224232, extends to February 27, 2037) covering composition of matter and

method of use for its whole-cell cancer immunotherapy technology in Australia.).

BriaCell has also received an Issue Notification from the USPTO for the composition of matter and method of use of its personalized off-the-shelf
cell-based immunotherapy for cancer. The patent was issued on January 24, 2023 as US Patent No. 11,559,574 B2 with the term extending to May 25,
2040.

On July 24, 2017, BriaCell obtained the exclusive license to certain patents related to PKCδ inhibitor technology, including patents to specific
compounds, methods of using the compounds, and methods of assessing patients regarding the compounds. These patents include U.S. Patent No.
9,364,460, which was issued on June 14, 2016; U.S. Patent No. 9,572,793, which issued on February 21, 2017; U.S. Patent No. 9,844,534, which was
issued December 19, 2017; and EP Patent No. 2897610, which was issued on January 10, 2018.

To the knowledge of the Company’s management, there are no contested proceedings or third-party claims over any of our patent applications.
Our success depends upon our ability to protect our technologies through intellectual property agreements including patents, trademarks, know-how, and
confidentiality agreements. However, there can be no assurance that the above-mentioned patent applications will be approved by the appropriate agencies.

All of the technology for which patents are currently sought is owned by the Company. Our patents are entirely owned or exclusively licensed by

the Company.

Competition

Cancer immunotherapy has become a significant growth area for the biopharmaceutical industry, attracting large pharmaceutical companies as
well as small niche players. Generally, our principal competitors in the cancer immunotherapy market comprise both companies with currently approved
products for various indications, such as manufacturers of approved bispecific antibodies, CAR-T cells, and checkpoint inhibitors, as well as companies
currently engaged in cancer immunotherapy clinical development. The large and medium-size players who have successfully obtained approval for cancer
immunotherapy products include Bristol-Myers Squib Company, Merck & Co., Inc., Genentech, Inc. (a subsidiary of Roche Holding AG), AstraZeneca
PLC, Celgene Corporation, Johnson & Johnson/Janssen Pharmaceuticals, Amgen, Novartis, Acerta Pharmaceuticals (a subsidiary of AstraZeneca), Juno
Therapeutics, Inc. (a subsidiary of Celgene), Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc. and Pfizer, Inc./EMD Serono, Inc. Most
of these companies, either alone or together with their collaborative partners, have substantially greater financial resources than does BriaCell.

Companies developing novel products with similar indications to those we are pursuing are expected to influence our ability to penetrate and
maintain market share. For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the chance of long-
term disease-free survival. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In
addition, the HER2 targeted drug trastuzumab (HERCEPTIN), alone or in combination with pertuzumab (PERJETA), both manufactured and marketed by
Roche/Genentech, may be given to patients with tumors with high expression of HER2 (IHC 3+), as well as other novel targets such as MUC1, which may
be useful in treating breast cancer. In addition, the FDA approved the first ever immunotherapy regimen for breast cancer to the Roche/Genentech PD-L1
checkpoint inhibitor atezolizumab (TECENTRIQ), combined with Celgene’s nab-paclitaxel (ABRAXANE) for TNBC that cannot be removed with surgery
and is locally advanced or metastatic.

There are a number of cancer vaccines in development for breast cancer, including but not limited to TPIV200 (Marker Therapeutics, Inc.), AE-37
(Antigen Express), and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, and AE-37 has published
data in the HER2 breast cancer patient population, there is no guarantee that any of these compounds will not in the future be indicated for treatment of
low-to-intermediate HER2 breast cancer patients and become directly competitive with NPS.

Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we
do, and also have greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly,
our competitors may be more successful than us in obtaining approval for cancer immunotherapy products and achieving widespread market acceptance.
Our competitors’ treatments may be more effectively marketed and sold than any products we may commercialize, thus causing limited market share
before we can recover the expenses of developing and commercializing of our cancer immunotherapy product candidate.

Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a
smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These activities may lead to consolidated efforts that allow for more rapid development of cancer
immunotherapy product candidates.

These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, the ability to work with
specific clinical contract organizations due to conflicts of interest, and the conduct of trials in the ability to recruit clinical trial sites and subjects for our
clinical trials.

We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, price and the
availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our
competitors develop and commercialize products that are viewed as safer, more convenient or less expensive than any products that we may develop. Our
competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our current product
candidates or any other future product candidate, which could result in our competitors establishing a strong market position before we are able to enter the
market.

Employees

As of the date of this filing, we had eleven full-time employees and one part-time employee, located in various US states including: NY, CA, PA,

SC, HI, and NJ. We also have international employees located in Canada and Israel.

For the year ended July 31, 2023, the average number of employees has been sixteen, of whom four were executive management (July 31, 2022 –

eight).

Research and Development Activities and Costs

For information regarding our clinical studies, please see above under the caption “Description of the Business – Clinical Trials.”

For the years ended July 31, 2023 and 2022, we incurred $14,264,048 and $7,585,926, respectively, of net research and development expenses

(excluding share based compensation allocated to research and development employees)

Manufacturing

We do not own or operate manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own
manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for all of our required raw materials, active
pharmaceutical ingredients, and finished product candidate for our clinical trials. We currently employ internal resources and third-party consultants to
manage our manufacturing contractors.

Bria-IMT™ is currently manufactured under current Good Manufacturing Practices (“cGMP”) pursuant to agreements with UC Davis and with

KBI, which is located in The Woodlands, Texas.

On June 11, 2015, the Company entered into an Agreement for Services with The Regents of the University of California, acting for and on behalf
of UC Davis, pursuant to which UC Davis manufactures Bria-IMT™ (previously known as BriaVax) at its GMP facility. The Company pays UC Davis
certain hourly rates depending on the specific services provided by UC Davis in connection with its manufacturing of Bria-IMT™.

Pursuant to the Company’s master services agreement with KBI, dated March 17, 2017, KBI has conducted developmental studies to derive and
optimize a cryopreserved formulation of Bria-IMT™ (previously known as BriaVax) as a research working cell bank of final drug product doses suitable
for cold chain shipment (the “KBI Services”). The Company pays for the cost of materials, consumables, and third party services, plus an additional 5% fee
to compensate KBI for the cost of purchasing, material handling, inventory and administration and management of third party services necessary for KBI to
perform the KBI Services. The master services agreement with KBI terminates on May 4, 2027.

On July 5, 2022, BriaCell announced that it had entered into a manufacturing service agreement with Waisman Biomanufacturing at the University
of Wisconsin–Madison (“Waisman”), to manufacture Bria-Pros™, BriaCell’s off-the-shelf personalized immunotherapy for prostate cancer, for anticipated
use in clinical studies. Waisman is a leading contract manufacturing organization with experience in the manufacturing of cellular therapies for clinical
trials. Under the terms of the agreement, Waisman will be responsible for GMP manufacturing of Bria-Pros™ for anticipated use in clinical studies.
Waisman’s expert team will be working closely with BriaCell’s scientific and product development teams to ensure timely production of Bria-Pros™ in
compliance with applicable regulatory requirements by the FDA.

Sales and Marketing

Our future commercial strategy may include the use of strategic partners, distributors, a contract sale force, or the establishment of our own
commercial and specialty sales force, as well as similar strategies for regions and territories outside the United States. We plan to further evaluate these
alternatives as we approach approval for the use of our product candidates for one or more indications.

Property, Plant and Equipment

The Company does not own any real property. BriaCell’s corporate offices in Canada are located at Suite 300, Bellevue Centre, 235-15th Street,
West Vancouver, BC V7T 2XI, and its corporate and research offices in the United States are located at 2929 Arch Street 3rd Floor, Philadelphia, PA 19104.

We consider our current office space sufficient to meet our anticipated needs for the foreseeable future and suitable for the conduct of our

business.

Government Regulation

The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other
things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution,
record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are
developing. Along with third-party contractors, we will be required to navigate the various preclinical, clinical and commercial approval requirements of
the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our current or future product
candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and
regulations require the expenditure of substantial time and financial resources. A company can make only those claims relating to safety and efficacy,
purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.

●

The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:

completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s current Good Laboratory Practices (“GLP”)
regulations;

submission to the FDA of an Investigational New Drug Application (“IND”), which must become effective before clinical trials may begin and
must be updated annually or when significant changes are made;

approval by an independent Institutional Review Board (“IRB”) or ethics committee at each clinical site before the trial is begun;

performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product
candidate for its intended purpose;

preparation of and submission to the FDA of a Biologics License Application (“BLA”), after completion of all pivotal clinical trials;

satisfactory completion of an FDA Advisory Committee review, if applicable;

a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;

satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to
assess compliance with cGMP, and to assure that the facilities, methods and controls are adequate to preserve the biological product’s continued
safety, purity and potency, and of selected clinical investigations to assess compliance with current Good Clinical Practices (“GCP”); and

FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States, which
must be updated annually when significant changes are made.

The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our
current or future product candidates will be granted on a timely basis, if at all. Prior to beginning the first clinical trial with a product candidate, we must
submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug to humans. The central focus of
an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies
assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls
information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human
clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises
safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA
must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA
authorization to begin a clinical trial.

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety
and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during
product development and for any subsequent protocol amendments. Furthermore, an IRB for each site proposing to conduct the clinical trial must review
and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the clinical trial until
completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by a Data &
Safety Monitoring Board (“DSMB”) organized by the clinical trial sponsor, which provides authorization for whether or not a clinical trial may move
forward at designated check points based on access to certain data from the clinical trial, and may halt the clinical trial if it determines that there is an
unacceptable safety risk for subjects, or based on other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting
of ongoing clinical studies and clinical trial results to public registries.

For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.

●

Phase 1-The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These
studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side
effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.

Phase 2-The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical
trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. In some cases, FDA will grant
preliminary marketing authorization for drugs treating areas of high unmet medical need based on Phase 2 clinical trials. If granted, they will also
require confirmatory Phase 3 evaluation post-marketing. BriaCell is evaluating Bria-IMT in patients with breast cancer who have failed at least
two prior lines of therapy. In this population there is no approved therapy. Therefore, the development plan for Bria-IMT is an area of high unmet
medical need. It is anticipated that BriaCell will not need to complete Phase 3 clinical trials prior to submitting the marketing application for Bria-
IMT in patients with advanced breast cancer who have failed at least two prior lines of therapy. In this case, a confirmatory Phase 3 evaluation
post-marketing will be required. It is anticipated that this would consist of a randomized, controlled clinical trial of Bria-IMT in combination with
immune checkpoint inhibitors compared with best available therapy. However, this design is subject to negotiation with the FDA.

Phase 3-The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These
clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product
approval.

Phase 4-In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA.

Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data
collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and
develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in
commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics,
the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that
the product candidate does not undergo unacceptable deterioration over its shelf life.

BLA Submission and Review by the FDA

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more
indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as
well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among
other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number
of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to FDA, and the
sponsor of an approved BLA is also subject to annual product and establishment user fees. These fees are typically increased annually. A waiver of user
fees may be obtained under certain limited circumstances.

Once a BLA has been submitted, the FDA’s goal is to review the application within ten months after it accepts the application for filing, or, if the
application relates to an unmet medical need in a serious or life-threatening indication, six months after the FDA accepts the application for filing. The
review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among
other things, whether a product is safe, pure and potent and whether the facility in which it is manufactured, processed, packed, or held meets standards
designed to assure the product’s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on
application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA
will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and
adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically
inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing
facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the
submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. The FDA
may not grant approval on a timely basis, or at all, and we may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental
approvals, which could delay or preclude us from marketing our products. After the FDA evaluates a BLA and conducts inspections of manufacturing
facilities where the investigational product and/or drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter.
An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response
Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter may request
additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional
testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.

If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed.
For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy plan to mitigate risks, which could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications.
Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if
problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess
and monitor the product’s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these
post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA’s
policies may change, which could delay or prevent regulatory approval of our products under development.

A sponsor may seek approval of its product candidate under programs designed to accelerate FDA’s review and approval of new drugs and
biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to
treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a product candidate with
Fast Track designation, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant
criteria are met. A Fast Track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action
on the BLA at six months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed product
would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria are not met for
priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review
designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.

Under the Accelerated Approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to
predict clinical benefit, or a clinical endpoint that can be measured earlier than irreversible morbidity or mortality and that is reasonably likely to predict an
effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to
verify the biologic’s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit.

In addition, a sponsor may seek FDA designation of its product candidate as a Breakthrough Therapy, if the product candidate is intended, alone or
in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence
indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to
expedite the development and review of the application. Breakthrough designation also allows the sponsor to file sections of the BLA for review on a
rolling basis.

Fast Track, Priority Review and Breakthrough Therapy designations do not change the standards for approval but may expedite the development

or approval process.

Other Healthcare Laws and Compliance Requirements

Our sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and
law enforcement authorities in the United States in addition to the FDA, including potentially the Federal Trade Commission, the Department of Justice, the
Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services, and state and local governments. Our
promotional and scientific/educational programs must comply with the federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, the False Claims
Act (“FCA”), the Veterans Health Care Act, physician payment transparency laws, privacy laws, security laws, and additional state laws similar to the
foregoing.

The federal Anti-Kickback Statute prohibits, among other things, the offer, receipt, or payment of remuneration in exchange for or to induce the
referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs.
Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. The
government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham research or consulting and other
financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to
have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-
Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Many states have similar laws that apply to their state health care
programs as well as private payors.

The FCA imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a
federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for
services not provided as claimed, or for services that are not medically necessary. Actions under the FCA may be brought by the Attorney General or as a
qui tam action by a private individual in the name of the government. Violations of the FCA can result in significant monetary penalties and treble
damages. For example, the federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of
pharmaceutical and biotechnology companies throughout the country, in connection with the promotion of products for unapproved uses and other sales
and marketing practices. The government has obtained multi-million and multibillion dollar settlements under the FCA in addition to individual criminal
convictions under applicable criminal statutes. In addition, companies have been forced to implement extensive corrective action plans, and have often
become subject to consent decrees or corporate integrity agreements, restricting the manner in which they conduct their business. The federal Health
Insurance Portability and Accountability Act of 1996 (“HIPAA”) also created federal criminal statutes that prohibit, among other things, knowingly and
willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for
healthcare benefits, items or services. Given the significant size of actual and potential settlements, it is expected that the government will continue to
devote substantial resources to investigating healthcare providers’ and manufacturers’ compliance with applicable fraud and abuse laws.

In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Affordable Care
Act”), among other things, imposed new reporting requirements on drug manufacturers for payments or other transfers of value made by them to
physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit
required information may result in civil monetary penalties. Certain states also mandate implementation of commercial compliance programs, impose
restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians
and other healthcare professionals.

We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
HIPAA, as amended by the Health Information Technology and Clinical Health Act (“HITECH”) and their respective implementing regulations, imposes
specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH
makes HIPAA’s privacy and security standards directly applicable to “business associates,” defined as independent contractors or agents of covered entities
that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH
also increases the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gives state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees
and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain
circumstances, many of which differ from each other in significant ways and may not have the same effect.

If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to it, we may be subject to
penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from
participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our
financial results. Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their
intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business. We cannot assure you that our
internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners,
collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact
on our business, results of operations and reputation.

Coverage and Reimbursement

Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party payors include
government health administrative authorities, managed care providers, private health insurers and other organizations. Although we currently believe that
third-party payors will provide coverage and reimbursement for our product candidates, if approved, these third-party payors are increasingly challenging
the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of
newly approved healthcare products. We may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of our product
candidates. Seeking coverage and reimbursement from third-party payors can be time consuming and expensive. Moreover, a payor’s decision to provide
coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement may not be available or sufficient to
allow us to sell our products on a competitive and profitable basis.

Foreign Regulation

In addition to regulations in the United States, we are and will be subject, either directly or through our distribution partners, to a variety of

regulations in other jurisdictions governing, among other things, clinical trials and commercial sales and distribution of our products, if approved.

Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have processes
that require the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In Europe, for example, a
clinical trial application (“CTA”) must be submitted to the competent national health authority and to independent ethics committees in each country in
which a company plans to conduct clinical trials. Once the CTA is approved in accordance with a country’s requirements, clinical trials may proceed in that
country.

The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country,
even though there is already some degree of legal harmonization in the European Union (the “E.U.”) member states resulting from the national
implementation of underlying E.U. legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory
requirements.

To obtain regulatory approval of a new drug or medicinal product in the E.U., a sponsor must obtain approval of a marketing authorization

application. The way in which a medicinal product can be approved in the E.U. depends on the nature of the medicinal product.

The centralized procedure results in a single marketing authorization granted by the European Commission that is valid across the E.U., as well as
in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as
genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes,
neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated as “orphan drugs” and (iv) advanced-
therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant
also be used for human drugs which do not fall within the above mentioned categories if the human drug (a) contains a new active substance which was not
authorized in the European Community; or (b) the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical
innovation or that the granting of authorization in the centralized procedure is in the interests of patients or animal health at the European Community level.

Under the centralized procedure in the E.U., the maximum timeframe for the evaluation of a marketing authorization application by the EMA is
210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the
Committee for Medicinal Products for Human Use (“CHMP”)), with adoption of the actual marketing authorization by the European Commission
thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health
interest from the point of view of therapeutic innovation, defined by three cumulative criteria: (i) the seriousness of the disease to be treated, (ii) the
absence of an appropriate alternative therapeutic approach, and (iii) anticipation of exceptional high therapeutic benefit. In this circumstance, EMA ensures
that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.

The Mutual Recognition Procedure (“MRP”) for the approval of human drugs is an alternative approach to facilitate individual national marketing
authorizations within the E.U. The MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is applicable
to the majority of conventional medicinal products, and is based on the principle of recognition of an already existing national marketing authorization by
one or more member states.

The characteristic of the MRP is that the procedure builds on an already existing marketing authorization in a member state of the E.U. that is used
as reference in order to obtain marketing authorizations in other E.U. member states. In the MRP, a marketing authorization for a drug already exists in one
or more member states of the E.U. and subsequently marketing authorization applications are made in other E.U. member states by referring to the initial
marketing authorization. The member state in which the marketing authorization was first granted will then act as the reference member state. The member
states where the marketing authorization is subsequently applied for act as concerned member states.

The MRP is based on the principle of the mutual recognition by E.U. member states of their respective national marketing authorizations. Based
on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member states. In such case, the
reference member state shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies of the report are sent
to all member states, together with the approved summary of product characteristics, labeling and package leaflet. The concerned member states then have
90 days to recognize the decision of the reference member state and the summary of product characteristics, labeling and package leaflet. National
marketing authorizations shall be granted within 30 days after acknowledgement of the agreement.

Should any E.U. member state refuse to recognize the marketing authorization by the reference member state, on the grounds of potential serious
risk to public health, the issue will be referred to a coordination group. Within a timeframe of 60 days, member states shall, within the coordination group,
make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The opinion of this EMA
Committee is then forwarded to the Commission, for the start of the decision-making process. As in the centralized procedure, this process entails
consulting various European Commission Directorates General and the Standing Committee on Human Medicinal Products or Veterinary Medicinal
Products, as appropriate.

For other countries outside of the E.U., such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance
with GCP and the other applicable regulatory requirements.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials,

suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Plan of Arrangement

On August 31, 2023, the Company closed a plan of arrangement spinout transaction (the “Arrangement”). Pursuant to the Arrangement, certain
pipeline assets of the Company were spun-out to BriaPro Therapeutics Corp. (“BriaPro” or “SpinCo”), including Bria-TILsRx™ and protein kinase C delta
(PKCδ) inhibitors for multiple indications including cancer (the “BriaPro Assets”), resulting in a two-third (2/3) owned subsidiary of the Company with the
remaining one-third (1/3) held by the Company’s shareholders. BriaPro has acquired the entire right and interest in and to the BriaPro Assets in
consideration for the issuance by BriaPro to the Company of BriaPro’s common shares. Under the terms of the Arrangement, for each common share of the
Company held immediately prior to closing, the shareholders of the Company received one common share of BriaPro, and one new common share of the
Company (retiring their old share) having the same terms and characteristics as the existing common shares of the Company. The Company’s common
shares and public warrants remained listed on the Nasdaq Capital Market and the common shares remained listed on the Toronto Stock Exchange, and
SpinCo is an unlisted reporting issuer in Canada. As part of the Arrangement, the Company obtained a third-party independent valuation for BriaPro which
amounted to $1.75 million. Based on the number of issued shares of BriaPro, this amounts to $0.0365 per BriaPro share.

BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s
own cancer-fighting cells to destroy cancerous tumors. Using artificial intelligence (“AI”) with ImmunoPrecise Antibodies and Receptor AI, BriaPro will
identify drug candidates.

The lead drug discovery candidates for BriaPro includes:

● Bria-TILsRx™: Multi-Specific Binding Reagents – Immunotherapy for Cancer: being developed in collaboration with ImmunoPrecise

Antibodies.

● Small Molecule Program: Protein Kinase C delta (PKCδ) Inhibitors being developed with Receptor AI.

The power of AI in drug candidate selection has been hailed by experts and investments in AI-driven drug discovery companies have tripled over
the past four years, reaching $24.6 billion in 2022.2 Using AI technology to identify the next blockbuster therapies can help eliminate some of the
guesswork that typically requires hundreds of lab experiments—often spread over many years—to identify promising molecules.

Instead of coming up with tens of thousands of compounds to figure out, computers suggest testing ten compounds in a lab, then getting feedback
from the lab results. The machines learn from those results to make a better prediction to provide the next hundred candidates for testing and ultimately
filter to one molecule.

Over the course of the next year, BriaPro expects to screen several different multi specific binding reagents for activity in vitro as well as in mouse
models of cancer. BriaPro also expects to select at least one candidate to advance into IND enabling studies. Human clinical studies are expected to be
initiated in the first half of 2025. In parallel, BriaPro will continue to optimize the structure of its proprietary protein kinase C delta inhibitors and advance
to the candidates election stage. Human clinical studies are expected to be initiated in the second half of 2025.

Recent Developments

On May 9, 2023, the Company entered into a Master Service and Technology Agreement (the “MST Agreement”) with Prevail InfoWorks, Inc.
(“InfoWorks”) pursuant to which InfoWorks will provide clinical services and technologies for the Company’s upcoming pivotal study in advanced
metastatic breast cancer. The Company has agreed to pay InfoWorks $5,379,945 upon signing of the MST Agreement and pay InfoWorks additional fees
upon the achievement of certain milestones.

On May 12, 2023, the Company entered into a stock purchase agreement (the “Prevail Partners Purchase Agreement”) with Prevail Partners, LLC,
an investment fund and affiliate of InfoWorks, pursuant to which the Company agreed to issue 463,408 common shares for an aggregate purchase price of
$4,000,000. The funds received were used to pay amounts owed to InfoWorks under the MST Agreement.

ITEM 1A. RISK FACTORS

An investment in our securities involves a high degree of risk. An investor should carefully consider the risks described below as well as other information
contained in this Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission (“SEC”). The risks and
uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are
immaterial may also impair our business operations. If any of the following risks actually occur, our business, financial condition or results of operations
could be materially adversely affected, the value of our securities could decline, and investors in our company may lose all or part of their investment.

Risks Related to Our Business

We have a history of losses, may incur future losses and may not achieve profitability

BriaCell is a development stage immune-oncology biotechnology corporation that to date has not recorded any revenues from the sale of
diagnostic or therapeutic products. Since incorporation, BriaCell has accumulated net losses and expects such losses to continue as it commences product
and pre-clinical development and eventually enters into license agreements for its technology. We incurred net losses of $20,302,394 and $26,838,903 in
the fiscal years ended 2023 and 2022, respectively. Management expects to continue to incur substantial operating losses unless and until such time as
product sales generate sufficient revenues to fund continuing operations. BriaCell has neither a history of earnings nor has it paid any dividends, and it is
unlikely to pay dividends or enjoy earnings in the immediate or foreseeable future.

We are a pre-revenue clinical stage company

The Company is developing novel technologies that may not be efficacious or safe. The Company expects to spend a significant amount of capital
to fund research and development. As a result, the Company expects that its operating expenses will increase significantly and, consequently, it will need to
generate significant revenues to become profitable. Even if the Company does become profitable, it may not be able to sustain or increase profitability on a
quarterly or annual basis. The Company cannot predict when, if ever, it will be profitable. There can be no assurances that the intellectual property of
BriaCell, or other technologies it may acquire, will meet applicable regulatory standards, obtain required regulatory approvals, be capable of being
produced in commercial quantities at reasonable costs, or be successfully marketed. The Company will be undertaking additional laboratory studies or trials
with respect to the intellectual property of BriaCell, and there can be no assurance that the results from such studies or trials will result in a commercially
viable product or will not identify unwanted side effects.

We have an unproven market for our product candidates

The Company believes that the anticipated market for its potential products and technologies if successfully developed will continue to exist and
expand. These assumptions may prove to be incorrect for a variety of reasons, including competition from other products and the degree of commercial
viability of the potential product.

We may not succeed in adapting to and meeting the business needs associated with our anticipated growth

Anticipated growth in all areas of BriaCell’s business is expected to continue to place a significant strain on its managerial, operational and
technical resources. The Company expects operating expenses and staffing levels to increase in the future. To manage such growth, the Company must
expand its operational and technical capabilities and manage its employee base while effectively administering multiple relationships with various third
parties. There can be no assurance that the Company will be able to manage its expanding operations effectively. Any failure to implement cohesive
management and operating systems, to add resources on a cost-effective basis or to properly manage the Company’s expansion could have a material
adverse effect on its business and results of operations.

BriaPro may not generate revenue as expected

We are a majority shareholder of BriaPro. BriaPro may not generate financial returns or may not yield the desired business outcome. The success
of our investment in a company is sometimes dependent on the availability of additional funding on favorable terms or a liquidity event such as an initial
public offering. We may record impairment charges in relation to our strategic investments which will have a negative impact on our financial position.

This may expose us to additional reputational, financial, legal, compliance or operational risks. This could impact our return on our investment. In

the event BriaPro fails to generate revenue, this may erode or dilute its value to our shareholders.

We are heavily reliant on third-parties to carry out a large portion of our business

The Company does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful, a
product must be manufactured and packaged in commercial quantities in compliance with regulatory requirements and in reasonable time frames and at
accepted costs. The Company intends to contract with third parties to develop its products. No assurance can be given that the Company or its suppliers
will be able to meet the supply requirements in respect of the product development or commercial sales.

Production of therapeutic products may require raw materials for which the sources and amount of supply are limited, or may be hindered by
quality or scheduling issues in respect of the third party suppliers over which the Company has limited control. An inability to obtain adequate supplies of
raw materials could significantly delay the development, regulatory approval and marketing of a product. The Company has limited in-house personnel to
internally manage all aspects of product development, including the management of multi-center clinical trials. The Company is significantly reliant on
third-party consultants and contractors to provide the requisite advice and management. There can be no assurance that the clinical trials and product
development will not encounter delays which could adversely affect prospects for the Company’s success.

To be successful, an approved product must also be successfully marketed. The market for the Company’s product being developed by the
Company may be large and will require substantial sales and marketing capability. At the present time, the Company does not have any internal capability
to market pharmaceutical products. The Company intends to enter into one or more strategic partnerships or collaborative arrangements with
pharmaceutical companies or other companies with marketing and distribution expertise to address this need. If necessary, the Company will establish
arrangements with various partners for geographical areas. There can be no assurance that the Company can market, or can enter into a satisfactory
arrangement with a third party to market a product in a manner that would assure its acceptance in the marketplace. However, if a satisfactory arrangement
with a third party to market and/or distribute a product is obtained; the Company will be dependent on the corporate collaborator(s) who may not devote
sufficient time, resources and attention to the Company’s programs, which may hinder efforts to market the products.

Should the Company not establish marketing and distribution strategic partnerships and collaborative arrangements on acceptable terms, and
undertake some or all of those functions, the Company will require significant additional human and financial resources and expertise to undertake these
activities, the availability of which is not guaranteed. The Company will rely on third parties for the timely supply of raw materials, equipment, contract
manufacturing, and formulation or packaging services. Although the Company intends to manage these third-party relationships to ensure continuity and
quality, some events beyond the Company’s control could result in complete or partial failure of these goods and services. Any such failure could have a
material adverse effect on the financial conditions and result of operation of the Company.

Due to the complexity of the process of developing pharmaceutical products, the Company’s business may depend on arrangements with
pharmaceutical and biotechnology companies, corporate and academic collaborators, licensors, licensees and others for the research, development, clinical
testing, technology rights, manufacturing, marketing and commercialization of its products. Such agreements could obligate the Company to diligently
bring potential products to market, make milestone payments and royalties that, in some instances, could be substantial, and incur the costs of filing and
prosecuting patent applications. There can be no assurance that the Company will be able to establish or maintain collaborations that are important to its
business on favorable terms, or at all.

A number of risks arise from the Company’s potential dependence on collaborative agreements with third parties. Product development and
commercialization efforts could be adversely affected if any collaborative partner terminates or suspends its agreement with the Company, causes delays,
fails to on a timely basis develop or manufacture in adequate quantities a substance needed in order to conduct clinical trials, fails to adequately perform
clinical trials, determines not to develop, manufacture or commercialize a product to which it has rights, or otherwise fails to meet its contractual
obligations. The Company’s collaborative partners could pursue other technologies or develop alternative products that could compete with the products
the Company is developing.

The Company has signed Non-Disclosure Agreements (“NDA”) with many different third parties. As is customary in the industry. There is no
guarantee that, despite the terms of the NDA which bind third parties, the Company will ultimately be able to prevent from such third parties from
breaching their obligations under the NDA. Use of the Company’s confidential information in an unauthorized manner is likely to negatively affect the
Company.

Pre-clinical studies and initial clinical trials are not necessarily predictive of future results

Pre-clinical tests and Phase I/II clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to
understand the side effects of product candidates at various doses and schedules. Success in pre-clinical and early clinical trials does not ensure that later
large-scale efficacy trials will be successful, nor does it predict final results. Favorable results in early trials may not be repeated in later trials.

A number of companies in the life sciences industry have suffered significant setbacks in advanced clinical trials, even after positive results in
earlier trials. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Negative or
inconclusive results or adverse medical events during a clinical trial could cause a clinical trial to be delayed, repeated or terminated. Any pre-clinical data
and the clinical results obtained for BriaCell’s technology may not predict results from studies in larger numbers of subjects drawn from more diverse
populations or in the commercial setting, and also may not predict the ability of our products to achieve their intended goals, or to do so safely.

An inability to obtain raw materials or product supply could have a material adverse effect on the Company’s business, financial condition and results
of operations

Raw materials and supplies are generally available in quantities to meet the needs of the Company’s business. The Company will be dependent on
third-party manufacturers for the pharmaceutical products that it markets An inability to obtain raw materials or product supply could have a material
adverse impact on the Company’s business, financial condition and results of operations.

We must obtain additional capital to continue our operations

The Company anticipates that additional capital will be required to complete its current research and development programs. It is anticipated that
future research, additional pre-clinical and toxicology studies and manufacturing initiatives, including to prepare for market approval and successful
product market launch, will require additional funds. Further financing may dilute the current holdings of shareholders and may thereby result in a loss for
the shareholders. There can be no assurance that the Company will be able to obtain adequate financing, or financing on terms that are reasonable or
acceptable for these or other purposes, or to fulfill the Company’s obligations under various license agreements. Failure to obtain such additional financing
could result in delay or indefinite postponement of further research and development of the Company’s technologies with the possible loss of license rights
to these technologies.

We are highly dependent on our key personnel

Although the Company is expected to have experienced senior management and personnel, the Company will be substantially dependent upon the
services of a few key personnel, particularly Dr. William V. Williams, Dr. Giuseppe Del Priore, Dr. Miguel Lopez-Lago and other professionals for the
successful operation of its business. Phase I of the Company’s research and development is planned to be completed by qualified professionals and is
expected to concentrate on treatment of advanced breast cancer. The loss of the services of any of these personnel could have a material adverse effect on
the business of the Company. The Company may not be able to attract and retain personnel on acceptable terms given the intense competition for such
personnel among high technology enterprises, including biotechnology and healthcare companies, universities and non-profit research institutions. If we
lose any of these persons, or are unable to attract and retain qualified personnel, our business, financial condition and results of operations may be
materially and adversely affected.

BriaCell in the future may acquire businesses, products or technologies that it believes complement or expand its existing business.

Acquisitions of this type involve a number of risks, including the possibility that the operations of the acquired business will not be profitable or
that the attention of the Company’s management will be diverted from the day-to-day operation of its business. An unsuccessful acquisition could reduce
the Company’s margins or otherwise harm its financial condition.

If the Company experiences a data security breach and confidential information is disclosed, the Company may be subject to penalties and experience
negative publicity

The Company and its customers could suffer harm if personal and health information were accessed by third parties due to a system security
failure. The collection of data requires the Company to receive and store a large amount of personally identifiable data. Recently, data security breaches
suffered by well-known companies and institutions have attracted a substantial amount of media attention, prompting legislative proposals addressing data
privacy and security. The Company may become exposed to potential liabilities with respect to the data that it collects, manages and processes, and may
incur legal costs if information security policies and procedures are not effective or if the Company is required to defend its methods of collection,
processing and storage of personal data. Future investigations, lawsuits or adverse publicity relating to its methods of handling such information could have
a material adverse effect on the Company’s business, financial condition and results of operations due to the costs and negative market reaction relating to
such developments.

We may not succeed in completing the development of our products, commercializing our products or generating significant revenues

Since commencing our operations, we have focused on the research and development and limited clinical trials of our product candidates. Our
ability to generate revenues and achieve profitability depends on our ability to successfully complete the development of our products, obtain market
approval and generate significant revenues. The future success of our business cannot be determined at this time, and we do not anticipate generating
revenues from product sales for the foreseeable future. In addition, we face a number of challenges with respect to our future commercialization efforts,
including, among others, that:

● we may not have adequate financial or other resources to complete the development of our product, including two stages of clinical

development that are necessary in order to commercialize our products;

● we may not be able to manufacture our products in commercial quantities, at an adequate quality or at an acceptable cost;

● we may not be able to maintain our CE mark due to regulatory changes;

● we may never receive FDA or Health Canada approval for our intended development plans;

● we may not be able to establish adequate sales, marketing and distribution channels;

● healthcare professionals and patients may not accept our product candidates;

● technological breakthroughs in cancer detection, treatment and prevention may reduce the demand for our product candidates;

● changes in the market for cancer treatment, new alliances between existing market participants and the entrance of new market participants

may interfere with our market penetration efforts;

● third-party payors may not agree to reimburse patients for any or all of the purchase price of our products, which may adversely affect

patients’ willingness to purchase our product candidates;

● uncertainty as to market demand may result in inefficient pricing of our product candidates;

● we may face third-party claims of intellectual property infringement;

● we may fail to obtain or maintain regulatory approvals for our products candidates in our target markets or may face adverse regulatory or

legal actions relating to our product candidates even if regulatory approval is obtained; and

● we are dependent upon the results of ongoing clinical studies relating to our product candidates and the products of our competitors. We may

fail in obtaining positive results.

If we are unable to meet any one or more of these challenges successfully, our ability to effectively commercialize our product candidates could be

limited, which in turn could have a material adverse effect on our business, financial condition and results of operations.

If product liability lawsuits are brought against us, we may incur substantial liabilities and the commercialization of our drug candidates may be
affected

As our drug candidates are currently in clinical trials, we face an inherent risk of product liability suits and will face an even greater risk if we
obtain approval to commercialize any drugs. For example, we may be sued if our drug candidates cause or are perceived to cause injury or are found to be
otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in
manufacturing, defects in design, a failure to warn of dangers inherent in the drug, negligence, strict liability or a breach of warranties. Claims could also be
asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our drug candidates. Even successful defense would require significant financial and management
resources. Regardless of the merits or eventual outcome, liability claims may result in:

● decreased demand for our drugs;

● injury to our reputation;

● withdrawal of clinical trial participants and inability to continue clinical trials;

● initiation of investigations by regulators;

● costs to defend the related litigation;

● diversion of management’s time and our resources;

● substantial monetary awards to trial participants or patients;

● product recalls, withdrawals or labeling, marketing or promotional restrictions;

● loss of revenue;

● exhaustion of any available insurance and our capital resources;

● the inability to commercialize any drug candidate; and

● a decline in the price of our common shares.

We believe that we currently have appropriate insurance covering clinical trials. However, it may transpire that the amount of such insurance
coverage may not be adequate, we may be unable to maintain such insurance, or we may not be able to obtain additional or replacement insurance at a
reasonable cost, if at all. Any inability to maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability
claims could prevent or inhibit the commercialization of drugs we develop, alone or with collaborators. Our insurance policies may also have various
exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or
negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such
indemnification may not be available or adequate should any claim arise.

Additionally, we may be sued if the products that we commercialize, market or sell cause or are perceived to cause injury or are found to be

otherwise unsuitable, and may result in:

● decreased demand for those products;

● damage to our reputation;

● costs incurred related to product recalls;

● limiting our opportunities to enter into future commercial partnerships; and

● a decline in the price of our common shares.

Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and conflicts,
such as the conflict between Russia and Ukraine and rising tensions in the Middle East, could make it more difficult for us to access financing and
could adversely affect our business and operations.

Our ability to raise capital is subject to the risk of adverse changes in the market value of our stock. Periods of macroeconomic weakness or
recession and heightened market volatility caused by adverse geopolitical developments could increase these risks, potentially resulting in adverse impacts
on our ability to raise further capital on favorable terms. The impact of geopolitical tension, such as rising tensions in the Middle East, a deterioration in the
bilateral relationship between the US and China or an escalation in conflict between Russia and Ukraine, including any resulting sanctions, export controls
or other restrictive actions that may be imposed by the US and/or other countries against governmental or other entities in, for example, Russia, also could
lead to disruption, instability and volatility in global trade patterns, which may in turn impact our ability to source necessary reagents, raw materials and
other inputs for our research and development operations.

We may be adversely affected by the effects of inflation.

Inflation has the potential to adversely affect our business, results of operations, financial position and liquidity by increasing our overall cost
structure, particularly if we are unable to achieve commensurate increases in the prices we charge our customers. The existence of inflation in the economy
has the potential to result in higher interest rates and capital costs, supply shortages, increased costs of labor and other similar effects. As a result of
inflation, we may experience increases in the costs of labor, materials, and other inputs, such as engineering consultants. Although we may take measures
to mitigate the impact of this inflation, if these measures are not effective our business, results of operations, financial position and liquidity could be
materially adversely affected. Even if such measures are effective, there could be a difference between the timing of when these beneficial actions impact
our results of operations and when the cost inflation is incurred.

Risks Related to Our Intellectual Property

We may not successfully develop, maintain and protect our proprietary products and technologies

BriaCell’s success depends to a significant degree upon its ability to develop, maintain and protect proprietary products and technologies. BriaCell
files patent applications in the United States and other countries as part of its global strategy to protect its intellectual property and maintains certain U.S.
and Non-U.S. patents in its intellectual property portfolio. However, patents provide only limited protection of BriaCell’s intellectual property. The
assertion of patent protection involves complex legal and factual determinations and is therefore uncertain and can be expensive. BriaCell cannot provide
assurances that patents will be granted with respect to any of its pending patent applications, or that the scope of any of its granted patents, or any patents
granted in the future, will be sufficiently broad to offer meaningful protection, or that it will develop and file patent applications on additional proprietary
technologies that are patentable, or, if patentable, that any patents will be granted from such patent applications. BriaCell’s current or future patents could
be successfully challenged, invalidated or circumvented. This could result in BriaCell’s patent rights failing to create an effective competitive barrier.
Losing a significant patent or failing to get a patent to issue from a pending patent application that BriaCell considers significant could have a material
adverse effect on BriaCell’s business. The laws governing the scope of patent coverage in various countries continue to evolve. The laws of some foreign
countries may not protect BriaCell’s intellectual property rights to the same extent as the laws of the United States. BriaCell has applied for patent
protection only in selected countries. Therefore, third parties may be able to replicate BriaCell technologies covered by BriaCell’s patent portfolio in
countries in which it does not have patent protection.

BriaCell’s future success and competitive position depends in part upon its ability to maintain its intellectual property portfolio. There can be no

assurance that any patents will be issued on any existing or future patent applications.

We are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages or prohibit us from selling our
product candidates

There is a substantial amount of litigation over patent and other intellectual property rights in the biotechnology industry. Whether or not a product
infringes a patent involves complex legal and factual considerations, the determination of which is often uncertain. Our management is presently unaware
of any other parties’ patents and proprietary rights which our products under development would infringe. Searches typically performed to identify
potentially infringed patents of third parties are often not conclusive and, because patent applications can take many years to issue, there may be
applications now pending, which may later result in issued patents which our current or future products may infringe or be alleged to infringe. In addition,
our competitors or other parties may assert that our product candidates and the methods employed may be covered by patents held by them. If any of our
products infringes a valid patent, we could be prevented from manufacturing or selling such product unless we are able to obtain a license or able to
redesign the product in such a manner as to avoid infringement. A license may not always be available or may require us to pay substantial royalties. We
also may not be successful in any attempt to redesign our product to avoid infringement, nor does a later redesign protect BriaCell from prior infringement.
Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate and can divert our
management’s attention from operating our business.

The steps we have taken to protect our intellectual property may not be adequate, which could have a material adverse effect on our ability to compete
in the market

BriaCell’s ability to establish and maintain a competitive position may be achieved in part by prosecuting claims against others who it believes to
be infringing its rights. In addition, enforcement of BriaCell’s patents in foreign jurisdictions will depend on the legal procedures in those jurisdictions. In
addition to filing patent applications, we rely on confidentiality, non-compete, non-disclosure and assignment of inventions provisions, as appropriate, in
our agreements with our employees, consultants, and service providers, to protect and otherwise seek to control access to, and distribution of, our
proprietary information. These measures may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or
misappropriation, for the following reasons:

● the agreements may be breached, may not provide the scope of protection we believe they provide or may be determined to be unenforceable;

● we may have inadequate remedies for any breach;

● proprietary information could be disclosed to our competitors; or

● others may independently develop substantially equivalent or superior proprietary information and techniques or otherwise gain access to our

trade secrets or disclose such technologies.

Specifically, with respect to non-compete agreements, both state law and precedent varies greatly from state to state and we may be unable to
enforce these agreements, in whole or in part, and it may be difficult for us to restrict our competitors from gaining the expertise that our former employees
gained while working for us. If our intellectual property is disclosed or misappropriated, it could harm our ability to protect our rights and could have a
material adverse effect on our business, financial condition and results of operations.

We may need to initiate lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could
cause us to lose some of our intellectual property rights, which would harm our ability to compete in the market

We rely on patents, confidentiality and trade secrets to protect a portion of our intellectual property and our competitive position. Patent law
relating to the scope of claims in the technology fields in which we operate is still evolving and, consequently, patent positions in the
biotechnology/pharmaceutical industry can be uncertain. In order to protect or enforce our patent rights, we may initiate patent and related litigation against
third parties, such as infringement suits or requests for injunctive relief. BriaCell’s ability to establish and maintain a competitive position may be achieved
in part by prosecuting claims against others who it believes to be infringing its rights. In addition, enforcement of BriaCell’s patents in foreign jurisdictions
will depend on the legal procedures in those jurisdictions. Any lawsuits that we initiate could be expensive, take significant time and divert our
management’s attention from other business concerns and the outcome of litigation to enforce our intellectual property rights in patents, copyrights, trade
secrets or trademarks is highly unpredictable. Litigation also puts our patents at risk of being invalidated or interpreted narrowly and our patent applications
at risk of not issuing, or adversely affect its ability to distribute any products that are subject to such litigation. In addition, we may provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, including attorney fees, if any,
may not be commercially valuable. The occurrence of any of these events could have a material adverse effect on our business, financial condition and
results of operations.

We may be subject to damages resulting from claims that we or our employees or contractors have wrongfully used or disclosed alleged trade secrets of
their former employers

Many of our employees and contractors were previously employed at universities or other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or any employee or
contractor have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of his or her former employers. Litigation may
be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize certain
therapeutic candidates, which could severely harm our business, financial condition and results of operations. Even if we are successful in defending
against these claims, litigation could result in substantial costs and be a distraction to management.

If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such
authorities do not grant our products appropriate periods of exclusivity before approving generic versions of our products, the sales of our products
could be adversely affected.

Once a new drug application is approved, the product covered thereby becomes a “reference listed drug” in the FDA’s publication, “Approved
Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the Orange Book. Manufacturers may seek approval of generic versions of
reference listed drugs through submission of abbreviated new drug applications in the United States. In support of an abbreviated new drug applications, a
generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage
form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the
reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring
to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the
introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.

The FDA may not approve abbreviated new drug applications for a generic product until any applicable period of non-patent exclusivity for the
reference listed drug has expired. The United States Federal Food, Drug, and Cosmetic Act provides a period of five years of non-patent exclusivity for a
new drug containing a new chemical entity (“NCE”). Specifically, in cases where such exclusivity has been granted, abbreviated new drug applications
may not be submitted to the FDA until the expiration of five years, unless the submission is accompanied by a Paragraph IV certification that a patent
covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application
four years following approval of the reference listed drug.

While we believe that our products contain active ingredients that would be treated as NCEs by the FDA and, therefore, if approved, should be
afforded five years of data exclusivity, the FDA may disagree with that conclusion and may approve generic products after a period that is less than five
years. If the FDA were to award NCE exclusivity to someone other than us, we believe that we would still be awarded three year “Other” exclusivity
protection from generic competition, which is awarded when an application or supplement contains reports of new clinical investigations (not
bioavailability studies) conducted or sponsored by an applicant and essential for approval. Manufacturers may seek to launch these generic products
following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product. If we do not maintain patent
protection and data exclusivity for our product candidates, our business may be materially harmed.

Competition that our products may face from generic versions of our products could materially and adversely impact our future revenue,

profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years
from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is
limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive
products, including generics or biosimilars. Given the amount of time required for the development, testing, and regulatory review of new product
candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed
patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Risks Related to Regulations

Changes in legislation and regulations may affect our revenue and profitability

Existing and proposed changes in the laws and regulations affecting public companies may cause the Company to incur increased costs as the
Company evaluates the implications of new rules and responds to new requirements. Failure to comply with new rules and regulations could result in
enforcement actions or the assessment of other penalties. New laws and regulations could make it more difficult to obtain certain types of insurance,
including director’s and officer’s liability insurance, and the Company may be forced to accept reduced policy limits and coverage or incur substantially
higher costs to obtain the same or similar coverage, to the extent that such coverage remains available.

The impact of these events could also make it more difficult for the Company to attract and retain qualified persons to serve on the Board, or as
executive officers. The Company may be required to hire additional personnel and utilize additional outside legal, accounting and advisory services, all of
which could cause the Company’s general and administrative costs to increase beyond what the Company currently has planned. Although the Company
evaluates and monitors developments with respect to new rules and laws, the Company cannot predict or estimate the amount of the additional costs the
Company may incur or the timing of such costs with respect to such evaluations and/or compliance and cannot provide assurances that such additional
costs will render the Company compliant with such new rules and laws.

If we or our licensees are unable to obtain U.S., Canadian and/or foreign regulatory approval for our product candidates, we will be unable to
commercialize our therapeutic candidates

To date, we have not marketed, distributed or sold an approved product. Our therapeutic candidates are subject to extensive governmental
regulations relating to development, clinical trials, manufacturing and commercialization of drugs. We may not obtain marketing approval for any of our
therapeutic candidates in a timely manner or at all. In connection with the clinical trials for our product candidates and other therapeutic candidates that we
may seek to develop in the future, either on our own or throughout licensing arrangements, we face the risk that:

● a product candidate may not prove safe or efficacious;

● the results with respect to any product candidate may not confirm the positive results from earlier preclinical studies or clinical trials;

● the results may not meet the level of statistical significance required by the FDA, Health Canada or other regulatory authorities; and

● the results will justify only limited and/or restrictive uses, including the inclusion of warnings and contraindications, which could significantly

limit the marketability and profitability of the therapeutic candidate.

Any delay or failure in obtaining the required regulatory approvals will materially and adversely affect our ability to generate future revenues from
a particular product candidate. Any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market
the product or may impose restrictive conditions of use, including cautionary information, thereby limiting the size of the market for the product. We and
our licensees, as applicable, also are, and will be, subject to numerous foreign regulatory requirements that govern the conduct of clinical trials,
manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks
associated with the FDA approval process that we describe above, as well as risks attributable to the satisfaction of foreign requirements. Approval by the
FDA does not ensure approval by regulatory authorities outside the United States. Foreign jurisdictions may have different approval processes than those
required by the FDA and may impose additional testing requirements for our therapeutic candidates.

If the third parties on which we rely to conduct our clinical trials and clinical development do not perform as contractually required or expected, we
may not be able to obtain regulatory clearance or approval for, or commercialize, our product candidates

We do not have the ability to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as
contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not
successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the
quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other
reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain
regulatory clearance for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results and prospects
may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of
their control.

Modifications to our product candidates, or to any other product candidates that we may develop in the future, may require new regulatory clearances
or approvals or may require us or our licensees, as applicable, to recall or cease marketing these therapeutic candidates until clearances are obtained

Modifications to our product candidates, after they have been approved for marketing, if at all, or to any other pharmaceutical product that we may
develop in the future, may require new regulatory clearance, or approvals, and, if necessitated by a problem with a marketed product, may result in the
recall or suspension of marketing of the previously approved and marketed product until clearances or approvals of the modified product are obtained. The
FDA requires pharmaceutical products manufacturers to initially make and document a determination of whether or not a modification requires a new
approval, supplement or clearance. A manufacturer may determine in conformity with applicable regulations and guidelines that a modification may be
implemented without pre-clearance by the FDA; however, the FDA can review a manufacturer’s decision and may disagree. The FDA may also on its own
initiative determine that a new clearance or approval is required. If the FDA requires new clearances or approvals of any pharmaceutical product or medical
device for which we or our licensees receive marketing approval, if any, we or our licensees may be required to recall such product and to stop marketing
the product as modified, which could require us or our licensees to redesign the product and will have a material adverse effect on our business, financial
condition and results of operations. In these circumstances, we may be subject to significant enforcement actions.

The results of our clinical trials may not support our product claims or may result in the discovery of adverse side effects

Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product claims or that any regulatory
authority whose approval we will require in order to market and sell our products in any territory will agree with our conclusions regarding them. Success
in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that clinical trials will
replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and
effective for the proposed indicated uses, which could cause us to abandon a product and may delay development of others. Any delay or termination of our
clinical trials will delay the filing of our regulatory submissions and, ultimately, our ability to commercialize our product candidates and generate revenues.
It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate’s profile.

Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of
future trial results

We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including FDA approval.
Clinical trials are expensive and complex, can take many years and have uncertain outcomes. We cannot predict whether we or our licensees will encounter
problems with any of the completed, ongoing or planned clinical trials that will cause us, our licensees or regulatory authorities to delay or suspend clinical
trials, or delay the analysis of data from completed or ongoing clinical trials. We estimate that clinical trials of our most advanced therapeutic candidates
will continue for several years, but they may take significantly longer to complete. Failure can occur at any stage of the testing and we may experience
numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future
therapeutic candidates, including but not limited to:

● delays in securing clinical investigators or trial sites for the clinical trials;

● delays in obtaining institutional review board and other regulatory approvals to commence a clinical trial;

● slower than anticipated patient recruitment and enrollment;

● negative or inconclusive results from clinical trials;

● unforeseen safety issues;

● uncertain dosing issues;

● an inability to monitor patients adequately during or after treatment; and

● problems with investigator or patient compliance with the trial protocols.

A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have
suffered significant setbacks in advanced clinical trials, even after seeing promising results in earlier clinical trials. Despite the results reported in earlier
clinical trials for our therapeutic candidates, we do not know whether any phase 3 or other clinical trials we or our licensees may conduct will demonstrate
adequate efficacy and safety to result in regulatory approval to market our therapeutic candidates. If later-stage clinical trials of any therapeutic candidate
do not produce favorable results, our ability to obtain regulatory approval for the therapeutic candidate may be adversely impacted, which will have a
material adverse effect on our business, financial condition and results of operations.

The pharmaceutical business is subject to increasing government price controls and other restrictions on pricing, reimbursement and access to drugs,
which could adversely affect our future revenues and profitability

To the extent our products are developed, commercialized, and successfully introduced to market, they may not be considered cost-effective and
third-party or government reimbursement might not be available or sufficient. Globally, governmental and other third-party payors are becoming
increasingly aggressive in attempting to contain health care costs by strictly controlling, directly or indirectly, pricing and reimbursement and, in some
cases, limiting or denying coverage altogether on the basis of a variety of justifications, and we expect pressures on pricing and reimbursement from both
governments and private payors inside and outside the U.S. to continue.

In the U.S., we are subject to substantial pricing, reimbursement, and access pressures from state Medicaid programs, private insurance programs
and pharmacy benefit managers, and implementation of U.S. health care reform legislation is increasing these pricing pressures. The Affordable Care Act
instituted comprehensive health care reform, and includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all
individuals to have health insurance (with limited exceptions), and impose new and/or increased taxes. The future of the Affordable Care Act and its
constituent parts are uncertain at this time.

In almost all markets, pricing and choice of prescription pharmaceuticals are subject to governmental control. Therefore, the price of our products
and their reimbursement in Europe and in other countries is and will be determined by national regulatory authorities. Reimbursement decisions from one
or more of the European markets may impact reimbursement decisions in other European markets. A variety of factors are considered in making
reimbursement decisions, including whether there is sufficient evidence to show that treatment with the product is more effective than current treatments,
that the product represents good value for money for the health service it provides, and that treatment with the product works at least as well as currently
available treatments.

The continuing efforts of government and insurance companies, health maintenance organizations, and other payors of health care costs to contain
or reduce costs of health care may affect our future revenues and profitability or those of our potential customers, suppliers, and collaborative partners, as
well as the availability of capital.

United States federal and state privacy laws, and equivalent laws of other nations, may increase our costs of operation and expose us to civil and
criminal sanctions

HIPPA, and the regulations that have been issued under it, and similar laws outside the United States, contains substantial restrictions and
requirements with respect to the use and disclosure of individuals’ protected health information. The HIPAA privacy rules prohibit “covered entities,” such
as healthcare providers and health plans, from using or disclosing an individual’s protected health information, unless the use or disclosure is authorized by
the individual or is specifically required or permitted under the privacy rules. Under the HIPAA security rules, covered entities must establish
administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic protected health information
maintained or transmitted by them or by others on their behalf. While we do not believe that we will be a covered entity under HIPAA, we believe many of
our customers will be covered entities subject to HIPAA. Such customers may require us to enter into business associate agreements, which will obligate us
to safeguard certain health information we obtain in the course of our relationship with them, restrict the manner in which we use and disclose such
information and impose liability on us for failure to meet our contractual obligations.

In addition, under HITECH, which was signed into law as part of the U.S. stimulus package in February 2009, certain of HIPAA’s privacy and
security requirements are now also directly applicable to “business associates” of covered entities and subject them to direct governmental enforcement for
failure to comply with these requirements. We may be deemed as a “business associate” of some of our customers. As a result, we may be subject as a
“business associate” to civil and criminal penalties for failure to comply with applicable privacy and security rule requirements. Moreover, HITECH
created a new requirement obligating “business associates” to report any breach of unsecured, individually identifiable health information to their covered
entity customers and imposes penalties for failing to do so.

In addition to HIPAA, most U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical
information, and many U.S. states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security
standards, and data security breach notification requirements. These U.S. state laws, which may be even more stringent than the HIPAA requirements, are
not supplanted by the federal requirements, and we are therefore required to comply with them to the extent they are applicable to our operations.

These and other possible changes to HIPAA or other U.S. federal or state laws or regulations, or comparable laws and regulations in countries
where we conduct business, could affect our business and the costs of compliance could be significant. Failure by us to comply with any of the standards
regarding patient privacy, identity theft prevention and detection, and data security may subject us to penalties, including civil monetary penalties and in
some circumstances, criminal penalties. In addition, such failure may damage our reputation and adversely affect our ability to retain customers and attract
new customers.

The protection of personal data, particularly patient data, is subject to strict laws and regulations in many countries. The collection and use of
personal health data in the E.U. is governed by the provisions of Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on
the protection of individuals with regard to the processing of personal data and on the free movement of such data (the “Data Protection Directive”). The
Data Protection Directive imposes a number of requirements, including an obligation to seek the consent of individuals to whom the personal data relates,
the information that must be provided to the individuals, notification of data processing obligations to the competent national data protection authorities of
individual E.U. member states and the security and confidentiality of the personal data. The Data Protection Directive also imposes strict rules on the
transfer of personal data out of the E.U. to the U.S.. Failure to comply with the requirements of the Data Protection Directive and the related national data
protection laws of the E.U. member states may result in fines and other administrative penalties and harm our business. We may incur extensive costs in
ensuring compliance with these laws and regulations, particularly if we are considered to be a data controller within the meaning of the Data Protection
Directive.

If we fail to comply with the U.S. federal Anti-Kickback Statute and similar state and foreign country laws, we could be subject to criminal and civil
penalties and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third country
programs, which would have a material adverse effect on our business and results of operations

A provision of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, prohibits the knowing and willful offer,
payment, solicitation or receipt of any form of remuneration, directly or indirectly, in cash or in kind, to induce or reward the referring, ordering, leasing,
purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable, in whole or in part, by Medicare, Medicaid
or any other federal healthcare program. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback
Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are
drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor may be subject to scrutiny. The federal Anti-Kickback Statute is
very broad in scope and many of its provisions have not been uniformly or definitively interpreted by existing case law or regulations. In addition, most of
the states have adopted laws similar to the federal Anti-Kickback Statute, and some of these laws are even broader than the federal Anti-Kickback Statute
in that their prohibitions may apply to items or services reimbursed under Medicaid and other state programs or, in several states, apply regardless of the
source of payment. Violations of the federal Anti-Kickback Statute may result in substantial criminal, civil or administrative penalties, damages, fines and
exclusion from participation in federal healthcare programs.

All of our future financial relationships with U.S. healthcare providers, purchasers, formulary managers, and others who provide products or
services to federal healthcare program beneficiaries will potentially be governed by the federal Anti-Kickback Statute and similar state laws. We believe
our operations will be in compliance with the federal Anti-Kickback Statute and similar state laws. However, we cannot be certain that we will not be
subject to investigations or litigation alleging violations of these laws, which could be time-consuming and costly to us and could divert management’s
attention from operating our business, which in turn could have a material adverse effect on our business. In addition, if our arrangements were found to
violate the federal Anti-Kickback Statute or similar state laws, the consequences of such violations would likely have a material adverse effect on our
business, results of operations and financial condition.

There are other federal and state laws that may affect our ability to operate, including the federal civil False Claims Act, which prohibits, among
other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or
knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly
concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Moreover, we may be
subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-
government health benefit programs. Moreover, there are analogous state laws. Violations of these laws can result in substantial criminal, civil or
administrative penalties, damages, fines and exclusion from participation in federal healthcare programs.

Moreover, the provisions of the Foreign Corrupt Practices Act of 1997 and other similar anti-bribery laws in other jurisdictions generally prohibit
companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international
organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law
enforcement activity by U.S. regulators, with more aggressive and frequent investigations and enforcement by both the SEC and the Department of Justice.
A determination that our operations or activities violated U.S. or foreign laws or regulations could result in imposition of substantial fines, interruption of
business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. In
addition, lawsuits brought by private litigants may also follow as a consequence.

In both domestic and foreign markets, the development, formulation, manufacturing, packaging, labeling, handling, distribution, import, export,
licensing, sale and storage of pharmaceuticals and medical devices are affected by a body of laws, governmental regulations, administrative
determinations, including those by Health Canada and the FDA, court decisions and similar constraints.

Such laws, regulations and other constraints can exist at the federal, provincial or local levels in Canada and at all levels of government in foreign
jurisdictions. There can be no assurance that the Company and the Company’s partners are in compliance with all of these laws, regulations and other
constraints. The Company and its partners may be required to incur significant costs to comply with such laws and regulations in the future, and such laws
and regulations may have an adverse effect on the business. The failure of the Company or its partners to comply with current or future regulatory
requirements could lead to the imposition of significant penalties or claims and may have a material adverse effect on the business. In addition, the
adoption of new laws, regulations or other constraints or changes in the interpretations of such requirements might result in significant compliance costs or
lead the Company and its partners to discontinue product development and could have an adverse effect on the business.

The Company’s international operations expose it and its representatives, agents and distributors to risks inherent to operating in foreign
jurisdictions that could materially adversely affect its operations and financial position.

These risks include:

● country specific taxation policies;

● imposition of additional foreign governmental controls or regulations;

● export license requirements;

● changes in tariffs and other trade restrictions; and

● complexity of collecting receivables in a foreign jurisdiction.

Moreover, applicable agreements relating to business in foreign jurisdictions are governed by foreign laws and are subject to dispute resolution in
the courts of, or through arbitration proceedings in, the country or region in which the parties are located or another jurisdiction agreed upon by the parties.
The Company cannot accurately predict whether such jurisdictions will provide an effective and efficient means of resolving disputes that may arise in the
future. Even if it obtains a satisfactory decision through arbitration or a court proceeding, the Company could have difficulty in enforcing any award or
judgment on a timely basis or at all.

Risks Related to Our Securities

If we are not able to comply with the applicable continued listing requirements or standards of the TSX Exchange or Nasdaq, TSX Exchange or
Nasdaq could delist our common shares

In order to maintain the listing of our common shares on the TSX Exchange and the Nasdaq Capital Market, we must satisfy minimum financial
and other continued listing requirements and standards, including those regarding director independence and independent committee requirements,
minimum stockholders’ equity, minimum share price, and certain corporate governance requirements. There can be no assurances that we will be able to
comply with such applicable listing standards.

Future issuance of our common shares could dilute the interests of existing shareholders

We may issue additional common shares in the future. The issuance of a substantial number of common shares could have the effect of
substantially diluting the interests of our shareholders. In addition, the sale of a substantial amount of common shares in the public market, in the initial
issuance, in a situation in which we acquire a company and the acquired company receives common shares as consideration and the acquired company
subsequently sells its common shares, or by investors who acquired such common shares in a private placement, could have an adverse effect on the market
price of our common shares.

Short sellers may be manipulative and may drive down the market price of our common shares

Short selling is the practice of selling securities that the seller does not own, but rather has borrowed or intends to borrow from a third party with
the intention of buying identical securities at a later date to return to the lender. A short seller hopes to profit from a decline in the value of the securities
between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it
received in the sale. It is therefore in the short seller’s interest for the price of the stock to decline, and some short sellers publish, or arrange for the
publication of, opinions or characterizations regarding the relevant issuer, often involving misrepresentations of the issuer’s business prospects and similar
matters calculated to create negative market momentum, which may permit them to obtain profits for themselves as a result of selling the stock short.

As a public entity, we may be the subject of concerted efforts by short sellers to spread negative information in order to gain a market advantage.
In addition, the publication of misinformation may also result in lawsuits, the uncertainty and expense of which could adversely impact our reputation,
business, financial condition, and operating results. There are no assurances that we will not face short sellers’ efforts or similar tactics in the future, and
the market price of our common shares may decline as a result of their actions.

We have a significant number of restricted share units, options and warrants outstanding, and while these options and warrants are outstanding, it may
be more difficult to raise additional equity capital

As of October 25, 2023, we had outstanding restricted share units, options and warrants to purchase 10,314,012 common shares, respectively. The
holders of these restricted share units, options and warrants are given the opportunity to profit from a rise in the market price of our common shares. We
may find it more difficult to raise additional equity capital while these options and warrants are outstanding. At any time during which these warrants are
likely to be exercised, we may be unable to obtain additional equity capital on more favorable terms from other sources. Additionally, the exercise of these
options and warrants will cause the increase of our outstanding Common shares, which could have the effect of substantially diluting the interests of our
current shareholders.

Sales of a substantial number of our common shares in the public market by our existing shareholders could cause our share price to fall

Sales of a substantial number of our common shares in the public market, or the perception that these sales might occur, could depress the market
price of our common shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our common shares. As of October 25, 2023, we have 10,314,012 shares issuable upon exercise of
restricted share units, options and warrants. Sales of shares by these shareholders could have a material adverse effect on the trading price of our common
shares. We intend to register the offering, issuance, and sale of all common shares that we may issue under our equity compensation plans. Once we register
these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements.

We are an Emerging Growth Company, which may reduce the amount of information available to investors

The Jumpstart Our Business Start-ups Act (the “JOBS Act”), and our status as a foreign private issuer will allow us to postpone the date by which
we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports
filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price of our Common shares.

For as long as we remain an “emerging growth company” as defined in the JOBS Act, we intend to take advantage of certain exemptions from

various requirements that are applicable to public companies that are not emerging growth companies including:

● the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the

effectiveness of our internal control over financial reporting;

● any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement

to the auditor’s report on the financial statements.

We intend to take advantage of these exemptions until we are no longer an “emerging growth company.” We will remain an emerging growth
company until the earlier of (1) the last day of the fiscal year of the fifth anniversary of our initial public offering in the United States, (b) in which we have
total annual gross revenue of at least US$1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our
Common shares that is held by non-affiliates exceeds US$700 million as of the prior June 30; and (2) the date on which we have issued more than US$1.0
billion in non-convertible debt during the prior three-year period.

We cannot predict if investors will find our common shares or listed warrants (“Warrants”) less attractive because we may rely on these
exemptions. If some investors find our common shares or Warrants less attractive as a result, there may be a less active trading market for our common
shares or Warrants, and our common share or Warrant price may be more volatile and may decline.

We have never paid cash dividends on our capital stock and we do not anticipate paying any dividends in the foreseeable future. Consequently, any
gains from an investment in our common shares will likely depend on whether the price of our Common shares increases, which may not occur

We have not paid cash dividends on any capital stock to date and we currently intend to retain our future earnings, if any, to fund the development
and growth of our business. Consequently, in the foreseeable future, you will likely only experience a gain from your investment in our common shares if
the price of our common shares increases beyond the price in which you originally acquired the common shares.

In the event a market develops for our common shares or Warrants, the market price of our common shares or Warrants may be volatile

In the event a market develops for our common shares or Warrants, the market price of our common shares or Warrants may be highly volatile.
Some of the factors that may materially affect the market price of our common shares or Warrants are beyond our control, such as changes in financial
estimates by industry and securities analysts, conditions or trends in the industry in which we operate or sales of our common shares or Warrants. These
factors may materially adversely affect the market price of our common shares or Warrants, regardless of our performance. In addition, the public stock
markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many
companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect
the market price of our Common shares.

Our executive officers, directors and principal shareholders will maintain the ability to exert significant control over matters submitted to our
shareholders for approval

Our executive officers, directors and principal shareholders who owned more than 5% of our outstanding common shares will, in the aggregate,
beneficially own shares representing approximately 21.16% of our share capital. As a result, if these shareholders were to act together, they would be able
to control all matters submitted to our shareholders for approval, as well as our management and affairs. For example, these persons, if they act together,
would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting
power could delay or prevent an acquisition of our company on terms that other shareholders may desire or result in management of our company that our
public shareholders disagree with.

If we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences as a result

Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to
assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign
investment company (“PFIC”) for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest gains from
commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income (including amounts
derived by reason of the temporary investment of funds raised in offerings of our shares) and rents and royalties other than rents and royalties which are
received from unrelated parties in connection with the active conduct of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may
suffer adverse tax consequences, including having gains realized on the sale of our common shares treated as ordinary income, rather than capital gains, the
loss of the preferential rate applicable to dividends received on our common shares by individuals who are U.S. holders, and having interest charges apply
to distributions by us and gains from the sales of our shares.

Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets. Asset value is
based on which the fair market value of each asset, including goodwill and going concern value (which may be determined by reference to the market value
of our common shares, which may be volatile). Our status will also depend, in part, on when and how we utilize the cash proceeds from any securities
offerings our business. Based upon the value of our assets, including any goodwill, and the nature and composition of our income and assets, we believe
that we will be classified as a PFIC for the taxable year ending July 31, 2023, and possibly for succeeding years. However, even if we are classified as a
PFIC for the year ending July 31, 2023, under an exception to the PFIC classification rules, we may be able to avoid such classification altogether if we can
meet certain conditions set forth in the exception. (See the discussion of PFIC status under “Taxation, U.S. Federal Income Taxation”, below. Because the
determination of whether we are a PFIC for any taxable year is a factual determination made annually after the end of each taxable year, there can be no
assurance as to our status as a PFIC in any taxable year.

The tax consequences that would apply if we are classified as a PFIC would also be different from those described above if a U.S. shareholder
were able to make a valid qualified electing fund (“QEF”) election. If we are classified as a PFIC, then we expect to provide U.S. shareholders with the
information necessary for a U.S. shareholder to make a QEF election but there is no assurance that we will do so. See the discussion of PFIC status under
“Taxation, U.S. Federal Income Taxation”, below.

If estimates of revenue, expenses, or capital or liquidity requirements change or are inaccurate, or if cash generated from operations is insufficient
to satisfy liquidity requirements, the Company may arrange additional financings

BriaCell expects that its current cash and cash equivalent reserves will be sufficient to meet its anticipated needs for working capital and capital
expenditures for the near future. In the future, the Company may also arrange financings to give it the financial flexibility to pursue attractive acquisition or
investment opportunities that may arise. The Company may pursue additional financing through various means, including equity investments, issuances of
debt, joint venture projects, licensing arrangements or through other means. The Company cannot be certain that it will be able to obtain additional
financing on commercially reasonable terms or at all. The Company’s ability to obtain additional financing may be impaired by such factors as the status of
capital markets, both generally and specifically in the pharmaceutical and medical device industries, and by the fact that it is a new enterprise without a
proven operating history. If the amount of capital raised from additional financing activities, together with revenues from operations (if any), is not
sufficient to satisfy the Company’s capital needs, it may not be able to develop or advance its products, execute its business and growth plans, take
advantage of future opportunities, or respond to competitive pressures or unanticipated customer or partner requirements. If any of these events occur, the
Company’s business, financial condition, and results of operations could be adversely affected. Any future equity financings undertaken are likely to be
dilutive to existing shareholders. Finally, the terms of securities issued in future capital transactions may include preferences that are more favourable to
new investors.

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely
change their recommendations or publish negative reports regarding our business or our shares, our share price and trading volume could decline

The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our
business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or
provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our shares, or provide more
favorable relative recommendations about our competitors, the market value of our securities would likely decline. If any analyst who may cover us were to
cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the
price of our common shares and Warrants and our trading volume to decline.

Certain Canadian legislation contains provisions that may have the effect of delaying or preventing a change in control

Canadian legislation could discourage potential acquisition proposals, delay or prevent a change in control and limit the price that certain investors
may be willing to pay for our subordinate voting shares. For instance, a non-Canadian must file an application for review with the Minister responsible for
the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a “Canadian business” within the meaning of the Investment
Canada Act, where prescribed financial thresholds are exceeded. Furthermore, limitations on the ability to acquire and hold our subordinate voting shares
and multiple voting shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition to review any
acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. Otherwise,
there are no limitations either under the laws of Canada or British Columbia, or in our articles on the rights of non-Canadians to hold or vote our
subordinate voting shares and multiple voting shares. Any of these provisions may discourage a potential acquirer from proposing or completing a
transaction that may have otherwise presented a premium to our shareholders.

Because we are a corporation incorporated in British Columbia and some of our directors and officers are resident in Canada or other countries, it
may be difficult for investors in the United States to enforce civil liabilities against us based solely upon the federal securities laws of the United States.
Similarly, it may be difficult for Canadian investors to enforce civil liabilities against our directors and officers residing outside of Canada

We are a corporation incorporated under the laws of British Columbia with our principal place of business in West Vancouver. Some of our
directors and officers and the auditors or other experts named herein are residents of Canada and all or a substantial portion of our assets and those of such
persons are located outside the United States. Consequently, it may be difficult for U.S. investors to effect service of process within the United States upon
us or our directors or officers or such auditors who are not residents of the United States, or to realize in the United States upon judgments of courts of the
United States predicated upon civil liabilities under the Securities Act. Investors should not assume that Canadian courts: (1) would enforce judgments of
U.S. courts obtained in actions against us or such persons predicated upon the civil liability provisions of the U.S. federal securities laws or the securities or
blue sky laws of any state within the United States, or (2) would enforce, in original actions, liabilities against us or such persons predicated upon the U.S.
federal securities laws or any such state securities or blue sky laws.

Similarly, some of our directors and officers are residents of countries other than Canada and all or a substantial portion of the assets of such
persons are located outside Canada. As a result, it may be difficult for Canadian investors to initiate a lawsuit within Canada against these non-Canadian
residents. In addition, it may not be possible for Canadian investors to collect from these non-Canadian residents judgments obtained in courts in Canada
predicated on the civil liability provisions of securities legislation of certain of the provinces and territories of Canada. It may also be difficult for Canadian
investors to succeed in a lawsuit in the United States, based solely on violations of Canadian securities laws.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

As of September 2023, the Company commenced a month-to-month lease arrangement for office and lab space in Philadelphia, Pennsylvania, in the
amount of approximately $36,000 per month.

ITEM 3. LEGAL PROCEEDINGS

We may be involved from time to time in ordinary litigation, negotiation, and settlement matters that will not have a material effect on our operations or
finances.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF
EQUITY SECURITIES

Market information

Our common shares and Warrants to purchase common shares trade on The Nasdaq Capital Market under the symbols “BCTX” and “BCTXW”,
respectively, since February 24, 2021 and on the Toronto Stock Exchange (“TSX”) under the symbol “BCT” since December 31, 2021, and prior to that, on
the TSX Venture Exchange from December 3, 2014.

Number of Shareholders

As of October 25, 2023, we have approximately 48 shareholders of record of our common shares.

Dividend Policy

Historically, we have not paid any cash dividends to the holders of shares of our common shares and we do not expect to pay any such dividends in the
foreseeable future as we expect to retain our future earnings for use in the operation and expansion of our business.

Issuer Purchases of Equity Securities

None.

ITEM 6.

Not applicable.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this
Annual Report. This discussion and other parts of this Annual Report contain forward-looking statements based upon current expectations that involve
risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking
statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this Annual Report.

The preparation of financial statements in conformity with these accounting principles requires us to make estimates and assumptions that affect
the reported amounts of assets and liabilities, disclosure of contingent liabilities at the financial statement date and reported amounts of revenue and
expenses during the reporting period. On an on-going basis, we review our estimates and assumptions. The estimates were based on historical experience
and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates or other forward-
looking statements under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results
of operations. Our actual results may differ materially as a result of many factors, including those set forth under the headings entitled “Special Note
Regarding Forward-Looking Statements” and “Risk Factors”.

Overview

Critical Accounting Policies and Estimates

1. Critical Estimates and Judgements

The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes
could differ from these estimates. The financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are
pervasive throughout the financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are
recognized in the period in which the estimate is revised and also in future periods when the revision affects both current and future periods.

The critical judgments and significant estimates in applying accounting policies that have the most significant effect on the amounts recognized in

the consolidated financial statements are:

● Intangible assets are tested for impairment annually or more frequently if there is an indication of impairment. The carrying value of intangibles
with definite lives is reviewed each reporting period to determine whether there is any indication of impairment. If there are indications of
impairment the impairment analysis is completed and if the carrying amount of an asset exceeds its recoverable amount, the asset is impaired and
impairment loss is recognized.

● The Company uses the Black-Scholes option-pricing model to estimate fair value of options and the warrant liability at each reporting date. The
key assumptions used in the model are the expected future volatility in the price of the Company’s shares and the expected life of the warrants.

● Preparation of the consolidated financial statement on a going concern basis, which contemplates the realization of assets and payments of
liabilities in the ordinary course of business. Should the Company be unable to continue as a going concern, it may be unable to realize the
carrying value of its assets, including its intangible assets and to meet its liabilities as they become due

● Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors.
The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an
additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the
amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

2. New Accounting Policies Adopted

No new accounting policies were adopted during the year ended July 31, 2023.

Results of Operations

Comparison of the year ended July 31, 2023, compared to the year ended July 31, 2022

Research Costs

Research costs are comprised primarily of (i) salaries and wages to Company employees at our laboratory; and (ii) clinical trials and

investigational drug costs, which include the testing and manufacture of our investigational drugs and costs of our clinical trials.

The following is a breakdown of our research and development costs by project:

Clinical trials
Pre-clinical projects
Chemical, Manufacturing and Control Costs (“CMC Costs”)
Other

Year ended July 31,

2023

2022

7,843,760 $
3,787,673
1,801,287
1,903,918
15,336,638 $

3,540,955
2,076,127
1,346,810
1,057,597
8,021,489

Our clinical trial expenses include our immunotherapy program, Bria-IMT™, a 46-subject Phase I/IIa clinical trial. Clinical trial expenses increased in
2023 as we recruited more patients into the Bria-IMT™ trial and began setting up the Bria-OTS™ trial.

Pre-clinical projects include expenses incurred in our off-the-shelf personalized immunotherapies, including Bria-OTS+™, and Bria-PROS™. Our pre-
clinical costs have increased in 2023 as we hired more staff to accelerate our existing pre-clinical program and added an additional pre-clinical program
(sCD80).

CMC costs include the manufacturing of Bria-IMT™ and Bria-OTS™ and all quality control and quality assurance testing on the investigational product.
CMC costs increased in 2023 to support the additional patients in our trials.

Other costs are ancillary expenses we incur such as costs to maintain our patents, investigation of early-stage projects, scientific advisory board expenses,
contracts with vendors for pre-clinical work, and administration costs associated with all our research and development expenditure. Other costs increased
in 2023 as we investigated additional potential pre-clinical projects.

The following is a breakdown of our research and development costs by nature of expenses:

Clinical trial sites and investigational drug costs
Wages and salaries
Laboratory Rent
Supplies
Share-based compensation

Year ended July 31,

2023

2022

9,611,630 $
3,878,367
194,880
579,169
1,072,592
15,336,638 $

4,912,530
2,225,050
138,354
309,992
435,563
8,021,489

For the year ended July 31, 2023, research costs totaled $15,336,638, compared to $8,021,489 for the same period in 2022. The increase primarily
resulted from the expansion of the Company’s Bria-IMT™ trial and higher clinical trials and investigational drug costs, which rose from $4,912,530 in
2022 to $9,611,630 in 2023. Laboratory costs also increased due to the hiring of additional employees and higher supplies, growing from $138,354 to
$194,880 and $309,992 to $579,169, respectively. Additionally, non-cash share-based compensation expenses rose from $435,563 in 2022 to $1,072,592 in
2023, contributing to the overall increase in research and development expenses.

General and Administrative Expenses

For the year ended July 31, 2023, general and administrative expenses amounted to $7,935,626 as compared to $7,267,452 for the year ended July
31, 2022 The increase in general and administrative expenses primarily stems from higher insurance premiums, professional fees, and salaries, offset by a
decrease in share-based compensation expenses.

Financial income (expenses), net

For the year ended July 31, 2023, financial income, net amounted to $2,969,870 as compared to financial loss $11,549,962 for the year ended July
31, 2022. Financial income (expenses) comprises, primarily, changes in the fair value of the warrant liability and interest earned on our treasury. For the
year ended July 31, 2023, the value of the warrant liability decreased by $2,119,530. The decrease was primarily due to the decrease in the share price at
period end. For the year ended July 31, 2022, there was an increase in the value of the liability of $11,658,372 due to the increased share price at the period
end. Interest income for the year ended July 31, 2023 was $891,213 as compared to $136,731 for the year ended July 31, 2022. The increase in 2023 is
attributable to higher interest rates in North America.

Loss for the period

The Company reported a loss for the year ended July 31, 2023, of $20,302,394 as compared to $26,838,903 for the year ended July 31, 2022. The
loss in 2023 primarily stems from a substantial increase in operational spending, offset by a gain in from a decrease in the fair value of the warrant liability.
Conversely, the higher loss in the prior period can be attributed to a larger increase in the fair value of the warrant liability. These factors account for the
variance in the reported losses between the two periods, highlighting the impact of changes in warrant valuation and operational spending on the
Company’s financial performance.

Liquidity and Capital Resources

As of July 31, 2023, the Company has a working capital of 25,147,050 (July 31, 2022 – $41,405,613) and an accumulated deficit of $80,652,231

(July 31, 2022 - $60,349,837).

As of July 31, 2023, the Company’s capital resources consist primarily of cash and cash equivalents, comprised mostly of cash on deposit with
banks, investments in money market funds, investments in U.S. government securities, U.S. government agency securities, and investment grade corporate
debt securities. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements.

Historically, the Company has financed its operation through private and public placement of equity securities, as well as debt financing. The
Company’s ability to fund its longer-term cash requirements is subject to multiple risks, many of which are beyond its control. The Company intends to
raise additional capital, either through debt or equity financings in order to achieve its business plan objectives. Management believes that it can be
successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so. There is no assurance that any funds
raised will be sufficient to enable the Company to attain profitable operations or continue as a going concern. To the extent that the Company is
unsuccessful, the Company may need to curtail or cease its operations and implement a plan to extend payables or reduce overhead until sufficient
additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

During the year ended July 31, 2023, the Company’s overall position of cash and cash equivalents decreased by $19,790,560 from the year ended

July 31, 2022 (including effects of foreign exchange). This decrease in cash can be attributed to the following:

The Company’s net cash used in operating activities during the year ended July 31, 2023, was $23,744,860 as compared to $12,484,376 for the

year ended July 31, 2022.

Cash gained in financing activities for the year ended July 31, 2023, was $3,954,300, as compared to a loss of $3,742,657 for the year ended July

31, 2022.

Off-balance Sheet Arrangements

None.

Tabular Disclosure of Contractual Obligations

None.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the
information required under this Item 7A.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The report of independent registered public accounting firm with PCAOB ID: 1930 and financial information required by this Item is attached hereto at the
end of this report beginning on page F-1 and is hereby incorporated by reference.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure
that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and
procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely
decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal accounting and financial officer, has evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 under the Securities
Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Annual Report on Form 10-K. Our management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on
such evaluation, our principal executive officer and principal accounting and financial officer have concluded that as of July 31, 2023, our disclosure
controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act
Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management,
including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. All internal control
systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable
assurance with respect to financial statement preparation and presentation.

As of July 31, 2023, under the supervision and with the participation of our management, including our principal executive officer and principal financial
officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-
Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. All control deficiencies that contributed
to the material weakness as at Jul 31, 2022 were found to be effectively remediated. Management implemented the following remedial measures to address
the material weakness which we tested and found to be operating effectively:

● Periodic user access reviews of key applications
● Adequate segregation of incompatible duties.
● Approvals supporting transactions documented and evidence retained.
● Monthly and quarterly checklists to keep track of the review performed for every key control and to ensure the control was performed consistently.
● Adequate documentation to evidence key review procedures including appropriate documentation of the review.
● Mitigating controls to compensate for the lack of SOC 1 reports of service organizations to cover the entire fiscal year.

Based on this assessment, our management concluded that, as of July 31, 2023, our internal control over financial reporting was effective at the reasonable
assurance level.

Changes in Internal Control Over Financial Reporting

There has been no material changes in our internal control over financial reporting during the quarter ended July 31, 2023. No change in our internal
control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended July 31, 2023 that
has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except for our remediation efforts described
above.

ITEM 9B. OTHER INFORMATION

None.

ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Executive Officers, Directors and Key Employees

PART III

The following table sets forth the name, age and position of each of our executive officers, key employees and directors as of October 25, 2023. All
directors hold office until the next annual meeting of shareholders and the election and qualification of their successors. Officers serve at the discretion of
the board.

Name
William V. Williams, MD, FRCP
Gadi Levin, CA, MBA
Giuseppe Del Priore, MD, MPH
Miguel A. Lopez-Lago, PhD
Jamieson Bondarenko, CFA, CMT
Vaughn C. Embro-Pantalony, MBA, FCPA, FCMA, CDIR,
ACC
Marc Lustig, MSC, MBA
Martin E. Schmieg
Rebecca Taub, MD
Jane A. Gross, PhD

Age
68
50
61
54
39

66
51
61
71
66

Biographies

Position

President, Chief Executive Officer, and Director
Chief Financial Officer and Corporate Secretary
Chief Medical Officer
Chief Scientific Officer
Chairman of the Board of Directors

Director
Director
Director
Director
Director

William V. Williams, MD, President, Chief Executive Officer and Director, is a seasoned biopharmaceutical executive with over 35 years of industry and
academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams has served as President, Chief
Executive Officer and Director of the Company since November 1, 2016. Dr. Williams served as Vice President of Exploratory Development at Incyte
Corporation from March 2005 through November 2016. There he facilitated entry of over 20 compounds into the clinic, including ruxolitinib (Jakafi),
baricitinib (Olumiant), and epacadostat. Dr. Williams held several positions at GlaxoSmithKline Pharmaceuticals, including Head of Experimental
Medicine and Vice President of Clinical Pharmacology from December 2000 through March 2002; Director and Head of Clinical Pharmacology, Oncology,
Musculoskeletal and Inflammation from March 2002 through December 2004 and Director and Head of Clinical Pharmacology, Musculoskeletal,
Inflammation, Gastrointestinal and Urology from December 2004 through March 2005. He has also served as Assistant Professor of Medicine and the
Director of Rheumatology Research at the University of Pennsylvania from July 1991 through January 1998. Dr. Williams earned his BSc in Chemistry and
Biotechnology from Massachusetts Institute of Technology and Medical Doctorate from Tufts University School of Medicine. We believe that Dr. Williams
is qualified to serve as a member of our Board because of his experience as our President and Chief Executive Officer, as well as his depth of academic and
industry experience.

Gadi Levin, CA, MBA, Chief Financial Officer and Secretary, was appointed Chief Financial Officer and Secretary of the Company on February 1, 2016.
Mr. Levin has also served as Chief Financial Officer and Director of Vaxil Bio Ltd since March 1, 2016, and as the Finance Director of Eco (Atlantic) Oil
& Gas Ltd. since December 1, 2016. Mr. Levin has over 15 years of experience working with public U.S., Canadian and multi-jurisdictional public
companies. Previously, Mr. Levin served as Chief Financial Officer of DarioHeath Corp from November 2013 through January 2015. Mr. Levin also served
as the Vice President of Finance and Chief Financial Officer for two Israeli investment firms specializing in private equity, hedge funds and real estate. Mr.
Levin began his CPA career at the accounting firm Arthur Andersen, where he worked for nine years, specializing in U.S. listed companies involved in
initial public offerings. Mr. Levin has a Bachelor of Commerce degree in Accounting and Information Systems from the University of Cape Town, South
Africa, and a post graduate diploma in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa
and has an MBA from Bar Ilan University in Israel.

Giuseppe Del Priore, MD, MPH, Chief Medical Officer, was appointed Chief Medical Officer on February 16, 2022. Dr. Del Priore is a seasoned
healthcare executive with over 25 years of experience in research, drug development, and clinical trial management. Dr. Del Priore’s prior work experience
includes serving as a biotechnology company Chief Medical Officer, a National Director at the Cancer Treatment Centers of America, and faculty at
Indiana University School of Medicine, Weill Cornell Medicine, and New York University School of Medicine. Dr. Del Priore completed his MPH degree
in Biostatistics and Epidemiology at the University of Illinois Chicago School of Public Health, his medical degree with Distinction at The State University
of New York, and his BA, magna cum laude, in Philosophy, at The City University of New York, with additional training at Memorial Sloan Kettering
Cancer Center, The University of Chicago, Northwestern University, and the University of Rochester. He has authored numerous publications, was named
on several patents, and was listed as the “Best Doctors” by the U.S. News & World Report. He regularly appears in various media outlets as a Key Opinion
Leader in oncology. We believe that Dr. Del Priore is qualified to serve as Chief Medical Officer because of his medical and clinical trial experience.

Miguel A. Lopez-Lago, PhD, Chief Scientific Officer, was appointed Chief Scientific Officer on May 26, 2022, a promotion from his prior title of Senior
Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan Kettering Cancer Center, New
York. Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for mesothelioma and the
characterization of the biological mechanisms underlying cancer metastasis. More recently, Dr. Lopez-Lago has been interested in the study of the tumor
immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor T cell technologies. Since
2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his
doctorate in Molecular Biology from Santiago of Compostela University, Spain. We believe that Dr. Lopez-Lago is qualified to serve as Chief Scientific
Officer because of his scientific training, especially in immunology and cellular therapies.

Jamieson Bondarenko, CFA, CMT, Chairman of the Board, was appointed as a Director of the Company on February 12, 2019 and elected as Chairman
on April 24, 2019. Mr. Bondarenko provides strategic capital markets & corporate development advice to early-stage life sciences companies through his
merchant capital company, JGRNT Capital Corp., a company he founded in November 2016. From December 2016 through October 2017, he served as
Principal and Managing Director of the Equity Capital Markets group of Eight Capital. He also held several positions in the Capital Markets division of
Dundee Securities Ltd., including Managing Director from July 2016 through December 2016, Director from October 2015 through July 2016, Vice
President from December 2012 through October 2015 and Associate from February 2010 through December 2012. We believe that Mr. Bondarenko is
qualified to serve as a member of our Board because of his industry-specific and capital markets experience.

Vaughn C. Embro-Pantalony, MBA, FCPA, FCMA, CDIR, ACC, Director, has been a Director of the Company since his appointment on March 18,
2019. In February 2018, he joined the Board of Directors of Soricimed Biopharma Inc., a private clinical-stage biopharma company developing targeted
cancer therapies, and in August 2018 he was appointed Chairman of the Board of Soricimed, where he continues to serve in this capacity. He is also a
Director of Microbix Biosystems Inc., a public company and leading manufacturer of viral and bacterial antigens and reagents for the global diagnostis
industry. He originally joined the Microbix Board in February 2007, and he also served as its President and Chief Executive Officer from November 2012
to July 2017. He is President of Stratpath Management Inc., consulting on strategy and governance to the life sciences sector. He has held other executive
positions in life sciences with responsibility for finance, business development, strategic planning and information technology, including Vice President,
Finance, and Chief Financial Officer of Novopharm Limited from May 2003 through April 2006; Vice President, Information Technology, and Chief
Information Officer of Bayer Inc. from July 1999 through April 2003; Vice President, Finance and Administration of Bayer Healthcare from October 1996
through June 1999; and Director, Finance and Administration and Chief Financial Officer of Zeneca Pharma Inc. from March 1995 through August 1996.
He received his bachelor’s degree from Wilfrid Laurier University and his master of business administration degree from University of Windsor. He is a
Fellow Chartered Professional Accountant and a Chartered Director (C. Dir.) and is Audit Committee Certified (A.C.C.) through the Directors College,
McMaster University. We believe that Mr. Embro-Pantalony is qualified to serve as a member of our Board due to his extensive experience as a
pharmaceutical and life sciences executive.

Marc Lustig, Director, was appointed to the Company’s Board on September 1, 2021. Mr. Lustig is a highly regarded investor, entrepreneur, and corporate
finance veteran with a deep understanding of the life sciences industry, including biotechnology and pharmaceuticals, as well as the legal cannabis industry.
He holds MSc and MBA degrees from McGill University. His professional experience includes working at Merck & Co., and his capital markets career
includes roles in biotechnology equity research and corporate finance. Mr. Lustig was the founder and CEO of Origin House, which was sold to Cresco
Labs Inc. (CSE: CL; OTCQX: CRLBF) in 2020, where he currently serves as a director and as Head of Capital Markets. In addition to being a director of a
number of public companies, he founded the Lustig Family Medical Cannabis Research & Care Fund of the Cedars Cancer Foundation that provides
cannabis to palliative cancer patients. We believe that Mr. Lustig is qualified to serve as a member of our Board because of his industry-specific and capital
markets experience.

Martin Schmieg, Director, rejoined the Company’s Board on November 24, 2020. Having served as a member of BriaCell’s Board from 2016 to March
2019, Mr. Schmieg is a “C” level executive with 30 years of business experience and a diversified background in the global biotech, med-tech and
pharmaceutical industries. He currently serves as Co-Founder, Chief Operating and Financial Officer of Clear Intradermal Technologies, Inc. (formerly,
ClearIt LLC), a private company based in Texas. As a hands-on leader, Mr. Schmieg’s early career focused on accounting and financial management
responsibilities, serving as Chief Financial Officer to privately held Cytometrics, Inc. and Advanced Bionics Corporation, and publicly traded Sirna
Therapeutics, Inc. and Isolagen, Inc. We believe that Mr. Schmieg is qualified to serve as a member of our Board because of his long-term familiarity with
the Company and his perspective and experience in relevant industries.

Rebecca Taub, MD, Director, has been a Director of the Company since her appointment on March 18, 2019. Dr. Taub currently serves as the President of
Research and Development for Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company. She previously served as Vice President of
Research and Development from July 2016 through her recent promotion to President of Research and Development on June 27, 2019. She has also served
as Madrigal’s Chief Medical Officer since July 2016. Dr. Taub served as the CEO and a Director of Madrigal from September 2011 through Madrigal’s
merger with Synta Pharmaceuticals Corp. in July 2016. Prior to joining Madrigal, Dr. Taub served as Senior Vice President, Research and Development of
VIA Pharmaceuticals from 2008 to 2011 and as Vice President, Research, Metabolic Diseases at Hoffmann-LaRoche from 2004 to 2008. In those positions,
Dr. Taub oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases, including the conduct of a series of Phase I
and II proof of conduct clinical trials. Dr. Taub led drug discovery programs, including target identification, lead optimization and advancement of
preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical
Company, in a variety of positions, including Executive Director of CNS and metabolic diseases research. Before becoming a pharmaceutical executive,
Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania, and remains an adjunct professor. Dr. Taub is the author of
more than 120 research articles. Before joining the faculty of the University of Pennsylvania, Dr. Taub served as an Assistant Professor at the Joslin
Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. Dr. Taub
received her M.D. from Yale University School of Medicine and her B.A. from Yale College. We believe that Dr. Taub is qualified to serve as a member of
our Board due to her extensive experience as a pharmaceutical executive heading up major development programs in non-alcoholic steatohepatitis.

Jane Gross, Director, was appointed to the Company’s Board in November 2021. Dr. Gross is a highly experienced biotech executive with over 30 years in
leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer
and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independent Director for aTyr Pharmaceuticals (Nasdaq: LIFE), a
biotechnology company developing novel therapeutics for respiratory diseases and multiple cancer indications. Dr. Gross’s experience includes roles as
Chief Scientific Officer and SVP, Research and Non-Clinical Development at Aptevo Therapeutics (Nasdaq: APVO), during which she led the discovery of
novel antibody-based, bispecific protein therapeutics as immunotherapies to treat diseases like cancer. Previously, Dr. Gross served as VP, Applied
Research and Non-Clinical Development at Emergent BioSolutions (NYSE: EBS), during which she successfully introduced a drug to patients from the
design stage into the clinic stage. Formerly, as VP, Immunology Research at ZymoGenetics, Dr. Gross discovered and developed 30+ new product
candidates, completed partnerships and out-licensing of assets, and helped position ZymoGenetics for a successful acquisition by Bristol Myers Squibb
(NYSE: BMY) in 2010. Dr. Gross earned her Ph.D. in Immunology from the University of California, Berkeley and her Post-Doctoral Fellowship from the
University of Washington in Immunology. We believe that Dr. Gross is qualified to serve as a member of our Board due to her extensive industry
experience and academic background.

Family Relationships and Other Arrangements

There are no family relationships among our directors and executive officers. There are no arrangements or understandings between or among our

executive officers and directors pursuant to which any director or executive officer was or is to be selected as a director or executive officer.

Composition of our Board

Under our amended articles of incorporation, our Board consists of a minimum of three directors and up to that number which was last set by
ordinary resolution of the shareholders. Our Board is currently comprised of seven directors, and under the Business Corporations Act (British Columbia)
(“BCBCA”), as a reporting issuer, we must have no fewer than three directors. Under the BCBCA, a director may be removed with or without cause by a
resolution passed by at least two-thirds of the votes cast by shareholders present in person or by proxy at a meeting and who are entitled to vote. The
directors are appointed at the annual general meeting of shareholders and the term of office for each of the directors will expire at the time of our next
annual shareholders meeting. Our amended articles of incorporation provide that, between annual general meetings of our shareholders, the directors may
appoint one or more additional directors, but the number of additional directors may not at any time exceed one-third of the number of directors who held
office at the expiration of the last meeting of our shareholders. Under the BCBCA, there is no minimum number of directors required to be resident
Canadians as defined in the BCBCA.

Director Term Limits and Other Mechanisms of Board Renewal

Our Board has not adopted director term limits or other automatic mechanisms of Board renewal. Rather than adopting formal term limits,
mandatory age-related retirement policies and other mechanisms of Board renewal, the nominating and corporate governance committee of our Board will
develop a skills and competencies matrix for our Board as a whole and for individual directors. The nominating and corporate governance committee
conducts a process for the assessment of our board of directors, each committee and each director regarding his or her effectiveness and contribution, and
reports evaluation results to our Board on a regular basis.

Director Independence

Under the Nasdaq Rules, independent directors must comprise a majority of a listed company’s board of directors. For purposes of the Nasdaq
Rules, an independent director means a person other than an executive officer or employee of the company who, in the opinion of the board of directors,
has no relationship with the company that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Under
NI 58-101, a director is considered to be independent if he or she is independent within the meaning of Section 1.4 of National Instrument 52-110—Audit
Committees. Section 1.4 of NI 52-110 generally provides that a director is independent if he or she has no direct or indirect relationship with the issuer
which could, in the view of the issuer’s board of directors, be reasonably expected to interfere with the exercise of the director’s independent judgment.

Our Board has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her
background, employment and affiliations, our Board has determined that Dr. Gross, Dr. Taub, Mr. Embro-Pantalony, Mr. Schmieg, and Mr. Bondarenko,
representing five of the seven members of our Board, are “independent” as that term is defined under the Nasdaq Rules. In making this determination, our
Board considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our Board
deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director. Dr. Williams is not
independent by virtue of being the Company’s Chief Executive Officer. Mr. Lustig is not independent by virtue of being a significant securityholder of the
Company.

Certain members of our Board are also members of the boards of other public companies. Our Board has not adopted a director interlock policy,

but is kept informed of other public directorships held by its members.

Mandate of the Board of Directors

Our Board is responsible for supervising the management of our business and affairs, including providing guidance and strategic oversight to

management. Our Board’s mandate includes, among other things, the following matters:

● succession planning, including appointing, training and monitoring senior management;

● developing the corporate goals and objectives that management is responsible for meeting and reviewing the performance of our senior officers

against such corporate goals and objectives;

● taking steps to satisfy itself as to the integrity of our executive officers and that our executive officers create a culture of integrity throughout the

organization;

● reviewing and approving our code of conduct and reviewing and monitoring compliance with the code of conduct and our enterprise risk

management processes;

● reviewing and approving management’s strategic and business plans and our financial objectives, plans and actions, including significant capital

allocations and expenditures; and

● reviewing and approving material transactions not in the ordinary course of business.

Meetings of Independent Directors

Our Board holds regularly-scheduled quarterly meetings as well as ad hoc meetings from time to time. The independent members of our Board

also meet, as required, without the non-independent directors and members of management after each regularly scheduled board meeting.

A director who has a material interest in a matter before our Board or any committee on which he or she serves is required to disclose such interest
as soon as the director becomes aware of it. In situations where a director has a material interest in a matter to be considered by our Board or any committee
on which he or she serves, such director may be required to absent himself or herself from the meeting while discussions and voting with respect to the
matter are taking place. Directors are also required to comply with the relevant provisions of the BCBCA regarding conflicts of interest.

Position Descriptions

Our Board has adopted written terms of reference for the chairman which set out his or her key responsibilities, including duties relating to
determining the frequency, dates and locations of meetings and setting Board meeting agendas, chairing Board and shareholder meetings and carrying out
any other or special assignments or any functions as may be requested by our Board or management, as appropriate.

Our Board has also adopted written terms of reference for each of the committee chairs which set out each of the committee chair’s key
responsibilities, including duties relating to determining the frequency, dates and locations of meetings and setting committee meeting agendas, chairing
committee meetings, reporting to our Board and carrying out any other special assignments or any functions as may be requested by our Board.

In addition, our Board, in conjunction with our Chief Executive Officer, will develop and implement a written position description for the role of

our Chief Executive Officer.

Orientation and Continuing Education

We have implemented an orientation program for new directors under which a new director meets separately with the chairman of our Board,

members of the senior executive team and the secretary.

The nominating and corporate governance committee will be responsible for coordinating orientation and continuing director development
programs relating to the committee’s mandate. The chairman of our Board will be responsible for overseeing director continuing education designed to
maintain or enhance the skills and abilities of our directors and to ensure that their knowledge and understanding of our business remains current.

Code of Conduct

Our board of directors has adopted a Code of Ethics that applies to all of our directors, officers and employees. We have made the Code of Ethics
available on our website https://briacell.com/corporate/corporate-governance/. We intend to disclose future amendments to, or waivers of, our Code of
Ethics, as and to the extent required by SEC regulations, at the same location on our website identified above or in public filings.

Monitoring Compliance with the Code of Conduct

Our nominating and corporate governance committee will be responsible for reviewing and evaluating the code of conduct at least annually and
will recommend any necessary or appropriate changes to our Board for consideration. The nominating and corporate governance committee will assist our
Board with the monitoring of compliance with the code of conduct, and will be responsible for considering any waivers therefrom (other than waivers
applicable to members of the nominating and corporate governance committee, which shall be considered by the audit committee, or waivers applicable to
our directors or executive officers, which shall be subject to review by our Board as a whole).

Requirement for Directors and Officers to Disclose Interest in a Contract or Transaction

In accordance with the BCBCA, each director and officer must disclose the nature and extent of any interest that he or she has in a material
contract or material transaction whether made or proposed with us, if the director or officer is a party to the contract or transaction, is a director or an
officer or an individual acting in a similar capacity of a party to the contract or transaction, or has a material interest in a party to the contract or transaction.
Subject to certain limited exceptions under the BCBCA, no director may vote on a resolution to approve a material contract or material transaction which is
subject to such disclosure requirement.

As of the date hereof, except as otherwise disclosed in this Annual Report on Form 10-K, to the knowledge of the Board or the management of the
Company, there are no material interests, whether direct or indirect, of any informed person of the Company, any proposed director of the Company, or any
associate or affiliate of any informed person or proposed director, in any transaction since the commencement of the Company’s most recently completed
financial year or in any proposed transaction which has materially affected or would materially affect the Company of any of its subsidiaries.

Benefits upon Termination of Employment

The service contracts with our directors do not provide for any benefits upon termination of employment, other than a “tail” directors and officers

insurance policy.

Complaint Reporting

In order to foster a climate of openness and honesty in which any concern or complaint pertaining to a suspected violation of the law, our code of
conduct or any of our policies, or any unethical or questionable act or behavior, our code of conduct will require that our employees promptly report the
violation or suspected violation. In order to ensure that violations or suspected violations can be reported without fear of retaliation, harassment or an
adverse employment consequence, we will adopt a whistleblowing policy which will contain procedures that are aimed to facilitate confidential,
anonymous submissions of complaints by our directors, officers, employees and others.

Committees of the Board

We currently have an audit committee, a compensation committee and a nominating and corporate governance committee, with each committee

having a written charter.

Audit Committee

Our Audit Committee is currently comprised of Vaughn C. Embro-Pantalony, Martin Schmieg and Jane A. Gross, and chaired by Mr. Embro-
Pantalony. Our Board has determined that each of Mr. Schmieg and Mr. Embro-Pantalony is financially literate and meets the independence requirements
for directors, including the heightened independence standards for members of the audit committee under Rule 10A-3 under the Exchange Act and NI 52-
110. Our Board has determined that Mr. Embro-Pantalony is “financially sophisticated” within the meaning of the Nasdaq Rules, “financially literate”
within the meaning of NI 52-110, and a “financial expert” as defined by Rule 10A-3 under the Exchange Act.

We have adopted an Audit Committee Charter setting forth the purpose, composition, authority and responsibility of the audit committee. The
primary function of the audit committee is to assist the Board in fulfilling its financial oversight responsibilities by reviewing the financial reports and other
financial information provided by the company to regulatory authorities and the Company’s shareholders, the Company’s systems of internal controls
regarding finance and accounting and the Company auditing, accounting and financial reporting processes. Consistent with this function, the Committee
will encourage continuous improvement of, and should foster adherence to, Company’s policies, procedures and practices at all levels. The Committee’s
primary duties and responsibilities are to:

● Serve as an independent and objective party to monitor the Company’s financial reporting and internal control system and review Company’s

financial statements;

● Review and appraise the performance of the Company’s external auditors; and
● Provide an open avenue of communication among the Company’s auditors, financial and senior management and the Board.

During the year ended July 31, 2023, the Audit Committee held 5 meetings in person or through conference calls. As part of its job to foster open

communication, the Audit Committee meets at least annually with the external auditors.

To fulfill its responsibilities and duties, the Audit Committee:

● Reviews and updates the Audit Committee’s charter annually;
● Reviews the Company’s financial statements, Management Discussion & Analysis and any annual and interim earnings, press
releases before the Company publicly discloses this information and any reports or other financial information (including quarterly
financial statements), which are submitted to any governmental body, or to the public, including any certification, report, opinion, or
review rendered by the external auditors;

● Reviews annually, the performance of the external auditors who shall be ultimately accountable to the Board and the Committee as

representatives of the shareholders of the Company;

● Obtains annually, a formal written statement of external auditors setting forth all relationships between the external auditors and the

Company, consistent with Independence Standards Board Standard I;

● Reviews and discusses with the external auditors any disclosed relationships or services that may impact the objectivity and

independence of the external auditors;

● Takes, or recommends that the full Board takes, appropriate action to oversee the independence of the external auditors;
● Recommends to the Board the selection and, where applicable, the replacement of the external auditors nominated annually for

shareholder approval;

● Reviews and approves the Company’s hiring policies regarding partners, employees and former partners and employees of the

present and former external auditors of the Company;

● Reviews and pre-approves all audit and audit-related services and the fees and other compensation related thereto;
● In consultation with the external auditors, reviews with management the integrity of the Company’s financial reporting process, both

internal and external;

● Considers the external auditors’ judgments about the quality and appropriateness of the Company’s accounting principles as applied

in its financial reporting;

● Considers and approves, if appropriate, changes to the Company’s auditing and accounting principles and practices as suggested by

the external auditors and management;

● Reviews significant judgments made by management in the preparation of the financial statements and the view of the external

auditors as to appropriateness of such judgments;

● Following completion of the annual audit, reviews separately with management and the external auditors any significant difficulties

encountered during the course of the audit, including any restrictions on the scope of work or access to required information;

● Reviews any significant disagreement among management and the external auditors in connection with the preparation of the

financial statements;

● Reviews with the external auditors and management the extent to which changes and improvements in financial or accounting

practices have been implemented;

● Reviews any complaints or concerns about any questionable accounting, internal accounting controls or auditing matters;
● Reviews certification process; and
● Reviews any related-party transactions.

Principal Accountant’s Fees

External Audit Service Fees

The following table sets forth the aggregate fees paid to the Company’s external auditors, Chartered Professional Accountants, by the Company

during the financial years ended July 31, 2023 and 2022:

Audit Fees
Audit-Related Fees
Tax Fees
All Other Fees
Total:

Compensation Committee

Year ended
July 31, 2023

Year ended
July 31, 2022

153,000 $
113,000
81,400

347,400 $

232,884
-
11,900
17,134
261,918

Our compensation committee is comprised of Mr. Embro-Pantalony and Mr. Schmieg and is chaired by Mr. Schmieg. The Compensation
Committee is appointed by the Board to assist in promoting a culture of integrity throughout the Company, to assist the Board in setting director and senior
executive compensation, and to develop and submit to the Board recommendations with respect to other employee benefits as the Compensation
Committee sees fit. In the performance of its duties, the Compensation Committee is guided by the following principles:

● offering competitive compensation to attract, retain and motivate highly qualified executives in order for the Company to meet its goals; and

● acting in the interests of the Company and the shareholders by being fiscally responsible.

The Board relies on the knowledge and experience of the members of the Compensation Committee to set appropriate levels of compensation for
senior officers. Neither the Company nor the Compensation Committee currently has, or has had at any time since incorporation, any contractual
arrangement with any executive compensation consultant who has a role in determining or recommending the amount or form of senior officer
compensation.

When determining compensation payable, the Compensation Committee considers both external and internal data. External data includes general
market conditions and well as information regarding compensation paid to directors, CEOs and CFOs of companies of similar size and at a similar stage of
development in the industry. Internal data includes annual reviews of the performance of the directors, CEO and CFO in light of the Company’s corporate
objectives and considers other factors that may have impacted the Company’s success in achieving its objectives. During the year ended July 31, 2023, the
Compensation Committee held four meetings in person or through conference calls.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is appointed by the Board to assist in fulfilling its corporate governance responsibilities
under applicable laws. The Nominating and Corporate Governance Committee is responsible for, among other things, developing the Company’s approach
to governance issues and establishing sound corporate governance practices that are in the interests of shareholders and that contribute to effective and
efficient decision-making.

Our Nominating and Corporate Governance Committee is currently comprised of Mr. Marc Lustig and Dr. Taub and is chaired by Mr. Lustig.

During the year ended July 31, 2023, the Nominating and Corporate Governance Committee held one meeting in person.

Exculpation, Insurance and Indemnification of Directors and Officers

Under the BCBCA, a company may indemnify: (i) a current or former director or officer of that company; (ii) a current or former director or
officer of another corporation if, at the time such individual held such office, the corporation was an affiliate of the company, or if such individual held such
office at the company’s request; or (iii) an individual who, at the request of the company, held, or holds, an equivalent position in another entity (an
“indemnifiable person”) against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by
him or her in respect of any civil, criminal, administrative or other legal proceeding or investigative action (whether current, threatened, pending or
completed) in which he or she is involved because of that person’s position as an indemnifiable person, unless: (i) the individual did not act honestly and in
good faith with a view to the best interests of such company or the other entity, as the case may be; or (ii) in the case of a proceeding other than a civil
proceeding, the individual did not have reasonable grounds for believing that the individual’s conduct was lawful. A company cannot indemnify an
indemnifiable person if it is prohibited from doing so under its articles or by applicable law. A company may pay, as they are incurred in advance of the
final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an indemnifiable person in respect of that proceeding only if
the indemnifiable person has provided an undertaking that, if it is ultimately determined that the payment of expenses was prohibited, the indemnifiable
person will repay any amounts advanced. Subject to the aforementioned prohibitions on indemnification, a company must, after the final disposition of an
eligible proceeding, pay the expenses actually and reasonably incurred by an indemnifiable person in respect of such eligible proceeding if such
indemnifiable person has not been reimbursed for such expenses, and was wholly successful, on the merits or otherwise, in the outcome of such eligible
proceeding or was substantially successful on the merits in the outcome of such eligible proceeding. On application from an indemnifiable person, a court
may make any order the court considers appropriate in respect of an eligible proceeding, including the indemnification of penalties imposed or expenses
incurred in any such proceedings and the enforcement of an indemnification agreement. As permitted by the BCBCA, under Article 21.1, we are required
to indemnify our directors and former directors (and such individual’s respective heirs and legal representatives) and we will indemnify any such person to
the extent permitted by the BCBCA.

The BCBCA provides certain protections under Part 5 – Management, Division 5 - Indemnification of Directors and Officers and Payment of
Expenses, to our current and former directors and officers, as well as other eligible parties defined in Section 159 of the BCBCA (the “Eligible Parties”,
each an “Eligible Party”). The Company will indemnify the Eligible Parties, to the fullest extent permitted by law and subject to certain limitations listed in
Section 163 of the BCBCA, against any proceeding in which an Eligible Party or any of the heirs and personal or other legal representatives of the Eligible
Party, by reason of the Eligible Party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or
officer of, the Company or an associated corporation (a) is or may be joined as a party, or (b) is or may be liable for or in respect of a judgment, penalty or
fine in, or expenses related tom, the proceeding.

We maintain insurance policies relating to certain liabilities that our directors and officers may incur in such capacity.

ITEM 11. EXECUTIVE COMPENSATION

Summary Compensation Table

The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the years ended July 31, 2023 and
July 31, 2022.

Name and Principal Position
William V. Williams, MD, FRCP
President and Chief Executive Officer
Gadi Levin, CA, MBA
Chief Financial Officer and Corporate Secretary
Giuseppe Del Priore, MD, MPH(2)
Chief Medical Officer
Miguel A. Lopez-Lago, PhD(3)
Chief Scientific Officer

Year
2022
2023
2022
2023
2022
2023
2022
2023

Salary
($)
560,992
736,555
202,091
285,715
199,665
466,927
211,616
282,247

Bonus
($)
150,000
48,750
45,000
18,750
-
25,578
35,000
16,650

Stock
Awards
($)(1)

Option
Awards
($)
100,152
430,209
9,240
86,970
215,881
456,396
22,456
69,547

All Other
Compensation
($)

-
-
-
-
-
-
-
-

Total
($)
811,144
1,215,514
256,331
391,435
415,546
948,901
269,072
368,444

(1) This column represents the grant date fair value of the award in accordance with stock-based compensation rules under Accounting Standards
Codification Topic 718. For a more detailed discussion of the valuation model and assumptions used to calculate the fair value of each option award,
refer to Note 2 of the financial statements included in this annual report.

(2) Giuseppe Del Priore was appointed as the Chief Medical Officer on February 16, 2022

(3) Miguel A. Lopez-Lago was appointed as the Chief Scientific Officer on May 26, 2022

Outstanding Equity Awards at Fiscal Year-End

The following table provides information regarding option awards held by each of our named executive officers that were outstanding as of July 31, 2023.

Option Awards

Stock Awards

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

Option
Exercise Price
($)

Option
Expiration Date

Number of
shares or units
of
stock that
have not vested
(#)

Market value
of
shares or units
of
stock that
have not vested
($)

200,000
22,300
50,900
5,000
19,200(1)

75,000
12,500
10,150

112,500
5,000

13,125
5,000

-
-
50,900
35,000
-

-
7,500
10,150

37,500
5,000

1,875
5,000

4.24
8.47
6.14
6.03
0.00

4.24
4.71
6.14

7.51
6.14

8.47
6.14

03/29/26
01/13/27
08/02/27
06/20/28
08/02/27

03/29/26
05/20/27
08/02/27

02/16/27
08/02/27

01/13/27
08/02/27

-
-
-
-
-

-
-
-

-
-

-
-
-
-
-

-
-
-

-
-

Name

William V.
Williams, MD,
FRCP

Gadi Levin, CA,
MBA

Giuseppe Del
Priore, MD, MPH

Miguel A. Lopez-
Lago, PhD

(1) Restricted Share Units

Non-Employee Director Compensation

The following table presents the total compensation for each person who served as a non-employee member of our Board and received compensation for
such service during the fiscal year ended July 31, 2023. Other than as set forth in the table and described more fully below, we did not pay any
compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our Board in 2023.

Fees
Earned or
Paid in
Cash
($)
187,984

89,414
65,625
73,125
57,501
43,749

Stock
Awards
($)

-
-
-
-
-

Option
Awards
($)
489,092

All Other
Compensation
($)

97,818
97,818
97,818
37,936
97,818

-
-
-
-
-

Total
($)
677,076

187,232
163,443
170,943
95,437
141,567

Name
Jamieson Bondarenko, CFA, CMT
Vaughn C. Embro-Pantalony, MBA, FCPA, FCMA, CDIR,
ACC
Marc Lustig, MSC, MBA
Martin E. Schmieg
Rebecca Taub, MD
Jane A. Gross, PhD

Employment Agreements

Dr. Williams V. Williams

On August 31, 2021, we entered into a compensation package with Dr. Williams, our Chief Executive Officer (the “2021 Compensation Package”).
Pursuant to the 2021 Compensation Package, Mr. Williams receives $550,000 annually and may earn an equity incentive bonus compensation, which may
include a direct stock award of up to $125,000 based upon a performance review as of December 31, 2021 (the “Performance Review”). In addition, the
2021 Compensation Package provides for an option award to purchase up to $250,000 in common shares of the Company, in connection with the
Performance Review, which vests over a four year period and provides for an aggregate cash, stock and option award of up to $950,000.

On June 21, 2022, we entered into a compensation package with Dr. Williams (the “2022 Compensation Package”). Pursuant to the 2022 Compensation
Package, Mr. Williams receives $650,000 annually and an annual bonus of $150,000. In addition, the 2022 Compensation Package provides for a
performance stock option award of $250,000 and a total cash, bonus and option award of up to $1,050,000. On May 1, 2023, Dr. Williams’ annual salary
was increased to $675,000 per annum.

Giuseppe Del Priore

On February 14, 2022, we entered into an employment agreement with Dr. Giuseppe Del Priore, our Chief Medical Officer (the “Del Priore Employment
Agreement”). The Del Priore Employment Agreement provides for a full-time position, $350,000 annual salary and standard employee benefit plan
participation. In addition, Mr. Del Priore was granted an option to purchase 150,000 of the Company’s common shares. The Del Priore Employment
Agreement provides that Mr. Del Priore is eligible for an annual bonus in either cash or options to purchase common shares of the Company based on the
successful completion of certain corporate milestones selected by our Chief Executive Officer and reviewed in the sole discretion of our Board or a
compensation committee. On May 1, 2023, Dr. Giuseppe Del Priore’s annual salary was increased to $460,000 per annum.

Gadi Levin

On March 2, 2022, we entered into an executive employment agreement with Gadi Levin, our Chief Financial Officer (the “Levin Employment
Agreement”), effective January 1, 2022. The Levin Employment Agreement provides for a part-time position (80%), $350,000 annual salary (“Base
Salary”) and standard employee benefit plan participation. Our Board approved a annual discretionary bonus of (i) up to 30% of Mr. Levin’s yearly salary;
and (ii) $100,000 in stock options, which vest over a four year period per calendar year. In addition, Mr. Levin was granted 20,000 options in accordance
with the terms of the Company’s stock option plan. During August 2022, Mr. Levin’s Base Salary was increased to $250,000, retroactively to January 1,
2022. On May 1, 2023, Mr. Leving’s Base Salary was increased to $350,000 per annum.

Miguel Lopez-Lago

On May 26, 2022, we entered into an employment agreement with Miguel Lopez-Lago, our Chief Scientific Officer (the “Lopez-Lago Employment
Agreement”). The Lopez-Lago Employment Agreement provides for $210,000 annually for Mr. Lopez-Lago’s duties as our Chief Scientist Officer. On
May 1, 2023, Mr. Lopez-Lago’s annual salary was increased to $325,000 per annum.

Equity Compensation Plan Information

The following table summarizes the total number of outstanding awards and shares available for other future issuances of options under all of our

equity compensation plans as of July 31, 2023. All of the outstanding awards listed below were granted under our stock option plan.

Plan Category
Equity compensation plans approved by shareholders
Equity compensation plans not approved by shareholders

Number of Shares to
be Issued Upon
Exercise of
Outstanding
Options,

Warrants and Rights
10,299,702
-

Weighted-Average
Exercise Price of
Outstanding
Options,
Warrants and Rights
5.84
$
-

Number of Shares
Remaining Available
for Future Issuance
Under the Equity
Compensation Plan
(Excluding Shares in
First Column)

265,859
-

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS

The following table sets forth certain information regarding the beneficial ownership of our common shares as of October 25, 2023 by:

● each of our named executive officers;

● each of our directors;

● all of our current directors and executive officers as a group; and

● each shareholder known by us to own beneficially more than 5% of our common shares.

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
Common shares that may be acquired by an individual or group within 60 days of October 25, 2023, pursuant to the exercise of options or warrants, vesting
of common shares or conversion of preferred stock or convertible debt, are deemed to be outstanding for the purpose of computing the percentage
ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person
shown in the table. Percentage of ownership is based on 15,981,726 common shares issued and outstanding as of October 25, 2023.

Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all
common shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise indicated, the
address for each director and executive officer listed is: c/o BriaCell Therapeutics Corp., Suite 300 – 235 15th Street, West Vancouver, BC V7T 2X1.

Name of Beneficial Owner
Directors and Named Executive Officers
Jamieson Bondarenko, CFA, CMT(1)
William V. Williams, MD, FRCP(2)
Gadi Levin, CA, MBA(3)
Giuseppe Del Priore, MD, MPH(4)
Miguel A. Lopez-Lago, PhD(5)
Vaughn C. Embro-Pantalony, MBA, FCPA, FCMA, CDIR, ACC(6)
Marc Lustig, MSC, MBA
Martin E. Schmieg(7)
Rebecca Taub, MD(8)
Jane A. Gross, PhD(9)
All current named executive officers and directors as a group (10 persons)

5% or Greater Shareholders
Marc Lustig, MSC, MBA

* Represents beneficial ownership of less than 1%.

Notes :

Number of
Shares
Beneficially
Owned

Percentage
of Common
Shares
Beneficially
Owned

644,856
476,838
100,460
117,500
18,125
89,524
1,765,000
80,575
25,000
65,000
3,382,878

4.03%
2.98%
*
*
*
*

11.04%

*
*
*

21.16%

1,765,000

11.04%

(1)

(2)

(3)

(4)

(5)

Includes 150,000 BriaCell Options with an exercise price of $4.24, expiring on March 29, 2026, 250,000 BriaCell Options with an exercise price
of $8.47, expiring on January 13, 2027, 25,000 BriaCell Options with an exercise price of $6.03, expiring on June 20, 2028 and 100,000 BriaCell
Warrants to purchase common shares with an exercise price of $5.3125, expiring on February 26, 2026.
Includes 150,000 options with an exercise price of $4.35, expiring on March 29, 2026, 187,500 options with an exercise price of $8.47, expiring
on January 13, 2027, 100,000 warrants to purchase common shares with an exercise price of $5.3125, expiring on February 26, 2026 and 19,200
restricted share units.
Includes 200,000 BriaCell Options with an exercise price of $4.24, expiring on March 29, 2026, 22,300 BriaCell Options with an exercise price
of $8.47, expiring on January 13, 2027, 50,900 BriaCell Options with an exercise price of C$8.38, expiring on August 2, 2027, 5,000 BriaCell
Options with an exercise price of $6.03, expiring on June 20, 2028 and 29,802 BriaCell Warrants to purchase common shares with an exercise
price of $5.3125, expiring on February 26, 2026.
Includes 75,000 BriaCell Options with an exercise price of US$4.24, expiring on March 29, 2026, 12,500 BriaCell Options with an exercise price
of US$4.71, expiring on May 20, 2027 and 12,687 BriaCell Options with an exercise price of C$8.38, expiring on August 2, 2027.
Includes 112,500 BriaCell Options with an exercise price of US$7.51, expiring on February 16, 2027 and 10,000 BriaCell Options with an
exercise price of C$8.38, expiring on August 2, 2027.

(6) 11,250 BriaCell Options with an exercise price of $8.47, expiring on January 13, 2027 and 10,000 BriaCell Options with an exercise price of

(7)

C$8.38, expiring on August 2, 2027.
Includes 25,000 BriaCell Options with an exercise price of US$4.24, expiring on March 29, 2026, 50,000 BriaCell Options with an exercise price
of $8.47, expiring on January 13, 2027 and 5,000 BriaCell Options with an exercise price of $6.03, expiring on June 20, 2028.

(8) Securities held by L5 Capital Inc. includes 100,000 BriaCell Options with an exercise price of US$5.74, expiring on September 1, 2026 and 5,000

(9)

BriaCell Options with an exercise price of $6.03, expiring on June 20, 2028.
Includes 25,000 BriaCell Options with an exercise price of US$4.24, expiring on March 29, 2026 and 37,500 BriaCell Options with an exercise
price of $8.47, expiring on January 13, 2027 and 5,000 BriaCell Options with an exercise price of $6.03, expiring on June 20, 2028.

(10) Includes 5,000 BriaCell Options with an exercise price of US$4.24, expiring on March 29, 2026 and 5,000 BriaCell Options with an exercise

price of $8.47, expiring on January 13, 2027 and 5,000 BriaCell Options with an exercise price of $6.03, expiring on June 20, 2028.

(11) Includes 5,000 BriaCell Options with an exercise price of US$7.74, expiring on November 1, 2026 and 50,000 BriaCell Options with an exercise

price of $8.47, expiring on January 13, 2027 and 5,000 BriaCell Options with an exercise price of $6.03, expiring on June 20, 2028.

Section 16(A) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than 10% of a registered class of our equity securities, to
file reports of ownership and changes in ownership with the SEC. Officers, directors and greater than 10% shareholders are required by SEC regulations to
furnish us with copies of all Section 16(a) forms they file.

Based on a review of the copies of such forms received, we believe that during the fiscal year ending July 31, 2023, all filing requirements applicable to our
officers, directors and greater than 10% beneficial owners were complied with.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

There have been no transactions since August 1, 2022 to which we have been a party, including transactions in which the amount involved in the
transaction exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years, and in which any of
our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of
any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control
and other arrangements, which are described elsewhere in this Annual Report on Form 10-K. We are not a party to a current related party transaction, and

no transaction is currently proposed, in which the amount of the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets at year-
end for the last two completed fiscal years and in which a related person had or will have a direct or indirect material interest.

Director Independence

Our board of directors undertook a review of the independence of our directors and considered whether any director has a relationship with us that could
compromise that director’s ability to exercise independent judgment in carrying out that director’s responsibilities. Our board of directors has affirmatively
determined that Dr. Gross, Dr. Taub. Mr. Bondarenko, Mr. Empro-Pantalony, Mr. Lustig, and Mr. Schmieg are each an “independent director,” as defined
under the Nasdaq rules.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Audit Fees

The aggregate fees billed to us by MNP LLP, our independent registered public accounting firm, for the indicated services for each of the last two fiscal
years were as follows:

Audit fees (1)
Audit-related fees (2)
Tax fees
All other fees

2023

2022

153,000 $
113,000 $
81,400 $
- $

232,884
-
11,900
17,134

$
$
$
$

(1) Audit fees consist of fees for professional services performed by MNP LLP for the audit and review of our quarterly financial statements.
(2) Audit related fees consist of fees for preparation and filing of the carve-out financial statements related to the proxy statement filed.

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and
permissible non-audit services provided by our independent registered public accounting firm on a case-by-case basis. Our Audit Committee has
established a policy regarding approval of all audit and permissible non-audit services provided by our principal accountants. Our Audit Committee pre-
approves these services by category and service. Our Audit Committee has pre-approved all of the services provided by our independent registered public
accounting firm.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

Exhibit
Number

(b) Exhibits

(a)(1) Financial Statements

Description of Exhibit

The financial statements required by this item are submitted in a separate section beginning on page F-1 of this Annual Report on Form 10-
K.

Exhibit
3.1

Description
Articles of BriaCell Therapeutics Corp, dated July 26, 2006

3.2

3.3

3.4

3.5

3.6

3.7

4.1

10.1

10.2

10.3

10.4

10.5

10.6

10.7

10.8

10.9

Articles of BriaCell Therapeutics Corp, dated October 22, 2019

Notice of Articles, dated November 25, 2014

Notice of Articles, dated August 22, 2019

Alteration to Articles of BriaCell Therapeutics Corp., dated February 13, 2023

Notice of Articles filed August 31, 2023

Description of Securities Registered Under Section 12 of the Exchange Act

Stock Option Plan, dated November 25, 2014

Service Agreement with UC Davis, dated June 11, 2015

Clinical Study Agreement with Cancer Insight, LLC, dated May 2, 2016

Amendment #1 to Service Agreement with UC Davis, dated June 12, 2016

Licensing Agreement between Faller & Williams Technology LLC and Sapientia Pharmaceuticals, Inc., dated March 16, 2017

Master Services Agreement with KBI Biopharma, Inc., dated March 17, 2017

Clinical Study Agreement with Cancer Insight, LLC, dated September 29, 2017

Amendment #2 to Service Agreement with UC Davis, dated August 27, 2018

First Supplement to Clinical Study Agreement with Cancer Insight, LLC, dated October 18, 2018

10.10

Amendment #1 to Services Agreement with Colorado State University, dated April 2, 2019

10.11

10.12

10.13

Stem Cell Program Services Agreement with UC Davis, May 3, 2019

HLA Typing Services Agreement with Histogenetics, dated October 3, 2019

Procurement Agreement with Catalent Pharma Solutions, LLC, dated June 13, 2019

10.14

10.15

10.16

10.17

10.18

10.19

10.20

10.21

Clinical Supply Services Agreement with Catalent Pharma Solutions, LLC, dated June 13, 2019

Quality Agreement with Catalent Pharma Solutions, LLC, dated June 25, 2019

Master Services Agreement, dated February 27, 2020

Cooperative Research and Development Agreement, dated October 28, 2020

Form of Securities Purchase Agreement (June 2021)

Form of Placement Agency Agreement (June 2021)

Form of Registration Rights Agreement (June 2021)

Form of Underwriting Agreement dated February 22, 2021

10.22+

Compensation Agreement with Dr. William V. Williams, dated August 31, 2021

10.23

Compensation Agreement with Dr. William V. Williams, dated June 21, 2022

10.24+

Employment Agreement with Giuseppe Del Priore, dated February 14, 2022

10.25+

Employment Agreement with Gadi Levin, dated March 2, 2022

10.26+

Employment Agreement with Miguel Lopez-Lago, dated May 26, 2022

10.27

10.28

10.29

10.30

10.31

21.1

31.1

31.2

32.1

Exclusive License Agreement

Omnibus Equity Incentive Plan (incorporated by reference from Schedule I to the Proxy Statement for BriaCell Therapeutics Corp. 2023

Annual and Special Meeting of Shareholders, filed with the SEC on January 17, 2023).

Master Service and Technology Agreement dated May 9, 2023

Stock Purchase Agreement dated May 12, 2023

Arrangement Agreement dated May 24, 2023

List of Subsidiaries

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley

Act of 2002**

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley

Act of 2002**

101.INS
101.SCH
101.CAL
101.LAB
101.PRE
101.DEF
104

Inline XBRL Instance Document
Inline XBRL Taxonomy Extension Schema
Inline XBRL Taxonomy Extension Calculation Linkbase
Inline XBRL Taxonomy Extension Labels Linkbase
Inline XBRL Taxonomy Extension Presentation Linkbase
Inline XBRL Taxonomy Extension Definition Linkbase
Cover Page Interactive Data File (embedded within the Inline XBRL document)

Indicates a management contract or compensatory plan or arrangement.
+
*
Filed herewith
** Furnished herewith

ITEM 16. FORM 10-K SUMMARY

None.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed

on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

October 25, 2023

BRIACELL THERAPEUTICS CORP.

/s/ William V. Williams
Chief Executive Officer (Principal Executive Officer and Principal
Accounting and Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the

Registrant and in the capacities and on the dates indicated.

SIGNATURE

TITLE

DATE

/s/ William V. Williams
William V. Williams

/s/ Gadi Levin
Gadi Levin

/s/ Jamieson Bondarenko
Jamieson Bondarenko

/s/ Vaughn C. Embro-Pantalony
Vaughn C. Embro-Pantalony

/s/ Marc Lustig
Marc Lustig

/s/ Martin E. Schmieg
Martin E. Schmieg

/s/ Rebecca Taub
Rebecca Taub

/s/ Jane A. Gross
Jane A. Gross

Chief Executive Officer, President and Director

October 25, 2023

(Principal Executive Officer)

Chief Financial Officer and Corporate Secretary (Principal
Accounting and Financial Officer)

October 25, 2023

Chairman of the Board of Directors

October 25, 2023

Director

October 25, 2023

Consolidated Financial Statements

For the Years Ended July 31, 2023 and 2022
Expressed in United States Dollars

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of BriaCell Therapeutics Corp.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of BriaCell Therapeutics Corp. (the Company) as of July 31, 2023 and 2022, and the
related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity, and cash flows for each of the years in the two-year
period ended July 31, 2023, and the related notes (collectively referred to as the consolidated financial statements).

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of July
31, 2023 and 2022, and the results of its consolidated operations and its consolidated cash flows for each of the years in the two-year period ended July 31,
2023, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain
an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis
for our opinion.

Chartered Professional Accountants
Licensed Public Accountants

We have served as the Company’s auditor since 2015.

Mississauga, Canada

October 25, 2023

F-2

BriaCell Therapeutics Corp
Consolidated Balance Sheets
As at July 31, 2023 and 2022
(Expressed in US Dollars, except share and per share data)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents
Amounts receivable
Prepaid expenses

Total current assets

NON-CURRENT ASSETS:

Investments
Intangible assets, net
Total non-current assets

Total assets

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables
Accrued expenses and other payables
Total current liabilities

NON-CURRENT LIABILITIES:

Warrant liability
Total non-current liabilities

CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:
Share Capital of no par value – Authorized: unlimited at July 31, 2023 and 2022; Issued and
outstanding: 15,981,726 and 15,518,018 shares at July 31, 2023 and 2022, respectively
Share-based payment reserved
Warrant reserve
Accumulated other comprehensive loss
Accumulated deficit
Total shareholders’ equity (deficit)

July 31,

2023

2022

21,251,092
18,873
5,678,542
26,948,507

2
215,068
215,070

41,041,652
24,103
1,280,945
42,346,700

2
230,339
230,341

27,163,577

42,577,041

1,123,739
677,718
1,801,457

463,280
477,807
941,087

29,139,301
29,139,301

31,307,022
31,307,022

69,591,784
7,421,950
-
(138,684)
(80,652,231)
(3,777,181)

65,589,293
5,228,160
-
(138,684)
(60,349,837)
10,328,932

Total liabilities and shareholders’ equity (deficit)

27,163,577

42,577,041

These consolidated financial statements were approved and authorized for issue on behalf of the Board of Directors on October 25, 2023 by:

On behalf of the Board:

“Jamieson Bondarenko”
Director

“William Williams”
Director

The accompanying notes are an integral part of these consolidated financial statements.

F-3

BriaCell Therapeutics Corp
Consolidated Statements of Operations and Comprehensive Loss
For the Years Ended July 31, 2023 and 2022
(Expressed in US Dollars, except share and per share data)

Research and development expenses
General and administrative expenses

Total operating loss

Financial income (expenses), net

Loss and comprehensive loss
Net loss per share attributable to ordinary shareholders, basic and diluted

Weighted average number of shares used in computing net loss per share attributable to
ordinary shareholders, basic and diluted

Year ended
July 31,

2023

2022

15,336,638
7,935,626

8,021,489
7,267,452

(23,272,264)

(15,288,941)

2,969,870

(11,549,962)

(20,302,394)
(1.30)

$
$

15,619,676

(26,838,903)
(1.73)

15,494,091

$
$

The accompanying notes are an integral part of these consolidated financial statements.

F-4

BriaCell Therapeutics Corp
Consolidated Statements of Changes in Shareholders’ Equity
For the Years Ended July 31, 2023 and 2022
(Expressed in US Dollars , except share and per share data)

Share capital

Number Amount

ADDITIONAL

PAID IN
CAPITAL

ACCUMULATED
OTHER

COMPREHENSIVE ACCUMULATED

INCOME (LOSS)

DEFICIT

TOTAL
SHAREHOLDERS’
EQUITY
(DEFICIT)

Balance, July 31, 2021
Exercise of Broker Warrants
Exercise of Private Placement
Warrants
Exercise of Public Offering
Warrants
Shares Issuance Costs
Issuance of Options
Shares Repurchased and
canceled
Expiration of options
Loss for the year
Balance, July 31, 2022
Issuance of Options
Exercise of warrants
Issuance of shares
Loss for the year
Balance, July 31, 2023

15,269,583 $ 54,774,172 $

2,178,130 $

(138,684) $

(29,141,897) $

219,453

2,730,754

997,200

12,162,001

63,454
-
-

683,905
(57,116)
-

(1,031,672)
-
-
15,518,018
-
300
463,408
-

(4,704,423)
-
-
65,589,293
-
2,491
4,000,000
-

-
-
3,074,584

-
(24,554)
-
5,228,160
2,193,790
-
-
-

-
-
-

-
-
-
(138,684)
-
-
-
-

15,981,726 $ 69,591,784 $

7,421,950 $

(138,684) $

-
-
-

(4,393,591)
24,554
(26,838,903)
(60,349,837)
-
-
-
(20,302,394)
(80,652,231)

27,671,721
2,730,754

12,162,001

683,905
(57,116)
3,074,584

(9,098,014)
-
(26,838,903)
10,328,932
2,193,790
2,491
4,000,000
(20,302,394)
(3,777,181)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

BriaCell Therapeutics Corp
Consolidated Statements of Cash Flows
For the Years Ended July 31, 2023 and 2021
(Expressed in US Dollars, except share and per share data)

Cash flow from operating activities:
Loss
Adjustments to reconcile loss to net cash used in operating activities:

Amortization
Share-based compensation
Interest expense
Gain from government grant
Change in fair value of warrants

Changes in assets and liabilities:

Decrease (increase) in amounts receivable
Increase in prepaid expenses
Increase in accounts payable
Increase in accrued expenses and other payables

Net cash used in operating activities

Cash flow from financing activities:
Proceeds from exercise of warrants
Share and warrant buyback program
Repayment government grant
Proceeds from issuance of shares
Share issuance costs

Net cash provided by (used in) financing activities

Decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year

Year ended
July 31,

2023

2022

(20,302,394) $

(26,838,903)

15,271
2,193,790
-
-
(2,119,530)

5,230
(4,397,597)
660,459
199,911
(23,744,860)

1,594
(47,294)
-
4,000,000
-
3,954,300

(19,790,560)
41,041,652
21,251,092 $

15,272
3,074,584
979
(3,388)
11,658,372

(11,530)
(764,054)
249,164
135,128
(12,484,376)

6,509,768
(10,171,732)
(23,577)
-
(57,116)
(3,742,657)

(16,227,033)
57,268,685
41,041,652

The accompanying notes are an integral part of these consolidated financial statements.

F-6

BriaCell Therapeutics Corp
Notes to the Consolidated Financial Statements
For the Years Ended July 31, 2023 and 2022
(Expressed in US Dollars, except share and per share data and unless otherwise indicated)

NOTE 1: GENERAL

a. BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) was incorporated under the Business Corporations Act (British Columbia) on July 26,
2006 and is listed on the Toronto Stock Exchange (“TSX”) under the symbol “BCT” and the Company also trades on the Nasdaq Capital Market
(“NASDAQ”) under the symbols “BCTX” and “BCTXW”.

b. BriaCell Therapeutics Corporation. (the “Company”), is an immuno-oncology biotechnology company. The Company is currently advancing its
Bria-IMT targeted immunotherapy program against end-stage breast cancer to Phase 3 study which has been approved by the FDA and is expected
to start before end of 2023. BriaCell is also developing a personalized off-the-shelf immunotherapy, Bria-OTS™, and a soluble CD80 protein
therapeutic which acts both as a stimulator of the immune system as well as an immune checkpoint inhibitor.

c. The Company continues to devote substantially all of its efforts toward research and development activities. In the course of such activities, the
Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of
July 31, 2023 was $80,652,231(July 31, 2022 - $60,349,837) and negative cash flows from operating activities during the year ended July 31,
2023 was $23,744,860 (July 31, 2022 - $12,484,376). The Company is planning to finance its operations from its existing and future working
capital resources and to continue to evaluate additional sources of capital and financing. The Company believes that its existing capital resources
will be adequate to satisfy its expected liquidity requirements for at least twelve months from the issuance of the consolidated financial statements.

d. The Company has two wholly-owned U.S. subsidiaries: (i) BriaCell Therapeutics Corp. (“BTC”), which was incorporated in April 3, 2014, under
the laws of the state of Delaware. (ii) BTC has a wholly-owned subsidiary, Sapientia Pharmaceuticals, Inc. (“Sapientia”), which was incorporated
in September 20, 2012, under the laws of the state of Delaware. The Company also has one Canadian subsidiary: BriaPro Therapeutics Corp,
(“BriaPro”) which was incorporated on May 15, 2023, was incorporated under the Business Corporations Act (British Columbia). As of July 31,
2023, BriaPro was a wholly-owned. See also note 15a. (Sapientia and BTC and BriaPro together, the “Subsidiaries”)

The Company has one operating segment and reporting unit.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

a. Basis of presentation of the financial statements:

The Company’s consolidated financial statements have been prepared in accordance with the United States generally accepted accounting
principles (U.S. GAAP) as set forth in the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (ASC).

F-7

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.)

b. Use of estimates, assumptions and judgements:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the
estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments
and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported
amount of expenses during the reporting periods. Actual results could differ from those estimates.

Going Concern

Preparation of the consolidated financial statement on a going concern basis, which contemplates the realization of assets and payments of
liabilities in the ordinary course of business. Should the Company be unable to continue as a going concern, it may be unable to realize the
carrying value of its assets, including its intangible assets and to meet its liabilities as they become due.

Warrants and options

The Company uses the Black-Scholes option-pricing model to estimate the fair value of options at the grant date, and the warrant liability at the
grant date and each reporting period date. The key assumptions used in the model are the expected future volatility in the price of the Company’s
shares and the expected life of the warrants.

Income Taxes

Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors.
The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an
additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the
amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

Intangible assets

Intangible assets are tested for impairment annually or more frequently if there is an indication of impairment. The carrying value of intangibles
with definite lives is reviewed each reporting period to determine whether there is any indication of impairment. If there are indications of
impairment the impairment analysis is completed and if the carrying amount of an asset exceeds its recoverable amount, the asset is impaired and
impairment loss is recognized.

c. Principal of consolidation:

The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have
been eliminated upon consolidation.

d. Consolidated financial statements in U.S dollars:

The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiary operates and
conducts their transactions. The Company’s management believes that the functional currency of the Company and its subsidiaries is the U.S.
dollar.

Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars at each reporting period end
in accordance with ASC No. 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are
reflected in the statements of operations as financing income or expenses as appropriate.

F-8

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.)

e. Cash and cash equivalents:

Cash equivalents are short-term highly liquid deposits that are readily convertible to cash with original maturities of three months or less, at the
date acquired, and investments with maturities of longer than three months where the investment can be liquidated before the maturity date
without a significant penalty.

f. Property and equipment, net:

Property and equipment with individual values of over $2,500 are stated at cost, net of accumulated depreciation. Depreciation is calculated using
the straight-line method over the estimated useful lives of the assets at the following annual rates:

Computers and peripheral equipment

g. Intangible assets, net:

%
20-33

Separately acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a
business combination are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding
capitalized development costs, are recognized in profit or loss when incurred.

Intangible assets with finite useful lives are amortized over their useful lives and whenever there is an indication that the asset may be impaired.
The evaluation is performed at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and
liabilities. Recoverability of these group of assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the
group of assets is expected to generate. If such review indicates that the carrying amount of intangible assets is not recoverable, the carrying
amount of such assets is reduced to fair value.

The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.

Intangible assets with indefinite useful lives are not systematically amortized and are tested for impairment annually, or whenever there is an
indication that the intangible asset may be impaired. The useful life of these assets is reviewed annually to determine whether their indefinite life
assessment continues to be supportable. If the events and circumstances do not continue to support the assessment, the change in the useful life
assessment from indefinite to finite life is accounted for prospectively as a change in accounting estimate and on that date the asset is tested for
impairment. Commencing from that date, the asset is amortized systematically over its useful life.

The details of intangible assets are as follows:

Useful life
Amortization method
In-house development or purchase

Patents
20 years
Straight-line
Purchase

For the years ended July 31, 2023 and 2022, no indicators of impairment have been identified.

F-9

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.)

h. Research and Development expenses:

Research and development expenses are recognized in the consolidated statements of operations and comprehensive loss when incurred. Research
and development expenses consist of intellectual property, development and production expenditures.

i. Fair value of financial instruments:

The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands
disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a
liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-
tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

Level 1 — Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value

hierarchy gives the highest priority to Level 1 inputs.

Level 2 — Observable inputs that are based on inputs not quoted on active markets but corroborated by market data.

Level 3 — Unobservable inputs are used when little or no market data are available.

The carrying amounts of cash and cash equivalents, trade payable and accrued expenses and other payables approximate their fair value due to the
short-term maturity of such instruments.

The carrying amount of warrant liabilities is recorded at the fair value at each reporting period.

F-10

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.)

j. Leases:

The Company accounts for leases according to ASC 842, “Leases”. The Company determines if an arrangement is a lease and the classification of
that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right
to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use
of the asset. An ROU asset represents the right to use an underlying asset for the lease term and lease liabilities represent the Company’s
obligation to make lease payments arising from the lease agreement. An ROU asset is measured based on the discounted present value of the
remaining lease payments, plus any initial direct costs incurred and prepaid lease payments, excluding lease incentives. The lease liability is
measured at lease commencement date based on the discounted present value of the remaining lease payments. The implicit rate within the
operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (“IBR”) based on the information
available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. An option to
extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company
will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.

The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize right-of-use
(“ROU”) assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and
non-lease components for its leases.

k. Share-based compensation:

The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation – Stock Compensation”, which requires
companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is
recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line basis when the
only condition to vesting is continued service.

The Company has selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The Company
recognizes forfeitures of equity-based awards as they occur. Restricted share units use the share price on the grant date to determine the fair value
of the restricted share unit award.

F-11

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (Cont.)

l. Income Taxes:

The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”, which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed.

ASC 740 offers a two-step approach for recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax
position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not
that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation
processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of July 31, 2023, and 2022 no liability for unrecognized tax benefits was recorded as a result of ASC 740.

m. Basic and diluted net loss per Share:

The Company’s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of
shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is
calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted
method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of
potentially dilutive ordinary shares are anti-dilutive.

n. Recently issued and adopted accounting standards:

As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or
revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The
Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflects this election.

In June 2016, the FASB issued ASU No. 2016-13 (Topic 326), Financial Instruments—Credit Losses: Measurement of Credit Losses on
Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial
asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company
for fiscal years beginning after December 15, 2022. Early adoption is permitted. Effective August 1, 2021, the Company early adopted ASU
2016-13. Adoption of the new standard did not have a material impact on the financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own
Equity (“ASU 2020-06”). The final guidance issued by the FASB for convertible instruments eliminates two of the three models in ASC 470-
20 that require separate accounting for embedded conversion features. Separate accounting is still required in certain cases. Additionally,
among other changes, the guidance eliminates some of the conditions for equity classification in ASC 815-40-25 for contracts in an entity’s
own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share
calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified
share-based payment awards. ASU 2020-06 is effective for the company for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2020. Effective August 1, 2021,
the Company early adopted ASU 2020-06. Adoption of the new standard did not have a material impact on the financial statements.

F-12

NOTE 3: PREPAID EXPENSES

Prepaid expenses as of July 31, 2023 includes an amount of $4,701,679 in respect of a Master Service and Technology Agreement (the “MST Agreement”)
signed with Prevail InfoWorks, Inc. (“InfoWorks”) pursuant to which InfoWorks will provide clinical services and technologies for the Company’s
upcoming pivotal study in advanced metastatic breast cancer. The Company paid InfoWorks an upfront fee of $5,379,945 upon signing of the MST
Agreement. These fees will be amortized over the period of the clinical trial.

NOTE 4: INTANGIBLE ASSETS. NET

Acquired intangible assets with finite lives consisted of the following as of July 31, 2023 and 2022:

Patents
Gross intangible assets
Less – accumulated amortization
Intangible assets, net

July 31,

2023

2022

305,130 $
305,130
(90,062)
215,068 $

305,130
305,130
(74,791)
230,339

The attributable intellectual property relates to Sapientia’s various patents, which the Company is amortizing over 20 years, consistent with its accounting
policy.

Amortization expenses for the years ended July 31, 2023 and 2022, were $15,271 and $15,271, respectively.

The estimated future amortization expense of intangible assets as of July 31, 2023 is as follows:

2024
2025
2026
2027
2028 and thereafter

See also note 14a regarding the transfer of the intangible asset.

NOTE 5: ACCRUED EXPENSES AND OTHER PAYABLES

Clinical activities
Professional services

15,271
15,271
15,271
15,271
153,984
215,068

July 31,

2023

2022

20,000
657,718
677,718 $

69,720
408,087
477,807

F-13

NOTE 6: CONTINGENT LIABILITIES AND COMMITMENTS

Legal proceedings:

On May 24, 2023, the Company reached a settlement agreement with an investor who made certain claims against the Company and was seeking
monetary and injunctive relief, and against which the Company had filed counterclaims. Pursuant to the settlement agreement, the Company paid
$230,000 for the full and final settlement of all of the investor’s claims, in full and final settlement of any and all existing claims that the Company
and investor had or may have had against each other. This amount has been included in general and administrative expenses in the consolidated
statements of operations and comprehensive loss.

b. Lease

The Company is currently on a month-to-month lease arrangement for office and lab space in Philadelphia, PA, in the amount of approximately
$16,500 per month. Commencing September 1, 2023 a new lease will commence, replacing the current month-to-month agreement with a 12-
month commitment (ending August 31, 2024) of approximately $36,000 per month.

NOTE 7: FAIR VALUE MEASUREMENTS

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of July 31, 2023 and 2022:

Level 1

July 31, 2023
Level 2

Total

Level 1

July 31, 2022
Level 2

Total

Fair Value Measurements at

Financial Assets:

Cash and cash equivalents

$ 21,251,092

21,251,092

41,041,652

Total assets measured at fair value

$ 21,251,092

21,251,092

41,041,652

Financial liabilities:
Warrants liability
Total liabilities measured at fair value

9,742,023
9,742,023

19,397,278
19,397,278

29,139,301
31,307,022
29,139,301 $ 11,151,608 $ 20,155,414 $ 31,307,022

11,151,608

20,155,414

We classify our cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active
markets.

The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for
the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.

F-14

NOTE 8: SHAREHOLDERS’ EQUITY

a. Authorized share capital

The authorized share capital consists of an unlimited number of common shares with no par value (“Share”).

b. Issued share capital

(i) The Company issued the following shares during the year ended July 31, 2022:

1. During the year, 554,991 compensation warrants with a weighted average exercise price of $5.68 per warrant were exercised into 219,453

Shares by way of a cashless exercise.

2. During the year, 63,454 warrants with an exercise price of $5.31 were exercised for gross proceeds of $337,099 and 997,200 warrants with an
exercise price of $6.19 were exercised for gross proceeds of $6,172,669. In total, the Company issued 1,060,654 shares in respect of the
exercise of these warrants.

(ii) The Company issued the following shares during the year ended July 31, 2023:

1. On April 14, 2023, 300 warrants with an exercise price of $5.31 were exercised for gross proceeds of $1,594. The Company issued 300 shares

in respect of the exercise of these warrants.

2. On May 12, 2023, the Company issued 463,408 Shares to Prevail Partners, LLC at a price per share of $8.63, resulting in aggregate gross

proceeds of $4,000,000.

c. Share buyback program

On September 9, 2021 the Company approved a repurchase program whereby the Company may purchase through the facilities of the TSX or NASDAQ
(i) up to 1,341,515 common shares (the “Common Shares”) and (ii) up to 411,962 publicly traded BCTXW warrants (the “Listed Warrants”) in total,
representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the “public float” as of September 8, 2021,
over the next 12 months (the “Buyback”). Independent Trading Group (ITG) Inc. will act as the Company’s advisor and dealer manager in respect of the
Buyback. The Company received final regulatory approval on September 22, 2021. On September 27, 2022, the Company completed the share buyback
program, repurchasing a total of 1,031,672 shares with a value of $9,098,014 (net of commissions), none of which were repurchased during the year ended
July 31, 2023, and 259,059 publicly traded warrants for $1,121,011 (net of commissions) with a fair value of $1,130,808, of which 15,736 were
repurchased and cancelled during the year ended July 31, 2023. All of the warrants and shares repurchased have been cancelled.

d. Share Purchase Warrants

A summary of changes in share purchase warrants for the years ending July 31, 2023 and 2022 is presented below:

Balance, July 31, 2021
Expired
Exercised
Repurchased and cancelled
Balance, July 31, 2022
Exercised
Repurchased and cancelled
Balance, July 31, 2023

Number of warrants
outstanding

Weighted average
exercise price

9,464,152 $
(22,489)
(1,060,654)
(243,323)
8,137,686 $
(300)
(15,736)
8,121,650 $

5.85
(28.08)
(6.14)
(5.31)
5.76
(5.31)
(5.31)
5.76

F-15

NOTE 8: SHAREHOLDERS’ EQUITY (Cont.)

As of July 31, 2023, warrants outstanding were as follows:

Number of
Warrants
outstanding as of
July 31, 2023

Exercise Price
4.11
5.31
6.19

51,698 $
3,896,809 $
4,173,143 $
8,121,650

Number of
Warrants
Exercisable as of
July 31, 2023

51,698
3,896,809
4,173,143
8,121,650

Expiry Date
November 16, 2025
February 26, 2026 – April 26, 2026
December 7, 2026

e) Compensation Warrants

A summary of changes in compensation warrants for the years ended July 31, 2023 and 2022 is presented below:

Balance, July 31, 2021
Exercised

Balance, July 31, 2022 and 2023 (*)

(*) There was no movement in compensation warrants during the year ended July 31, 2023.

As of July 31, 2023, compensation warrants outstanding were as follows:

Number of
Warrants
as of

July 31, 2023

4,890 $
17,074 $
24,688 $
46,652

Exercise Price
4.11
5.31
6.19

Exercisable
As of

July 31, 2023
4,890
17,074
24,688
46,652

f) Warrant liability continuity

Number of
warrants
outstanding

Weighted average
exercise price

601,643
(554,991)

46,652 $

5.68
(5.68)

5.66

Expiry Date
November 16, 2025
February 26, 2026
June 7, 2026

(i) The following table presents the summary of the changes in the fair value of the warrants recorded as a liability on the Balance Sheet (*):

Balance as of July 31, 2021

Warrant buyback program
Exercise of warrants
Change in fair value
Balance as of July 31, 2022

Exercise of warrants
Warrant buyback program
Change in fair value (*)

Balance as of July 31, 2023

Warrants liability

29,789,260

(1,073,718)
(9,066,892)
11,658,372
31,307,022

(897)
(47,294)
(2,119,530)

29,139,301

(*) Certain warrants were issued prior to August 1, 2022 in respect of public offerings and private placements that contain terms that require the warrants
to be recorded as a liability at fair value under US GAAP. As a result, these warrants are valued at the end of each reporting period. For the year ended
July 31, 2023, the Company recorded a gain on the revaluation of the total warrant liability of $2,119,530 in the consolidated statements of operations
and comprehensive loss.

(ii) The key inputs used in the valuation of the of the Public Offering Broker Warrants as of July 31, 2023 and at July 31, 2022 were as follows:

February 26,

April 12, 2021

July 31, 2023

July 31, 2022

Share price
Exercise price
Expected life (years)
Volatility
Dividend yield
Risk free rate

2021
(Issuance date)

(Issuance date)

$
$

3.40
5.31
5.00
100%
0%
0.88%

F-16

3.92
5.31
5.00
100%
0%
0.97%

6.69
$5.31-6.19
2.58-3.35

6.50
$5.31-6.19
3.58-4.35

100%
0%
4.51%

100%
0%
2.68%

NOTE 9: SHARE-BASED COMPENSATION

On August 2, 2022, the Company approved an omnibus equity incentive plan (“Omnibus Plan), which will permit the Company to grant incentive stock
options, preferred share units, restricted share units (“RSU’s”), and deferred share units (collectively, the “Awards”) for the benefit of any employee,
officer, director, or consultant of the Company or any subsidiary of the Company. The maximum number of shares available for issuance under the
Omnibus Plan shall not exceed 15% of the issued and outstanding Shares, from time to time, less the number of Shares reserved for issuance under all other
security-based compensation arrangements of the Company, including the existing Stock Option Plan. On February 9, 2023, the Omnibus Plan was
approved by the shareholders.

a. The following table summarizes the number of options granted under the Stock Option Plan for the year ended July 31, 2023 and related information:

Balance as of July 31, 2021
Granted (i)
Forfeited
Expired
Balance as of July 31, 2022
Granted (ii)
Balance as of July 31, 2023

Exercisable as of July 31, 2023

Number of
options

Weighted average
exercise price

674,666
818,300
(999)
(1,667)
1,490,300
641,100
2,131,400

1,585,655

4.38
7.81
30.04
46.80
6.20
6.16
6.19

6.18

Weighted average
remaining
contractual
term
(in years)

Aggregate
intrinsic value

2.91 $
3.44

4.09 $
4.63
3.55

573,466

447,090

1,065,700

3.19 $

808,684

(i)

The vesting periods of the 818,300 options granted to directors and employees during the year ended July 31, 2022 are as follows:

1.
2.
3.

110,000 of the options granted vested immediately.
482,300 of the options granted vest quarterly over the year from grant date.
226,000 of the options granted vest quarterly over the two years from grant date.

(ii)

(iii)

The 641,100 options granted to directors and employees during the year ended July 31, 2023 vest quarterly over the two years from grant
date.

The weighted-average grant date per-share fair value of stock options granted during 2023 and 2022 was $4.72 and $5.76, respectively.
As of July 31, 2023, there are $2,590,646 of total unrecognized costs related to share-based compensation that is expected to be
recognized over a period of up to 1.75 years.

b. The following table lists the inputs to the Black-Scholes option-pricing model used for the fair value measurement of equity-settled share options for the
above Options Plans for the years 2023 and 2022:

Dividend yield
Expected volatility of the share prices
Risk-free interest rate
Expected term (in years)

F-17

Year ended July 31,

2023

2022

0%
100%
3.99-4.23%

0%
100%
0.8%-2.83%

NOTE 9: SHARE-BASED COMPENSATION (Cont.)

c. The following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of July 31, 2023

Exercise
price

Options
outstanding as of
July 31, 2023

Weighted
average
remaining
contractual
term (years)

Options
exercisable as of
July 31, 2023

Weighted
average
remaining
contractual
term (years)

Expiry Date

$
$
$
$
$
$
$
$
$
$

6.03
7.16
6.36
4.71
7.51
8.47
7.53
5.74
4.24
4.24

d. Restricted Share Units

440,000
21,000
180,100
31,000
150,000
524,700
12,600
100,000
60,000
612,000
2,131,400

4.89
4.58
4.01
3.81
3.54
3.45
3.25
3.09
2.72
2.66

55,000
5,250
90,050
19,375
112,500
519,400
12,080
100,000
60,000
612,000
1,585,655

June 20, 2028

4.89
4.58 February 27, 2028
4.01 August 02, 2027
3.81 May 20, 2027
3.54 February 16, 2027
3.45
January 13, 2027
3.25 November 01, 2026
3.09 September 01, 2026
2.72 April 19, 2026
2.66 March 29, 2026

The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for year ended July 31, 2023:

Balance, July 31, 2021 and 2022
Granted (i)
Balance, July 31, 2023

Number of
RSU’s
outstanding

Aggregate
intrinsic value

- $

19,200
19,200 $

-
123,072
128,448

(i) On August 2, 2022, the Company issued 19,200 RSU’s to the CEO. The RSU’s vested immediately and have an aggregate intrinsic value of

$123,072.

d. The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the years ended July 31, 2023 and 2022
is comprised as follows:

Research and development expenses
General and administrative expenses
Total share-based compensation

Year ended July 31,

2023

2022

1,072,592 $
1,121,198
2,193,790 $

435,563
2,639,021
3,074,584

F-18

NOTE 10: TAXES ON INCOME

a. Components of income taxes excluding cumulative effects of changes in accounting principles, other comprehensive income, and equity in net
results of affiliated companies accounted for after-tax for the years ended July 31 were as follows:

b. The Company recorded loss before taxes on income as follows:

Domestic
Foreign

Year ended July 31,

2023

2022

(2,469,999) $
(17,832,395)
(20,302,394) $

(16,555,241)
(10,283,662)
(26,838,903)

c. The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 27% (2022 - 27%) to the effective tax rate is as
follows:

Net loss before recovery of income taxes
Expected income tax (recovery) expense
Tax rate changes and effect of taxes of subsidiaries at foreign rates
Share-based compensation and other non-deductible expenses
Foreign exchange loss
Share issuance cost booked directly to equity
Valuation allowance
Income tax (recovery)

Year ended July 31,

2023

2022

(20,302,394) $
(5,481,650)
1,068,270
622,220
-
-
3,791,160

- $

(26,838,903)
(7,246,504)
1,591,220
828,930
7,810
(15,420)
4,833,964
-

d. The Company had no income tax expense for the years ended July 31, 2023, and 2022, due to its history of operating losses and valuation
allowances.

e. Significant components of the Company’s deferred tax assets are as follows:

Deferred Tax Assets:

Property, plant and equipment
Marketable Securities
Warrant liability
Share issuance costs
Operating tax losses carried forward
Operating tax losses carried forward- USA
Research and Development

Total deferred tax assets
Valuation allowance
Net deferred tax assets

Deferred Tax Liability:
Intellectual Property
Convertible Debentures

Total net deferred tax liabilities
Valuation allowance
Net deferred tax assets (liabilities)

July 31,

2023

2022

730
11,760
3,776,710
734,300
3,842,320
4,913,950
2,685,825
15,965,594
(15,920,430)

45,160 $

(45,160) $

(45,160)
-
- $

730
11,760
4,330,580
1,105,220
2,714,150
4,015,960
-
12,178,400
(12,130,030)
48,370

(48,370)
-)
(48,370)
-
-

f. The Company has net deferred tax assets relating primarily to net operating loss (“NOL”) carryforwards and resource properties. Subject to
certain limitations, the Company may use these deferred tax assets to offset taxable income in future periods. Due to the Company’s history of
losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company’s deferred tax assets, as it is
more likely than not that such assets will not be realized. The net change in the total valuation allowance for the year ended July 31, 2023, was
$2,790,400.

F-19

NOTE 10: TAXES ON INCOME (Cont.)

At July 31, 2023, the Company had US federal NOL carryforwards of approximately $23,340,000. The federal net operating losses have expiry periods
ranging between 2033 and indefinitely. The Company also has Canadian net operating loss carryovers of approximately $14,231,000 as of July 31, 2023.
The Canadian net operating losses have expiry periods ranging between 2035 and 2043.

Utilization of the NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the
Internal Revenue Code (“IRC”) Sections 382 and 383, and similar state provisions. The Company has not completed an IRC 382/383 analysis regarding the
limitation of NOL and credit carryforwards. If a change in ownership were to have occurred, the annual limitation may result in the expiration of NOL
carryforwards and credits before utilization. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding
reduction in the valuation allowance.

The Company has adopted the provisions of ASC 740-10, which clarifies the accounting for uncertain tax positions. ASC 740-10 requires that the
Company recognize the impact of a tax position in its financial statements if the position is more likely than not to be sustained upon examination based on
the technical merits of the position. For the year ended July 31, 2023, the Company had no material unrecognized tax benefits, and based on the
information currently available, no significant changes in unrecognized tax benefits are expected in the next 12 months.

The Company’s policy is to recognize interest and penalties related to uncertain tax positions as income tax expense. The Company has no accruals for
interest or penalties on its accompanying consolidated balance sheets as of July 31, 2023, and 2022, and has not recognized interest or penalties in the
consolidated statements of operations for the years ended July 31, 2023, and 2022.

NOTE 11: RELATED PARTY TRANSACTIONS AND BALANCES

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the
other party in making operating and financial decisions. This would include the Company’s senior management, who are considered to be key management
personnel by the Company. Parties are also related if they are subject to common control or significant influence. Related parties may be individuals or
corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

a. The following related party salaries and directors’ fees are included in the consolidated statements of operations and comprehensive loss:

Directors (*)
Officers (**)

(*) Excluding the CEO who is a director

(**) Includes the CEO who is also a director

Year ended
July 31,

2023

2022

517,398 $

1,881,171
2,398,569 $

476,117
1,404,363
1,880,480

b. The following related party balances are included in the consolidated balance sheets:

Directors (*)
Officers (**)

July 31,

2023

2022

7,500 $
33,253
40,753 $

20,519
55,039
75,558

F-20

NOTE 12: FINANCIAL EXPENSE, NET

Interest income
Interest expense
Change in fair value of warrant liability
Gain on government grant
Foreign exchange loss
Financial income (expenses), net

Year ended July 31,

2023

2022

891,213 $

-
2,119,530
-
(40,873)
2,969,870 $

136,731
(979)
(11,658,372)
3,388
(30,730)
(11,549,962)

NOTE 13: BASIC AND DILUTED NET LOSS PER SHARE

Basic net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares
outstanding during each period. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted
average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period,
in accordance with ASC No. 260-10 “Earnings Per Share”. The Company experienced a loss in the year ended July 31, 2023 and 2022; hence all
potentially dilutive ordinary shares were excluded due to their anti-dilutive effect.

Year ended July 31,

2023

2022

Numerator:

Net loss available to shareholders of ordinary shares

(20,302,394)

(26,838,903)

Denominator:

Shares used in computing net loss per ordinary shares, basic and diluted

15,619,676

15,494,091

NOTE 14: LONG-LIVED ASSETS BY GEOGRAPHIC LOCATION

United States
Total long-lived assets*

July 31,

2023

2022

$
$

215,068 $
215,068 $

230,339
230,339

(*) Long-lived assets are comprised of property and equipment, net, investments and intangible assets, net.

NOTE 15: SUBSEQUENT EVENTS

a. On August 31, 2023, the Company closed a plan of arrangement spinout transaction (the “Arrangement”) pursuant to which certain pipeline
assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the
“BriaPro Assets”), were spun-out to BriaPro Therapeutics Corp. (“BriaPro”), resulting in a 2/3rd owned subsidiary of the Company with the
remaining 1/3rd held by BriaCell shareholders (“BriaCell Shareholders”).

Pursuant to the terms of the Arrangement, BriaPro has acquired the entire right and interest in and to the BriaPro Assets in consideration for
the issuance by BriaPro to the Company of BriaPro common shares. Under the terms of the Arrangement, for each BriaCell share held
immediately prior to closing, BriaCell Shareholders receive one (1) common share of BriaPro, and one (1) new common share of BriaCell
(retiring their old share) having the same terms and characteristics as the existing BriaCell common shares. The Company will remain listed
on the NASDAQ Stock Market and Toronto Stock Exchange, and BriaPro is an unlisted reporting issuer in Canada.

Immediately following the closing of the Arrangement, the Company controls 2/3rd of the BriaPro common shares representing
approximately 66.6% of the issued and outstanding common shares of BriaPro.

As a result of the Arrangement, there are approximately 47,945,178 BriaPro common shares issued and outstanding. The Company now
beneficially owns or controls approximately 31,963,452 BriaPro common shares, representing 2/3rd of the issued and outstanding BriaPro
common shares.

Pursuant to the Arrangement, each BriaCell warrant shall, in accordance with its terms, entitle the holder thereof to receive, upon the exercise
thereof, one BriaCell Share and one BriaPro Share for the original exercise price.

Upon the exercise of BriaCell Warrants, BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount for each one (1) BriaPro
Share so issued that is equal to the exercise price under the BriaCell Warrant multiplied by the fair market value of one (1) BriaPro Share at
the Effective Date divided by the total fair market value of one (1) BriaCell Share and one (1) BriaPro Share at the Effective Date.

Transition Services Agreement

On August 31, 2023, the Company and BriaPro executed a transition services agreement (the “Agreement”), pursuant to which BriaCell will
provide certain research and development and head office services (the “Services”) to BriaPro for a fixed monthly fee of $20,000.

Briacell and BriaPro acknowledged the transitional nature of the Services and accordingly, as promptly as practicable, BriaPro agreed to use
commercially reasonable efforts to transition each Service to its own internal organization or to obtain alternate third party providers to
provide the Services.

F-21

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.1

As of August 31, 2023, BriaCell Therapeutics Corp. (“we,” “our,” “us” or the “Company”) had the following classes of securities registered under
Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) our common shares and (ii) our public warrants, with each whole
warrant exercisable for one common share for $5.3125 per share (the “Public Warrants”).

Description of Common Shares

As of August 31, 2023, our authorized share capital, as described in our Notice of Articles, consisted of an unlimited number of common shares, without
par value, of which approximately 15,981,726 common shares were issued and outstanding. All of our outstanding common shares are validly issued, fully
paid and non-assessable.

Our common shares are the only securities with respect to which a voting right may be exercised at a meeting of the shareholders of the Company.

Dividends. Our shareholders are entitled to receive dividends, as may be declared from time to time and in the sole discretion of the Board. Dividends shall
be paid according to the number of Common Shares owned. Dividends may take the form of specific assets or of fully paid shares or of bonds, debentures
or other securities of the Company, or in any one or more of those ways. Shareholders are not entitled to notice of any dividend. We have never paid cash
dividends on our capital stock and we do not anticipate paying any dividends in the foreseeable future.

Voting Rights. Each common share is entitled to one vote at a meeting of shareholders of the Company.

Listing. Our common shares are traded on the Nasdaq Capital Market under the symbol “BCTX” and on the Toronto Stock Exchange under the symbol
“BCT”.

Description of Public Warrants

Securities Issuable Upon Exercise of the Public Warrants. Each Public Warrant is exercisable into one common share. As of August 31, 2023, 8,121,650
Public Warrants were issued and outstanding.

Exercisability. The Public Warrants are exercisable immediately, have an exercise price of $5.3125 per share, and expire five years from the date of
issuance. The exercise price and number of common shares issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting our common shares and the exercise price.

Cashless Exercise. If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for
the issuance of the underlying shares to the holder, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in
payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of common
shares determined according to a formula set forth in the Public Warrants.

Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the Public Warrants. As to any fraction of
a share which the holder would otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of
such fraction (in an amount equal to such fraction multiplied by the exercise price) or round the number of shares to be received by the holder up to the
next whole number.

Listing. Our Public Warrants are traded on the Nasdaq Capital Market under the symbol “BCTXW”.

Exhibit 31.1

I, William V. Williams, certify that:

I have reviewed this Annual Report on Form 10-K of BriaCell Therapeutics Corp.;

CERTIFICATIONS

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the

effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably

likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control

over financial reporting.

October 25, 2023

/s/ William V. Williams
William V. Williams
President and Chief Executive Officer
(Principal Executive Officer)

Exhibit 31.2

I, Gadi Levin, certify that:

I have reviewed this Annual Report on Form 10-K of BriaCell Therapeutics Corp.;

CERTIFICATIONS

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the

effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent

fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably

likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control

over financial reporting.

October 25, 2023

/s/ Gadi Levin
Gadi Levin
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

I, William V. Williams, President and Chief Executive Officer of BriaCell Therapeutics Corp. (the “Company”), hereby certify, pursuant to 18 U.S.C.
§1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Annual Report on Form 10-K of the Company for the year ended July 31, 2023 (the “Report”) fully complies with the requirements of Section

13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

October 25, 2023

/s/ William V. Williams
William V. Williams
President and Chief Executive Officer
(Principal Executive Officer)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.2

I, Gadi Levin, Chief Financial Officer of BriaCell Therapeutics Corp. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to
§906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Annual Report on Form 10-K of the Company for the year ended July 31, 2023 (the “Report”) fully complies with the requirements of Section

13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

October 25, 2023

/s/ Gadi Levin
Gadi Levin
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)